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ABSTRACT
FOAMING OF AMORPHOUS DRUG DELIVERY SYSTEMS PREPARED BY
HOT MELT MIXING AND EXTRUSION
by
Graciela Terife
Currently there is considerable interest from both academe and pharmaceutical industry in
exploring foaming processes and their products in drug delivery applications. However,
there is still little knowledge of the impact of the morphology of the foamed structures on
the performance of drug products in spite of some publications in this area. Therefore, the
main objective of this dissertation is to gain a fundamental understanding of the correlation
between foam morphology and performance of amorphous drug delivery systems, which
are comprised of an Active Pharmaceutical Ingredient (API) and Polymer excipient.
The Hot Melt Extrusion (HME) process is used to compound the following API /
polymer binary systems: Indomethacin (INM) with Soluplus® (PVCap-PVAc-PEG);
Carbamazepine (CBZ) with PVCap-PVAc-PEG; and INM with Eudragit® EPO.
Comprehensive characterization of these binary systems carried out by combining
Differential Scanning Calorimetry, Fourier Transform Infrared spectroscopy, X-Ray
Diffraction, and Scanning Electron Microscopy, shows that in all HME-prepared and
foamed samples the APIs are amorphous and dissolved in the polymer excipients.
The most important contributions of this dissertation can be grouped into three
areas: (a) an understanding of the mechanisms by which foamed dosage forms can lead to
faster API release, as well as the key morphological aspects of the cellular structures to
achieve this, (b) an understanding of the correlation between the mechanism controlling
the release of an API from an amorphous dosage and the enhancement in its release rate
upon foaming, and (c) an understanding of the impact of the morphology of the cellular

structures in the milling efficiency of HME products and the dissolution performance of
the particles produced.
In the first area, foamed amorphous solid solutions with three different
morphologies are produced through the batch foaming process. A strong correlation
between foam morphology and the enhancement in API release rate is observed. A
significant increase in API release rate is achieved by fast disintegration. Through a very
broad distribution of wall thicknesses, internal stresses are generated due to different
local swelling rates in the sample.

In this sense, such foam morphologies act as

disintegrant-less disintegrants, speeding up API release and release rates.
In the second area, the release controlling mechanisms of INM and CBZ from the
amorphous systems are identified by using the Power Law model.

Three distinct

mechanisms are observed: relaxation controlled, anomalous transport, and diffusion
controlled.

In all cases, the release rates of the APIs are increased upon foaming.

However, in cases where the API release is relaxation-controlled, the foamed structures
show to have the strongest impact at the initial stages of its in vitro release.
Finally, the Foam Hot Melt Extrusion process is used to produce foamed
amorphous solid solutions with two different morphologies. Their performance in terms
of milling efficiency and in vitro dissolution behavior is compared to that of the unfoamed extrudates of the same composition.

The milling efficiency is increased

appreciably through foamed extrudates, and smaller particles with narrower particle size
distributions are obtained compared to un-foamed extrudates. Additionally, it is found
that the enhancement of the release rate exhibited by milled foamed extrudates is the
most significant for the particles produced by milling the lower density foam extrudates.
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CHAPTER 1
INTRODUCTION

Pharmaceutical Hot Melt Extrusion (HME) has and is being incorporated into the units of
operation used to manufacture of drug delivery systems. This has been driven by the
Process Analytical Technology (PAT) initiative of the Food and Drug Administration
(FDA). The PAT initiative promotes the used of continuous manufacturing process with
in-line quality control (FDA 2004), which can be easily accomplished through the
extrusion process. HME is a continuous, solvent-free manufacturing process that allows
to uniformly distribute an Active Pharmaceutical Ingredient (API) in a polymeric
excipient or carrier; additionally, other intergranular excipients can be incorporated in a
single process. The API may exist in its native crystalline state or it may be dissolved in
an amorphous polymer excipient in order to produce single phase amorphous systems.
The latter case is of great value for solubilization of APIs with poor aqueous solubility.
Since amorphous systems make it possible to increase the release and apparent solubility
of an API, then, potentially its bioavailability can be enhanced.
In spite of extensive research conducted in the HME area since the 1980’s, there
still exist challenges associated to this process, specifically in view of the conservative
nature of the pharmaceutical industry. First, many APIs are susceptible to thermal
degradation during processing. Similarly, the majority of the polymer excipients used in
the manufacture of orally delivered dosage forms are not well suited (or were not
originally developed) to be melt processed. In other words, many of the polymer
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excipients used have high melt viscosities and very narrow processing windows which
makes them very difficult to be processed without plasticizers.
Other challenges associated with the HME process are related to the nature of the
extrudates produced after compounding. On the one hand, extrudates tend to be very
tough, and, thus, difficult to mill into suitable particle sizes with narrow distributions to
be used for tableting, to fill into capsules or to be used in liquid suspension.
Additionally, extrudates tend to be non-porous and, as result, their dissolution rates are
hindered by slow fluid absorption by the HME products.
In order to overcome the aforementioned challenges associated with HME,
foaming processes widely used in the polymer industry, such as foam extrusion and foam
injection molding, have been explored in the last decade. Physical blowing agents have
been used as “fugitive” plasticizers, foamed extrudates have shown to facilitate milling
operation, and cellular structures have been evaluated as a means to enhance API release
rate. Detailed literature review of these and other uses of foaming processes and foamed
products in pharmaceutics are presented in section 2.3 of Chapter 2.
Currently there is a lot of interest from both academe and pharmaceutical industry
in exploring foaming processes and their products in drug delivery applications. However,
there is still little knowledge of the impact of the morphology of the foamed structures on
the performance of drug products in spite of some publications in this area. Therefore, the
main objective of this dissertation is to gain a fundamental understanding of the
correlation between foam morphology and performance of amorphous drug delivery
systems using foam extrusion and batch foaming processes. Additionally, the effect of
the foaming processes on the state of the API is studied.
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In the first part of this dissertation the HME process is used to compound the
binary system comprising of Indomethacin (INM) as model API and Soluplus® (PVCapPVAc-PEG). Since this is the binary systems used for the majority of the foaming
studies, its general properties (i.e. solubility of INM is the excipient, in vitro dissolution
and CO2 solubility in the binary system) are studied in detail.
Since batch foaming is carried with supercritical carbon dioxide (ScCO2) as the
blowing agent, its effect on crystallization of INM from its amorphous state is
investigated. Amorphous samples of INM are subjected to different batch foaming
conditions, and their morphological changes are evaluated through Fourier Transform
Infrared Spectroscopy (FT-IR).
The Foam Hot Melt Extrusion process is used to produce foamed extrudates of
the INM / PVCap-PVAc-PEG binary system. The objective of the foam extrusion study
been to understand the effect of the morphology of the cellular structure on the milling
efficiency of extrudates and the in vitro dissolution performance of the particles
produced. In this study by varying the foam extrusion conditions two foam morphologies
were produced and their performance is compared to that of the un-foamed extrudate of
the same composition.
The batch foaming process is used perform two different studies. The main
objective of first batch foaming study is to understand the correlation between the
mechanisms controlling the release of an API from an amorphous dosage form and the
enhancement in its release rate upon foaming. The Power law model is used to identify
the API release mechanism from four amorphous systems: 30:70 INM / PVCap-PVAcPEG, 15: 75 Carbamazepine / PVCap-PVAc-PEG, and 30:70 INM / Eudragit® EPO in
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two aqueous buffer solutions with pHs 1.2 and 7.4. In addition, the effect of the batch
foaming process with ScCO2 as blowing agent in the physical state of the APIs is studied
combining Scanning Electron Microscopy (SEM), FT-IR, and X-ray diffraction (XRD).
The main objective of the second study performed through batch foaming, is to
gain an understanding of the mechanisms by which foamed dosage forms can lead to
faster API release as well as the key morphological aspects of the cellular structure
needed to achieve this. A secondary goal if this study is to evaluate the impact of the
cellular structure in the long term physical stability of an amorphous solid solution. The
30:70 INM / PVCap-PVAc-PEG binary system is used for this section of the dissertation.
Foamed samples with three distinct morphologies are produced by varying the batch
foaming conditions, and compared to the performance of compression molded (nonporous) samples of same weight and composition.

CHAPTER 2
LITERATURE REVIEW

2.1 Pharmaceutical Hot Melt Extrusion / Hot Melt Mixing
Pharmaceutical Hot Melt Extrusion (HME) has been an area of great interest in academe
and pharmaceutical industry since the 1980’s (Crowley et al. 2007), with many and
extensive investigations, as well as numerous patents and research papers published since
then. Briefly, HME is a polymer melt compounding process, adapted from the polymer
processing industry, where one or more active pharmaceutical ingredients (APIs) are fed
in an extruder with at least one polymeric excipient. The processed stream undergoes
melting of the polymer excipient, mixing and / or dissolution of the API, and is then
shaped into a continuous extrudate by pumping it through a die followed by cooling. The
typical applications of pharmaceutical HME include: sustained release delivery systems,
drug solubilization, target release and prevention of substance abuse. Some of these
applications can be seen in the list of drug products shown in Table 2.1, where a
summary of their commercial status and the purpose of the HME process are listed.
As can be seen in Table 2.1, a significant number of the drug delivery systems
currently manufactured by HME in the market are implants. In order words, these
products are drug delivery systems or medical devices that provide sustained API release,
where the HME process is used to produce an homogenous blend of the API – in either
its crystalline or amorphous form – with a polymer excipient or carrier and to provide the
desired shape of the device (Ghebre-Sellassie and Martin 2007). It should be pointed out
that manufacturing sustained release systems by HME is not limited to devices.
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Controlled release oral dosages have been also be manufactured by this process
(Follonier et al. 1995; Repka et al. 2007). The release of the API is delayed or modulated
by the carrier, which can be either insoluble or slow dissolving in body fluids (Follonier
et al. 1995).
Given that one of the prerequisites for absorption of an orally administered API is
that it must dissolve along the gastrointestinal tract (GI) (Amidon et al. 1995; Dahan and
Miller 2012), solubilization of APIs with poor aqueous solubility through HME is
another area where significant research efforts and interest lay. A significant portion of
the new discovered APIs have poor aqueous solubility (Crowley et al. 2007; Dahan and
Miller 2012); it has been estimated that more than 30 % of the APIs in the market have
poor solubility in an aqueous medium. Furthermore and more significantly, 70 % out of
all new molecule entities are expected to show poor aqueous solubility (Benet et al.
2006).
Through HME and Hot Melt Mixing (HMM), a batch melt compounding process
that can be used to perform feasibility assessment for HME, it is possible to dissolve an
API in a molten polymer excipient, and, thus increase its release rate and apparent
solubility (Breitenbach 2002; Crowley et al. 2007; Ghebre-Sellassie and Martin 2007;
Repka et al. 2007; Liu 2010). It is important though to bear in mind that this does not
necessarily result in enhanced bioavailability, since permeability of the API through the
GI track also plays a significant role in its absorption (Amidon et al. 1995; Dahan and
Miller 2012). However, rendering a poorly soluble API soluble is the starting point for
rendering poorly soluble APIs bioavailable. The dissolution mechanisms of the API in
the molten polymer are described in more detail below.

Table 2.1 Examples of Drug Products Manufactured by the HME Process
Polymer Delivery
Name
API
Excipient* Form

Indication

Status
b, c

HME Purpose

Dapivirine + Maraviroc a

EVAa

Implant

Anti-Viral (HIV)

Lacrisert®

None

HPMC

Implant

Dry eye syndrome

M

Shape

NuvaRing

Etonogestrel + Ethinyl Estradiol

EVAa

Implant

Contraceptive

M

Shape

Zoladex

Goserelin acetate

PLGA

Implant

Prostate cancer

M

Shape

Implanon

Etonogestrel

EVA

Implant

Contraceptive

M

Shape

Ozurdex®

Dexamethasone

PLGA

Implant

Macular Edema

M

Shape

Kaletra®

Lopinavir + Ritonavir

PVP-VA

Tablet

Anti-Viral (HIV)

M

Amorphous solution

Norvir®

Ritonavir

PVP-VA

Tablet

Anti-Viral (HIV)

M

Amorphous solution

HPMC

Tablet

Diabetes

M

Melt granulation

Dapivirine-Maraviroc

Eucreas®

Vildagliptin + Metformin
hydrochloric

UDa Shape

Zithromax®

Azithromycin

HPMC

Tablet

Antibiotic

M

Taste Masking

Gris-PEG®

Griseofulvin

PEG

Tablet

anti-fungal

M

Crystalline dispersion

Rezulin®

Troglitazone

PVP

Tablet

Diabetes

W

Amorphous solution

PalladoneTM

Hydrophone

EC + ERS

Tablet

Pain

W

Controlled release

Posaconazole

Posaconazole

-

-

Anti-fungal

Anacetrapib

Anacetrapib

-

-

UD Amorphous solution

Cardiovascular disease UD Amorphous solution
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*EVA: Ethyl Vinyl Acetate, HPMC: Hydroxypropyl methylcellulose, PLGA: Poly(lactic-co-glycolic acid), PVP-VA: Polyvinyl pyrrolidone co-vinyl acetate,
PEG: Polyethylene glycol, PVP: Polyvinyl pyrrolidone, EC: Ethyl cellulose, ERS: Eudragit® RS.
Source: a (Loxley 2010) b (DiNunzio 2011). c UD: Under development, M: Marketed product, and W: Withdrawn from the market
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Besides sustained release and API solubilization, HME allows to target the release
of an API to a specific section of the GI tract. This is accomplished by embedding the
API (either in its crystalline or amorphous form) in a polymer excipient that only
dissolves in a specific pH range (Doelker 1993; Follonier et al. 1995; Andrews et al.
2008) or through specific API / excipient interactions (Sriwongjanya and Bodmeier 1998;
Lele and Hoffman 2000). This is also of great interest for taste-masking applications.
Finally, HME allows the manufacturing of dosage forms that aid the prevention of
substance abuse (Oshlack et al. 2001; Arkenau-Maric and Bartholomaus 2008). Many
APIs have habit-forming side effects that may lead to addiction and substance abuse. For
example, in order to obtain a fast-acting and high dosage of such types of APIs, abusers
crush the dosage forms into fine powders, which then can be consumed nasally or can be
dissolved to be administered intravenously (Arkenau-Maric and Bartholomaus 2008).
Therefore, HME is used to manufacture very tough dosage forms – with breakage
strengths exceeding 500N (Arkenau-Maric and Bartholomaus 2008) – which makes it
very difficult to break and grind them.

2.1.1 Description of the HME Process and Mechanisms
The pharmaceutical HME process is carried out at temperatures 50 to 100 C above the
glass transition temperature (Tg) of the polymer (or above its melting point in the case of
semi-crystalline polymer excipients) and generally below the melting point of the API,
though it can also be carried out above the melting point of the API if thermal
degradation is not an issue.
From a general perspective, the HME process can be described by the following
elementary steps: solids conveying, melting, mixing, API’s dissolution in the excipient (if
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the system is miscible), devolatilization and pumping (Tadmor and Gogos 2006; Gogos
2012).
In more detail, the API and the polymer are fed as solids particulates, either
independently or as a dry blend. These solids are then conveyed by the screws, thereafter
the materials are heated and the polymer melts primarily by heat generated volume-wise
through frictional and plastic energy dissipation created by the action of kneading blocks
deforming fully-filled stream regions (Tadmor and Gogos 2006). Once the polymer is
melted, and if the system is miscible, the API can be progressively dissolved in the
polymer, by distributive laminar mixing flows.
Figure 2.1 shows the dissolution mechanism of API in a molten polymer of a
miscible system when compounding is carried out below the melting point of the active
ingredient. This schematic representation shows first the dry blend of the API and the
excipient, representing the feed, and once the polymer is melted the crystalline particles
are suspended in the melt. Then, dissolution of the API in the polymer commences by
the formation of a boundary layer along the surface of the crystalline particles, followed
by distributive and dispersing mixing, until the API is completely dissolved in the
polymer.
After melting and mixing, devolatilization or venting is necessary to remove
trapped air and steam in the melt (Todd 1998). Lastly, pressure is generated by the
rotating screws in order to pump the melt stream through the die. Finally, this API /
Polymer single phase mixture is cooled to room temperature and solidifies. As a result
the dissolved API is immobilized by the matrix in an amorphous state. Two factors
prevent recrystallization of the API; one is the greatly reduced mobility of the API in the
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glassy polymer matrix aided by choosing an API / Polymer system with a Tg considerably
above the storage temperature, and the other and most important, is the existence of
specific and strong interactions between the API and the polymer, such as hydrogen
bonding and ionic bonding (Breitenbach 2002; Bhugra and Pikal 2008).

Figure 2.1 Schematic representation of the dissolution mechanism of an API during the
HME process carried out at a temperature above the melting point of the API. Source:
(Liu et al. 2010)

2.2 Foams, Foaming Processes, and Mechanisms
The terms “foams” and “cellular structures” refer to solid porous structures, which can be
visualized as, and often is a honeycomb structure, in the case of closed cells foams shown
in Figure 2.2 (a), or as a rigid sponge, for the case of open cell foams, Figure 2.2 (b).
Foams are widely used in both food and plastic industries, and for the last decade the
applications of foamed products and foaming processes have grown dramatically, as the
need for thermal and sound insulation, as well as for light-weight vehicle components
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have grown. They have been also recently explored by the pharmaceutical industry to
investigate novel drug delivery methods.
Some examples of foams in the food industry include: bread, cakes and puffed
cereals and snacks. Some of the typical applications of foamed products in the plastic
industry include: insulation (thermal, acoustic and electrical), floating devices, shock
mitigation, packaging and cushioning among others.

The end use, as well as the

performance and properties of polymeric foams strongly depend on their physical
characteristics. For example open cell foams, where all the cells are interconnected, are
used for applications that require high permeability to gasses and higher capacity to
absorb fluids and moisture (Shutov 1991; Mills 2007). On the other hand, closed-cell
foams – where each cell is isolated from the rest – are preferred for thermal, noise and
electrical insulation over open-cell foams. (Mills 2007).
(a)

(b)

Figure 2.2 Schematic representation of: (a) a closed cell foam, and (b) an open cell
foam. Source: (Mills 2007).
2.2.1 Foaming Processes and Mechanism
Cellular structures can be commercially created through continuous processes, such as
foam extrusion, or through batch or semi-continuous processes, such as injection
molding.

From a general perspective, the foaming process involves the following

elementary steps: (1) dissolution of a gas in a polymer based formulation, (2) cell

12
nucleation, (3) bubble growth, and (4) stabilization of the cellular structure (Zhang and
Xanthos 2004), these are depicted schematically in Figure 2.3.

Figure 2.3 Schematic representation of the foaming elementary steps.

Independently of the method used for producing the foam structure, first the
polymer is saturated with a gas, and then a thermodynamic instability is induced by a
rapid increase in temperature or drop in pressure. As a result, the system becomes
oversaturated and cell nucleation and growth takes place. From a physical perspective, as
depicted in Figure 2.3, the first isolated spherical bubbles are formed by nucleation,
which then start to grow. Once these gas bubbles start to touch each other, their spherical
shapes start becoming hexagonal and the facets become planar, and, depending on the
strength of the material, the walls could either remain intact (i.e. forming a closed-cell
structure) or may break generating an open cell structure (Saunders 1991; Mills 2007).
Cell nucleation can be homogeneous, heterogeneous or of a mixed mode (Colton
and Suh 1987; Ramesh 2004). Homogenous nucleation occurs when the dissolved gas
coalesces forming a second phase. During the formation of this second phase the free
energy of the system changes according to expression 2.1 below, where the first term on
the right side of the equation corresponds to a reduction in free energy as the gas
molecules are incorporated into the bubble. The second term on the right side of the
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equation corresponds to an increase on free energy due to the formation of a new surface
and it is associated interfacial energy (Colton and Suh 1987).

(2.1)
Where Ghom is the change of free energy during homogenous nucleation, Vb is
the nucleus volume, P = Psat- Ps is the difference between saturation pressure (Psat) and
atmospheric pressure (Ps), Abp is the surface area of the nucleus, and bp is the surface
energy of the polymer-bubble interface (Colton and Suh 1987; Kumar and Suh 1990;
Goel and Beckman 1994a; Ramesh 2004).
As can be seen in Figure 2.4 (a), at the beginning of the nucleation process the
interfacial energy plays a dominant role, but once a critical nucleus size is reached (r*)
the energy barrier for nucleation is overcome and the bubble growth process is favored.
By assuming a spherical nucleus with radius r – since this is the geometry that will give
the minimum excess in energy (Colton and Suh 1987; Ramesh 2004) – then, from the
expression 2.1 the critical radius (r*) and the nucleation activation energy (

) can be

obtained as defined by the following expressions:

(2.2)

(2.3)

Another important parameter that defines the cellular structure is the nucleation
rate, which in the case of homogenous nucleation is given by equation 2.4.
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(

)

(2.4)

Where Jhom is the homogenous nucleation rate, fo is frequency of formation of
stable nuclei, Co is the gas concentration,

is the Boltzmann constant and T the absolute

temperature (Colton and Suh 1987).

(a)
(b)
Figure 2.4 Change in free energy as a function of radius (r) of the nucleus. (a) Change
in interfacial energy, volume free energy, and net free energy associated with
homogeneous nucleation process as a function of the radius of the nucleus. (b)
Comparison between homogenous and heterogeneous free energies of nucleation as a
function of the radius of the nucleus. Source: (Colton and Suh 1987).

By understanding the homogenous nucleation theory it is easy then to identify the
variables that affect the cellular morphology in a given process. From expressions 2.2
through 2.4 it is evident that by increasing the saturation pressure and/or reducing the
surface energy, both the r* and the activation energy are reduced, and hence the
nucleation rate can be significantly increased. From expression 2.4 it is also clear that
other parameters that can be utilized to affect the nucleation kinetics are the gas
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concentration and temperature, where an increase in either one results in faster nucleation
rate.
Finally, through heterogeneous nucleation, it is also possible to accelerate
nucleation, as shown schematically in Figure 2.4 (b). Nucleation agents are used to
reduce the nucleation activation energy by providing lower surface energy sites, or by
lowering the polymer surface tension (Saunders 1991; Ramesh 2004). Based on the
above, crystalline API particles suspended in the melt, whether insoluble or only partially
soluble in the polymer, may act as nucleating agents during foaming operations.
In general, by increasing the nucleation rate it is possible to produce foams with
smaller cells and lower densities.
Once critical size nuclei are formed, gas dissolved in the polymer diffuses into in
the gas bubbles, and as a result, the pressure inside the bubbles increases subjecting the
polymer to bi-axial tension and deformation. The rate of cell growth will depend on the
gas diffusion rate, heat transfer affecting melt temperature, and polymer strength (i.e.
melt strength and polymer-gas rheological and viscoelastic properties) (Holl et al. 1999;
Tadmor and Gogos 2006).
2.2.1.1 Types of Foaming Agents. The sources of the gases that provide expansion
during foaming of the material are called “Foaming or Blowing Agents”. These are
divided into two categories: chemical blowing agents (CBAs) and physical blowing
agents (PBAs). CBAs are compounds added to a given formulation that, upon heating
and at CBA-specific temperature ranges decompose releasing a gas, such as nitrogen,
water, and carbon dioxide (CO2) (Throne 2004; Ahuja et al. 2007). An example of a
CBA that could be used in pharmaceutical applications and that is commonly used in
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food industry is sodium bicarbonate. In general, CBAs result in high density foams (Han
et al. 1976; Throne 2004).
In contrast to chemical foaming agents, PBAs do not undergo any chemical
reaction to produce a blowing gas. PBAs can be grouped into two categories: permanent
gases and volatile organic compounds (Throne 2004). Table 2.2 shows a summary of the
properties of PBAs that are used in the polymer industry and have direct applications in
the manufacture of pharmaceutical products. It should be noted that both water vapor
and CO2 are commonly used in the food industry to manufacture puffed snacks and
cereals through the foam “extrusion cooking” process (Moraru and Kokini 2003; Cho and
Rizvi 2010).

Table 2.2 Properties of Commonly Used Physical Blowing Agents
Boiling
Critical
Density at 23C
PBA
Point [C]
Temperature [C]
[g/cm3]

Critical
Pressure [MPa]

Nitrogen

1.146

-

-147

3.40

Carbon dioxide

1.811

-78.5

31

7.39

Water vapor

1.000

100

374.1

22.1

Source: (Throne 2004)

2.2.1.2 Batch Foaming. During the batch foaming process with PBAs the polymeric
sample is saturated with a gas at high pressure, then a thermodynamic instability is
introduced to the process to initiate cell nucleation In general two approaches are used:
(1) a low temperature gas saturation method, and (2) a high temperature gas saturation
method or sometimes called the pressure quenching method.
When the low temperature approach is used, the sample is saturated with gas at a
temperature below the system’s Tg. Then the gas-saturated sample is immersed in a high
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temperature bath to raise its temperature above the Tg of the polymer-gas system. As a
result the system becomes oversaturated with gas and, due to the increased molecular
mobility, the nucleation process is triggered (Colton and Suh 1987; Kumar and Suh 1990;
Ramesh et al. 1991; Goel and Beckman 1994a). Afterwards, the cellular structure is
stabilized by quench-cooling the foamed sample (Goel and Beckman 1994b).
On the other hand, through the pressure quenching method the polymeric sample
is saturated with gas at a temperature above its Tg and at a high pressure. The driving
force for nucleation in this case is a sudden depressurization of the system which makes
the system oversaturated with gas. Therefore, very fast and extensive nucleation can be
promoted and, thus, foams with very small cells can be produced (Goel and Beckman
1994a; Arora et al. 1998; Sun et al. 2002).

It should be mentioned that the

depressurization step takes place at a constant temperature, even though the temperature
of gases tends to decrease, due to expansion following the Joule-Thomson effect (Burnett
1923). The overall temperature change can be considered negligible. Goal and Beckman
(Goel and Beckman 1994b) reported only 2 to 3 C drop in temperature during the
pressure quenching batch foaming process with supercritical carbon dioxide (ScCO2).
Figure 2.5 shows a summary of the variables that affect the properties of foams
produced by batch foaming. As in any other process, these are grouped in terms of
process, material and design variables.

However, these groups of variables are not

independent of each other, in the sense that even the independent process variables are
chosen based on the properties of the material been foamed.
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Figure 2.5 Summary of the variables that affect the properties of foams produced by the
batch foaming process.

2.2.1.3 Foam Extrusion. In contrast to the batch foaming process, where the sample is
exposed to the PBA at a temperature close to its Tg, during foam extrusion the gas is
dissolved in the molten polymer inside an extruder. Figure 2.6 shows schematically the
elementary steps during the foam extrusion process in the presence of an API, which is
miscible with the excipient.

Prior to gas injection, the foam extrusion process is

equivalent to the conventional HME process described above. However, a melt seal must
be created upstream, that is before the gas injection in order to prevent gas back flow and,
thus, gas loss thought the hopper. Such melt seal is achieved by having a fully-filled
screw section, which is generated in a co-rotating twin screw extruder through reversing
self-wiping screw elements. Subsequently, downstream of the gas injection site, the gas
must be dissolved in the melt and this “solution” has to be cooled in order to increase the
melt viscosity and melt elasticity and provide the necessary melt strength to sustain the
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cellular structure without collapsing.

Finally, foaming occurs along the die as the

pressure is rapidly dropped to atmospheric conditions. (Lee 2000; Zhang and Xanthos
2004)

Figure 2.6 Schematic representation of the foam extrusion process. Extruder sketch
modified from: (Lee and Scholz 2009)

Figure 2.7 shows schematically a summary of the process, design and material
variables that affect the morphology of the cellular structure. It is important to have in
mind that all these variables are not fully independent, as mentioned above. As an
example, the amount of PBA dissolved is dependent not only on the material variables,
such as the miscibility and viscosity of the melt, but it also depends on processing
variables such as pressure, temperature, and screw speed, and design variables such as
screw configuration (Zhang and Xanthos 2004). Among the design variables, die
geometry is one of the most important design variables, since it defines the
depressurization rate and it has a very strong influence on the magnitude of the pressure
drop.
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Process variables:
•Independent variables: screw
speed, temperature profile,
feeding rate.
•Dependent variables: die
pressure, melt temperature,
torque.

Design variable:
•Extruder design: L/D
•Screw design: screw
configuration, OD/ID and
screw diameter
•Die geometry

Foam properties:
•Cell size, type,
density.
•Performance
Material variables:
•Rheological properties
•Thermal properties
•Type of blowing agent: gas yield
or concentration, solubility,
diffusivity and permeability.
•Polymer – API system

Figure 2.7 Summary of the variables that affect the properties of foams produced by the
foam extrusion process.
2.3 Use of Foaming Technology in the Manufacture of Drug Products
Even though for the last decade research work has been conducted and published related
to foams and foaming processes in drug delivery products, results are very scarce and
further studies must be conducted in order to gain fundamental understanding of the
impact of foaming on the performance of HME products.
The application of polymeric foams in drug delivery can be grouped in four
categories: (1) the use of PBAs as “fugitive” plasticizers (Verreck et al. 2005; Verreck et
al. 2006a; Verreck et al. 2006b; Lyons et al. 2007; Verreck et al. 2007; Nikitine et al.
2010; Nagy et al. 2012), (2) floating oral dosages (Nakamichi et al. 2001; Streubel et al.
2003; Fukuda et al. 2006), (3) foams as intermediate products (Hsu et al. 1996; Hsu et al.
1997; Verreck et al. 2005; Verreck et al. 2006b; Verreck et al. 2007; Nagy et al. 2012),
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and (4) foams to increase release rate of amorphous systems (Breitenbach and Baumgartl
2000; Clarke 2005; Lyons et al. 2007; Andrews et al. 2010; McKelvey et al. 2010).

2.3.1 Physical Blowing Agents as “Fugitive” Plasticizers
Many APIs are susceptible to thermal degradation under HME processing conditions.
Thus, they may become inactive or lose their functionality (Verreck et al. 2007).
Similarly, many polymeric excipients in the market have very narrow processing
windows and high viscosity which makes them very difficult to be processed without
plasticizers.
However, adding permanent plasticizers may be unfavorable to the formulation
for several reasons: (1) they add “dead weight” to the dosage, which could become
unacceptably high (Verreck et al. 2006b). (2) Plasticizer volatilization during storage may
result in unexpected changes in product performance during the shelf life of the dosage
(Crowley et al. 2007). (3) Finally, plasticizers permanently increase the overall mobility
of the system; thus, it may be detrimental to the stability of the system, reducing the shelf
life of the product. Therefore the use of “fugitive” plasticizer during HME process is of
great interest for the pharmaceutical industry, because the processing temperature can be
decreased without affecting the long term stability of the product. Since it is well known
that, once a PBA is dissolved in a polymer can act as a plasticizer, these are great
candidates as “fugitive” plasticizers. For example Elkovitch and Tomasko (Elkovitch
and Tomasko 2000) observed a maximum decrease in viscosity for poly(methyl
methacrylate) and polystyrene of 80 and 70 %, respectively in the presence of CO2.
Verreck et al. (Verreck et al. 2005; Verreck et al. 2006b; Verreck et al. 2007)
evaluated the effect of CO2 as plasticizer during the HME process in a 18 mm twin screw
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extruder by determining the minimal temperature at which the maximum torque of the
extruder was reached with and without injecting CO2. In studies performed with pure
polymer excipients (placebos) a decrease in minimum temperature for PVP-VA,
Eudragit® E100 (EPO) and EC of 30, 15 and 65 C, respectively (Verreck et al. 2006b)
was observed. The same study was performed using two binary systems: Itraconazole /
EC (Verreck et al. 2007) and Itraconazole / PVP-VA (Verreck et al. 2005). In the former
case the minimum processing temperature was decreased by 30 and 65C and in the
latter case by 5 and 10 C, depending on API loading.
Verreck et al. (Verreck et al. 2006a) used CO2 as a fugitive plasticizer during
compounding of p-Amino salicylic acid – which is highly sensitive to thermal
degradation – with EC in an 18 mm twin screw extruder. The authors observed that
through a conventional HME process, 17 % of the API decomposed during
compounding, but by using CO2 as fugitive plasticizer the processing temperatures were
reduced and the amount of decomposed API was reduced to 5 %.
Other evidence of the plasticizing effect of CO2 in pharmaceutical materials can
be found in the literature. Nikitine et al. (Nikitine et al. 2010) observed a 27 – 43 %
reduction in torque by injecting CO2 when extruding EPO in a 30 mm single screw
extruder. Nagy et al. (Nagy et al. 2012) also observed a decrease in torque of 7 to 20 %
by using CO2 as PBA during compounding of the binary system of Carvedilol and EPO
in a 30 mm single screw extruder. Lyons et al. (Lyons et al. 2007) also observed a
decrease in toque and die pressure upon CO2 injection in a 16 mm co-rotating twin screw
extruder.
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2.3.2 Floating Oral Dosage Forms
Gastroretentive drug delivery systems, with up to 6 h of sustained release, are required
for some orally administered APIs. Some drugs must be absorbed in the stomach or
upper section of the intestine due to either therapeutic reasons or to instabilities of the
API at higher pH values (Nakamichi et al. 2001; Streubel et al. 2003; Fukuda et al. 2006).
Floating dosages, using polymeric foams have been studied for this application.
Fukuda et al. (Fukuda et al. 2006) produced floating oral dosages by foam
extrusion in a single screw extruder, using 5 - 10 wt% of sodium bicarbonate as CBA.
The polymeric matrix used for the study was Eudragit® RS, an ionic acrylic based copolymer which is highly hygroscopic but does not dissolve in aqueous solution or body
fluid, but only swells. Two model APIs were used in order to evaluate two different oral
dosage systems: (1) a miscible system using chlorpheniramine maleate (CMP), and (2) an
immiscible system using acetohydroxamic acid (AHA). The foamed extrudates produced
had average cell size of ~200 m and densities in the range 0.8 - 0.6 g/cm3. These
foamed dosages maintained their buoyancy for 24 h in an acid aqueous solution. API
release profiles obtained for all samples (foamed and un-foamed) showed sustained API
release in a 24 h period. Nonetheless, the miscible system showed an increase in release
rate upon foaming (approximately 80 % of CMP was released from the foamed sample in
24 h whereas only approximately 40 % from the un-foamed sample). In contrast, no
appreciable variation was observed for the immiscible system. The influences of cell size
and foam density on API’s release profiles were not explored.
Nakamichi et al. (Nakamichi et al. 2001) used foam extrusion with water as PBA
to produce floating dosages of Hydroxypropyl methylcellulose acetate succinate
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(HPMCAS), an enteric polymer (i.e. soluble only in aqueous solution with pH 5 or
higher), containing nicardipine hydrochloride (NH) as the model drug. Compounding
and foaming was conducted in a co-rotating twin screw extruder. In addition, Calcium
phosphate dehydrate (CP) was added to the formulation as nucleating agent. Closed-cell
foams were produced with cell size in the range 1-350 m and porosities ranging from 5
% up to 72 %. The porosity as well as the average cell size increased as the CP
concentration increased. Buoyancy and dissolution tests were conducted in aqueous
solution with pH 1.2. An increase in initial buoyancy was observed as the porosity
increased; however, for high CP loading the dosage form disintegrates due to CP’s
dissolution and its buoyancy was lost. Cell size showed negligible effect over the release
profile of the API.
Streubel et al. (Streubel et al. 2003) developed a floating oral dosage by
incorporating into the formulation foamed Polypropylene (PP) powder. Tablets were
produced by direct compression of HPMC, the API, foamed PP particles and other
excipients. The tablets showed good floating behavior for 8 hours, but it was lost
afterwards due to dissolution of the HPMC phase.

2.3.3 Foams as Intermediate Products
While for gastroretentive applications the foamed samples is the final product, in
some other cases the foamed material is just an intermediate product during the
manufacture of the final dosage form. Two approaches can be found in the literature for
foamed intermediate products: milling of HME products and API infusion. Since the
former is of greater interest to the pharmaceutical industry, milling of foamed extrudates
will be discussed in more detail.
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After HME compounding, the extrudates are often milled. The final dosage form
is produced by pressing the ground material into tablets, filling capsules with it or using
the particles in suspension for liquid formulations. However, extrudates tend to be very
difficult to mill into suitable particle sizes with narrow distribution (Verreck et al. 2005;
Verreck et al. 2006b; McKelvey et al. 2010; Brown et al. 2011).
Verreck et al. (Verreck et al. 2005; Verreck et al. 2006b; Verreck et al. 2007) used
foamed extrudates to improve the milling efficiency of HME products. The studies were
carried out using a pure polymer excipient (i.e. placebos) (Verreck et al. 2006b), and two
polymer-API pairs (Verreck et al. 2005; Verreck et al. 2007). Compounding and foaming
was carried out in an 18 mm co-rotating TSE, employing CO2 as PBA. The milling
efficiency was determined by grinding 25 g of each extrudate for 30 s with a Bamix
blender; the resulting particle size distributions were determined through a vibrating sieve
method. In all cases, the particles produced by grinding foamed extrudates had smaller
measured average particles size, higher porosity and bigger specific surface area than the
particles produced from un-foamed extrudates, thus, improving the milling efficiency of
drug products.
In the cases of the polymers alone (Verreck et al. 2006b) and the Itraconazole /
EC binary system (Verreck et al. 2007), API release rates of milled foams were faster
than that of the ground un-foamed extrudates.

Faster API release rates were a

consequence of smaller particle size with higher surface area and porosity.
Surprisingly, for the system Itraconazole / PVP-VA Verreck et al. (Verreck et al.
2005) observed that API release from particles obtained by milling the foamed extrudates
had much slower release rate than the ones obtained from milled un-foamed extrudates.
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Since water absorption was very fast for the milled foams, particle agglomeration took
place slowing the API release rate.
On the other hand, Nagy et al. (Nagy et al. 2012) observed only a slight faster API
release for ground foams compared to the particles produced by milling un-foamed
extrudates. The small enhancement in the in vitro performance was attributed to higher
surface area in the case of the milled foams.
In summary, it has been shown in the literature that the milling process of foamed
extrudates is more efficient than that of un-foamed extrudates, and as expected, it yields
smaller particles with higher surface area and porosity. However, a direct relationship
between particle size distribution and cell size distribution has not been established.
Neither a target nor optimal cell size and density have been defined.
Another application of polymeric foams as intermediate product was explored by
Hsu et al. (Hsu et al. 1996; Hsu et al. 1997).

Lyophilization (i.e. freeze-drying

technology) was used to produce low density open cell foams of PLGA. Then the API
(Isoniazid, INH) was incorporated by immersing the foam in an INH aqueous solution.
Following drying, the drug impregnated foam was compression molded into the dosage
form.

2.3.4 Foams to Increase API Release Rate
One of the challenges of the HME process, which is inherent to the process, is
that the extrudates have very low porosity. This may slow down penetration of body
fluids into the sample and, thus, hinder API release (Andrews et al. 2010). Thus, foaming
could be used to introduce porosity into the matrix and facilitate dissolution.
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Andrews et al. (Andrews et al. 2010) observed that the release rate of Celecoxib
(CX) from PVP, a water soluble polymer, was significantly increased upon foaming; the
time for 100% release was reduced in half . Compounding was carried out in the conical
twin screw extruder MiniLab. Foams were produced through a batch foaming process of
the extrudates employing ScCO2 as PBA. The authors did not provide information
regarding average cell size or foam densities.
Verreck et al. (Verreck et al. 2007) also observed an increase in release rate for
the Itraconazole / EC system upon foaming. By the end of the dissolution test the amount
of API released from the foamed samples was approximately 11-fold higher than that
from un-foamed samples.
Lyons et al. (Lyons et al. 2007) also observed an increase in API release rate by
using foamed samples.

HME and foam extrusion of a ternary system comprising

Carvedilol, Polyethylene oxide (PEO) and EPO was carried out in a 16 mm co-rotating
twin screw extruder, with CO2 as the PBA. However, the morphologies of the cellular
structures produced were not shown or analyzed.
Since API’s release rate can be increased by foaming, then this process could be
used in the manufacture of orally disintegrating dosages (ODT). These types of dosages
must disintegrate within 30 s in the buccal cavity (FDA 2008) and are of great interest in
pediatrics or for adults when swallowing is difficult (Clarke 2005; Banbury and
MacGregor 2011). Commercially used ODT manufacturing techniques based on freezedrying technology include: Zydis®, Lyoc®, QuicksolvTM and Pharmafreeze (McLaughlin
et al. 2009; Badgujar and Mundada 2011; Banbury and MacGregor 2011). Freeze-drying
technology results in highly porous open cell structures with extremely fast disintegration
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times; in the case of dosages manufactured by Zydis® technology this has been reported
to be between 0 and 2 s (McLaughlin et al. 2009). However, this technology has some
limitations in terms of drug loading and friability of the dosage form (McKelvey et al.
2010; Badgujar and Mundada 2011).
McKelvey et al. (McKelvey et al. 2010), explored the used of foam injection
molding to produce fast dissolving dosage forms for pediatric applications. The in vitro
dissolution performance of the foamed dosage forms was compared to conventionally
compressed tablet.

The authors found that through foam injection molding it was

possible to attain the same dissolution performance as compressed tablets, but with a 40
% smaller dosage. However, the release times were not in the 30 s requirement for ODT
applications.
Clarke also proposed the use of foam injection molding to produce these “flashdissolving” dosage forms (Clarke 2005).

Similarly, the patent by Breitenbach and

Baumgartl (Breitenbach and Baumgartl 2000) proposes the use of foam extrusion process
to produce “flash-dissolving” foamed dosages. As an example the authors reported that
API release was 30-fold faster upon foaming. The model API used was Ibuprofen and
the carrier in a mixture of PVP and PVAc (Polyvinyl acetate); ScCO2 was used as the
PBA.

2.4 Brief Overview on the Applications of Supercritical Fluids in the Pharmaceutics
Since many of the foaming processes described here use ScCO2 as the PBA it is of
interest to briefly review the applications of supercritical fluids in pharmaceutical
applications. Some of its applications include: gas anti-solvent crystallization (GAS or
SAS) and particle manufacture.
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The use of ScCO2 for the GAS process is shown schematically in Figure 2.8.
Through this technology the API is first dissolved in a good solvent, then the supercritical
fluid is injected enabling API crystallization and as a result it precipitates; then, the
system is drained and the crystals are dried (Moribe et al. 2008; Brittain 2009). Other
anti-solvent approaches include: SEDS, solution-enhanced dispersion by supercritical
fluids; and ASES, aerosol solvent extraction system (Moribe et al. 2008). These antisolvent processes have been used to produce specific API polymorphs and particles
composed of an API and a polymeric excipient (Sethia and Squillante 2004; Davies et al.
2008; Moribe et al. 2008).

Figure 2.8 Schematics describing gas anti-solvent crystallization (GAS) process. Source:
(Brittain 2009)

Other processes that use supercritical fluids are rapid expansion of supercritical
fluid (RESS) and particles from gas-saturated solutions (PGSS). In both cases the API is
dissolved in the supercritical fluid followed by depressurization as the fluid is sprayed
through a nozzle producing drug particles. These techniques are used as a means to
reduce API particle size, manufacture of nanoparticles and induce API polymorphic
changes (Davies et al. 2008; Moribe et al. 2008).

CHAPTER 3
EXPERIMENTAL

3.1 Materials

3.1.1 Active Pharmaceutical Ingredients (APIs)
Two model Active Pharmaceutical Ingredients (APIs), Indomethacin (INM) and
Carbamazepine (CBZ) were evaluated. Their chemical structures are presented in Figure
3.1 and a summary of their properties in Table 3.1.
(a)

(b)
O
Cl
N
O

HO

NH2

O
O

Figure 3.1 Chemical structures of: (a) INM and (b) CBZ.
INM, purchased from Spectrum Chemical and Laboratory Products (Gardena,
CA), is an acidic nonsteroidal anti-inflammatory drug (NSAID), with pKa value of 4.5
(Yazdanian et al. 2004). The carboxylic group gives INM the capacity to form hydrogen
bonds with itself and with other molecules. Due to the ionizable character of carboxylic
group its solubility in aqueous solution is pH-dependent, being extremely low (1 mg/L) at
a pH 1.2 and higher at neutral or slightly basic pH (1300 mg/L at pH 7.4) (Yazdanian et
al. 2004).
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Table 3.1 Summary of Some of the Properties of INM and CBZ
Property
INM
Melting temperature [°C]

CBZ

Polymorph dependent

Polymorph dependent

46.3±0.1

53c-56d

357.79

239

Solubility parameter [MPa1/2]

22.1a

26.2

LogP

3.4b

2.3b

Glass transition temperature [C]
MW [g/mol]

Source: a(Forster et al. 2001), b(Wishart et al. 2012), c(Patterson et al. 2005), d(Li et al. 2000)

INM can exist in either of two crystalline polymorphic forms (namely -form and
-form) or in the amorphous state. -INM is the most stable form, while -form and
amorphous INM are metastable; the latter being the less stable state.

However,

crystallization of INM from its amorphous state into either γ or  forms is very slow and
temperature dependent; furthermore, it may exist as a glass by itself for several days
(Andronis and Zografi 2000). Table 3.2 summarizes the properties of its two crystalline
forms; the differences in density and melting behavior result from the differences in
molecular packing within their unit cells. In the case of -INM two molecules are packed
in the unit cell by forming cyclic dimmers through hydrogen bonds between carboxylic
groups. On the other hand, three molecules are packed into each unit cell in - INM
(Taylor and Zografi 1997; Andronis and Zografi 2000). Since molecular interactions are
weaker due to looser packing in the latter case; thus -INM has lower melting point and
melting enthalpy.
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Table 3.2 Main Properties of the Two Crystalline Forms of INM
Property
- INM
- INM
Melting temperature [°C]

161*

155

Melting Enthalpy [J/g]

116*

91

Density [g/cm ]

1.37

1.43

Crystal system

triclinic

monoclinic

3

Source: (Andronis and Zografi 2000). *Experimentally determined values in
this dissertation

Carbamazepine (CBZ), kindly donated by BASF, was also used as model API.
This drug substance is used as anticonvulsant to treat epilepsy and trigeminal neuralgia
(Matsuda et al. 1994; Rustichelli et al. 2000; Brittain 2009). CBZ has been reported to
have several polymorphs: triclinic, trigonal, and two monoclinic forms (Otsuka et al.
1999; Rustichelli et al. 2000; Ugaonkar et al. 2007; Brittain 2009), their differences are
summarized in Table 3.3. Solid-solid transitions between polymorphs can occur upon
heating (Lowes et al. 1987; Rustichelli et al. 2000; Brittain 2009). Among all forms,
monoclinic CBZ with four molecules per unit cell is the most stable form at room
temperature (Brittain 2009); it also provides the highest bioavailability (Kipouros et al.
2006).
Table 3.3 Summary of CBZ Polymorphs and their Properties
Crystal System
Property

Tm [C]
Molecules in unit cell
Density [g/cm3]
Source: (Brittain 2009)

Triclinic

Trigonal

p-Monoclinic

c-Monoclinic

192

183

176

Not reported

4

18

4

8

Not reported

1.235

1.35

1.31
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CBZ is considered a BSC Class II API (i.e. a low solubility, high permeability
compound) (Sethia and Squillante 2004). Its solubility in water is limited (170 mg/L at
25C) and is reported to have a low absorption rate when administrated orally due to its
slow dissolution rate (Moneghini et al. 2001; Ugaonkar et al. 2007).

3.1.2 Polymer Excipients
Two polymer excipients are used in this study Soluplus® (PVCap-PVAc-PEG) and
Eudragit® EPO. Their chemical structures are presented in Figure 3.2 (a) and (b),
respectively, and a summary of their properties is presented in Table 3.4.
(a)

HO

(b)
CH3
O

CH3

CH3

O
N

O

O

O

O

l

n

CH3

m

N

O

H3C

O

O

O

O

O

C4H9

CH3

n

HO

Figure 3.2 Chemical structure of: (a) Soluplus® and (b) Eudragit® EPO.
PVCap-PVAc-PEG, donated by BASF (Tarrytown, NY), is an amorphous
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (molar
ratio 57:30:13) (Kolter et al. 2010). Polyethylene glycol (PEG) is the backbone while
polyvinyl caprolactam (PVCap) and polyvinyl acetate (PVAc) are the branches. Even
though it is a graft copolymer it is reported to have a single glass transition temperature
(Tg) at 73  2C.
This polymer was specifically developed by BASF as polymeric excipient to be
used in pharmaceutical HME. It has pH independent solubility in aqueous solution, and a
critical micelle concentration of 7.6 mg/L (BASF 2010).

Its capability of forming
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micelles at temperatures close to body temperature (37 C) results from the PVCap
branches; the lower critical solution temperature of this polymer in water can be tailored
by its molecular weight (Meeussen et al. 2000). Since PVCap-PVAc-PEG is capable of
acting as a surfactant (by forming micelles in aqueous solution) it can increase the
apparent solubility of numerous APIs such as Carbamazepine, Griseofulvin, Cinnarizine,
Clotrimazole, and Estradiol, among others (Hardung et al. 2010) and therefore prevent
drug precipitation after release. In addition, it has the potential to solubilize, during
HME, multiple drugs with diverse functional groups due to its dual lipophilic and
hydrophilic character.
Table 3.4 Summary of Some Important Properties of PVCap-PVAc-PEG and EPO
Material
Property
PVCap-PVAc-PEG

EPO

Tg [˚C]

732

44.6±0.9

Tm [˚C]

-

-

Melting enthalpy [kJ/mol]

-

-

Onset degradation temperature in N2 [˚C]

300

276b

Onset degradation temperature in dry air [˚C]

293

-

Solubility parameter [MPa1/2]

19.4a

18.53 b

~118,000 a

47,000 b

1.0819

1.09c

0.6

-

MW [g/mol]
Density [g/cm3]
Bulk density [g/cm3]
Source: a (Kolter et al. 2010), b(Liu 2010), c(Ha 2011),

EPO, donated by Evonik Degussa (Piscataway, NJ), is an amorphous cationic
thermoplastic

poly(butyl

methacrylate-co-(2-dimethylaminoethyl)

methacrylate-co-
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methyl methacrylate) with molar ratio 1:2:1. This polymer has pH dependent solubility
in aqueous media; while soluble in acid conditions, at pH above 5.0 it only swells and is
permeable but does not dissolve (Rowe et al. 2009). Therefore, this excipient is a great
candidate for taste masking applications - since it will not dissolve in the buccal cavity and for targeting API release to the stomach.

3.1.3 Carbon Dioxide (CO2)
Supercritical CO2 (ScCO2) with 99% purity was purchased from GTS-Welco (Allentown,
PA). The phase diagram of CO2 is shown in Figure 3.3. Its critical point is 31C and
7.37MPa (Throne 2004; Sauceau et al. 2011).

Figure 3.3 Phase diagram of CO2. Source: (Leitner 2000).

3.2 Sample Preparation

3.2.1 Hot Melt Mixing (HMM)
A particulate physical mixture (PM) of PVCap-PVAc-PEG and 30 wt% of INM was
prepared using a mortar and pestle, and used as the feed material. HMM was carried out
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in a batch mixer Brabender FE-2000 (C.W. Brabender Instruments Inc., South
Hackensack, NJ) with counter- rotating screws operating at 50 rpm, 130 °C for 9 min.
The batch mixer was electrically heated and cooled by air.

3.2.2 Hot Melt Extrusion (HME)
Compounding through HME of the binary mixtures described in Table 3.5 was carried
out in a 16mm co-rotating twin screw extruder, the Nano16, manufactured by Leistritz
(Somerville, NJ). The screws diameter was 16 mm and the length to diameter ratio (L/D)
was 26. The extruder’s barrel is divided into five segments as shown schematically in
Figure 3.4. The feeding zone is water cooled; the remaining zones are electrically heated
and cooled with air. Physical mixtures were fed as powders using a volumetric single
screw feeder. The temperature settings, feeding rates, screw speeds and die size used are
summarized in Table 3.6.
Table 3.5 Composition of the Binary Systems Evaluated
System

Polymer Excipient

API

Polymer : API ratio

S10INM

PVCap-PVAc-PEG

INM

9:1

S30INM

PVCap-PVAc-PEG

INM

7:3

S50INM

PVCap-PVAc-PEG

INM

1:1

S75INM

PVCap-PVAc-PEG

INM

25:75

S15CBZ

PVCap-PVAc-PEG

CBZ

85:15

EPO30INM

EPO

INM

7:3

The screw elements of the Nano 16 have a tri-lobal design, with outer to inner
diameter ratio (OD/ID) of 1.18. As shown in in Figure 3.4 the screw configuration used
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consisted of only forward conveying elements with one mixing zone of 30 conveying
kneading blocks located at 15 L/D.

Figure 3.4 Schematics of the screw configuration used for HME. GFA = conveying
fully-intermeshing element x-yy-zz (x = number of flights, yy = pitch, zz = element
length in mm). KB =kneading block x-y-zz-vv (x = number of kneading segments, y =
number of flights, zz = length in mm, vv = phase angle of the individual kneading
segment). See Appendix A for more details on the screw elements.

Table 3.6 Summary of the HME Conditions Used
Temperature [C]
System

Screw Speed Feeding Rate Die Diameter

T1

T2

T3

Tdie

[rpm]

[g/min]

[mm]

S+INM*

120

130

130

138

200

4.7

1

S15CBZ

120

130

130

125

100

4.5

2

EPO30INM

110

130

140

138

200

3.3

2

*S10INM, S30INM, S50INM and S75INM
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3.2.3 Compression Molding
After HMM and HME the processed materials were milled in a laboratory coffee grinder
and molded into disks by compression molding. Four different dimensions were used
through the study: 5 x 1 mm (HMM samples), 19 x 0.3 mm (release mechanism
studies, HME samples), 16 x 1 mm (effect of foam morphology on release/dissolution
rates, HME samples) and 25.4 x 1mm. In all cases the following molding cycle was
used: 1 min at molding temperature without load, 3 min at molding temperature under
load and finally 2 min cooling under load. The molding temperatures and loads used for
each binary system are summarized in Table 3.7.
Table 3.7 Compression Molding Conditions Used
Temperature

Load

[C]

[kN]

S30INM (HMM)

100

44

5 x 1

S30INM (HME)

120

44

16 x 1, 19 x 0.3 & 25.4 x 1

EPO30INM

100

44

19 x 0.3

S15CBZ

100

44

19 x 0.3

PVCap-PVAc-PEG

100

44

16 x 1

Binary system

Disk Dimensions [mm]

3.2.4 Batch Foaming
Compression molded disks were foamed through a batch foaming process employing
ScCO2 at 10.34 MPa as the physical blowing agent (PBA). The experimental apparatus
used is schematically shown in Figure 3.5. The compression molded samples were
placed inside the mold cavity which was already preheated to the foaming temperature;
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air in the cavity was evacuated using a vacuum pump for 4 min.

Following the

application of vacuum, the PBA was injected into the vessel’s cavity and the system was
pressurized for pre-established dwelling times to allow for the dissolution of the PBA in
the polymer/API disk. Then, the pressure in the cavity was suddenly released, abruptly
causing a thermodynamic instability which induces very rapid cell nucleation. Foaming
temperatures and dwelling times for each of the sample sizes used are summarized in
Table 3.8. It should be mentioned that the mold was not cooled during depressurization.
Also due to the hygroscopic character of the polymer excipients, all the samples were
dried under vacuum at 60 C for 12 h prior to foaming.

Figure 3.5 Schematic representation of the batch foaming device.

Table 3.8 Batch Foaming Conditions Used
Foaming Temperature
Disk dimensions
System
[mm]
[C]

Dwelling Time
[min]

PVCap-PVAc-PEG

16 x 1

90

15

S30INM

16 x 1

100

S30INM

19 x 0.3

100

15

EPO30ONM

19 x 0.3

95

15

S15INM

19 x 0.3

110

15

15, 30 & 60
(F15, F30 & F60)

40
3.2.5 Foam Extrusion
Compounding and foaming was carried out in a single step through Extrusion Foaming in
a co-rotating fully intermeshing twin screw extruder with screws of 18 mm in diameter
and 40 L/D manufactured by Leistritz (Somerville, NJ). The barrel was equipped with a
die plate having eight capillaries of 0.8 mm diameter for forming eight extrudate strands.
Excipient and crystalline INM particulates were independently fed using two feeders.
Their feeding rates were set so as to produce foamed extrudates containing 30 wt% of
drug loading. As shown in Figure 3.6, the extruder barrel was divided in eight zones.
The first one (feeding zone) was continuously cooled with water, while the remaining
seven zones were electrically heated and cooled with air to control their temperature.
The adapter and die were electrically heated. Carbon Dioxide (CO2) was employed as
the physical blowing agent, and it was injected at 5.5 - 5.8 MPa at a barrel position 18
diameters downstream from the feed, as shown in Figure 3.6. The process conditions
studied are presented in Table 3.9.

Figure 3.6 Screw design used during foam extrusion experiments. GFF = conveying
freely cut element, GFA = conveying free-meshing element, GFM = conveying mixing
element x-yy-zz (x = number of flights, yy = pitch, zz = element length in mm). KB
=kneading block x-y-zz-vv (x = number of kneading segments, y = number of flights, zz
= length in mm, vv = phase angle of the individual kneading segment). See Appendix A
for more details on the screw elements.
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The 18 mm extruder screws were bilobal, and as shown in Figure 3.6 the screw
configuration had one reverse conveying element prior to the gas injection site in order to
create a melt hold-up, leading to a fully melt-filled section, which acts as a melt seal to
prevent the pressurized gas escaping through the hopper. The extruder was also equipped
with four mixing zones; the ones prior to the gas injection site were intended to complete
the elementary processing steps of polymer melting, laminar mixing, and dissolution of
API in the melt.

The mixing zones after CO2 injection were designed to promote

dissolution of the gas in the melt and homogenization of the polymer-API-gas system.
Table 3.9 Foam Extrusion Conditions Evaluated

run

Temperature Profile [C]
̇

[kg/h]

w/w %
T1

T2

T3

T4

T5

T6

T7

T8

T9

CO2

(coupler) (die)

1

1

122

135

135

122

101

99

96

96

115

12

2

1.5

122

140

140

130

115

90

90

90

118

4

3.2.6 Milling of Extrudates
Foamed and un-foamed extrudates of the binary mixtures S30INM were milled in a
laboratory coffee grinder. Batches of 20 g were ground for 25 s and collected for further
analysis.
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3.3 Characterization

3.3.1 Thermogravimetric Analysis (TGA)
The thermal stability of APIs and excipients was studied through TGA in a TA
Instruments Q50 Thermogravimetric Analyzer (New Castle, DE). Two different studies
were performed: ramp heating tests and isothermal tests. In the ramp heating studies,
5 – 10 mg of material was placed in an open aluminum pan, and heated from room
temperature up to 550 ˚C at a heating rate of 10 ˚C/min, and recording the sample weight
loss continuously. For the isothermal study, 5 - 10 mg of material in open aluminum
pans was heated at 10 ˚C/min from room temperature to a desired-established
temperature and held isothermally for 60 min, again recording sample weight loss
continuously. Both ramp and isothermal TGA studies were conducted in a dry air
atmosphere by purging the chamber with air at a flow rate of 40 mL/min.

3.3.2 Differential Scanning Calorimetry (DSC)
DSC analyses were carried out in a TA Instruments Q100 (New Castle, DE) equipment.
Between 5 and 10 mg of material was placed in closed/sealed aluminum pans. Heating
and cooling scans were performed at 10 C/min between 0 and 165 C. Samples were
held isothermally for 3 min at 0 C prior each heating scans in other to stabilize the
temperature of the samples, and before the cooling scans a 3 min isothermal at 165 C
was used to erase thermal history of the material. Throughout the study, the equipment’s
chamber was blanketed with nitrogen (N2) gas at a flow rate of 40 mL/min. Due to the
hygroscopic character of the PVCap-PVAc-PEG, all samples containing this excipient
were dried in a vacuum oven for 12 h at 60C prior to DSC analysis.
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First heating thermograms were used to assess the state of the APIs prior to
processing and after undergoing different processing steps. Second heating thermograms
were employed to evaluate the thermal properties of the materials after erasing their
thermal history.

3.3.3 Modulated Temperature Differential Scanning Calorimetry (MTDSC)
MTDSC was carried out in a TA Instruments Q100 (New Castle, DE) equipment.
Between 5 and 10mg of material was placed in closed aluminum pans. Samples were
heated from 0 to 180 C at 2 C/min with a 60 s temperature modulation period and 
1.25 C amplitude. Throughout the study, the equipment’s chamber was blanketed with
nitrogen (N2) gas at a flow rate of 40 mL/min.

3.3.4 Polarized Optical Microscopy (POM)
Polarized light optical microscopy was used to evaluate the presence of crystalline API
after compounding. Samples drawn from the batch mixer and extrudates were observed
with a Carl Zeiss microscope (Thornwood, NY) equipped with a digital camera Zeiss
AxioCam MRc5 (5 MB-pixel resolution).

3.3.5 Fourier Transform Infrared (FT-IR) Spectroscopy
FT-IR analyzes were carried out in a PerkinElmer Spectrum One Spectrometer
(Waltham, MA). Samples were analyzed in the 400 to 4000 cm-1 wavelength region
using Potassium Bromide (KBr) disks.

The KBr disks were prepared by grinding

together crystalline KBr and 1 wt% of sample into fine powders using a mortar and
pestle, and then pressing the mixture into ~1 mm thick disks.
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3.3.6 X-Ray Diffraction (XRD)
XRD analyzes were carried out in a Philips PW3040 X-Ray diffractometer (PANanytical
Inc., Westborough, MA), using Cu K radiation (λ=1.54 Å) generated from a copper
source operating at a power level of 40 KV and 40 mA. Samples were scanned over a 2θ
range between 5 and 30. Pure PVCap-PVAc-PEG and EPO were analyzed using disks
prepared by compression molding; all other samples were analyzed while in powder
form.

3.3.7 Scanning Electron Microscopy (SEM)
The morphology of cross-sections (or fracture surfaces) of foamed and un-foamed
samples, as well as milled extrudates was examined with a LEO 1530 Field Emission
Scanning Electron Microscope (Carl Zeiss SMT Inc., Peabody, MA). The fracture cross
section of the samples was coated with a thin layer of carbon by sputtering to improve the
conductivity and thus allow for the SEM images. The image processing software ImageJ
was used to measure the cell sizes and wall thicknesses.

3.3.8 Particle Size Distribution (PSD)
Particle size distributions of milled samples were determined employing a laser
diffraction particle size analyzer Beckman Coulter LS230 (Brea, CA). Analyses were
conducted in the dry state and in triplicate.

3.3.9 In Vitro Dissolution Test
Dissolution tests were carried out in a Distek 2100A USP apparatus (North Brunswick,
NJ) in triplicates. The analyses were conducted at 37.0 ± 0.5C in 900 mL of deionized
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water, pH 7.4 phosphate buffer solution, or pH 1.2 hydrochloric acid buffer solution. At
pre-established time intervals 5 mL samples were withdrawn from the dissolution
medium, filtered through polyvinylidene fluoride (PVDF) filters with pores size of
0.45 μm. Samples were then analyzed using a 10 mm quartz cell and an Agilent 8454
UV Spectrophotometer (Foster City, CA). The concentration of API or polymer in the
solution was determined through a UV absorbance calibration curve. A summary of the
in vitro dissolution test conditions used for the different samples is presented in
Table 3.10.
It should be mentioned that the filters were not used during the dissolution tests of
pure PVCap-PVAc-PEG; the polymer was trapped in the filter and no signal was
observed during the UV analysis. In addition “sinkers” were used in the case of samples
that showed tendency to float to assure full sample immersion.

Table 3.10 Conditions Used for the In Vitro Dissolution Tests
Dosage
Sample description
Strength [mg]

Apparatus

Agitation

Dissolution

UV wavelength

Type

Speed [rpm]

Medium**

[nm]

240*

Paddle

50

Deionized water

201

PM S30INM in capsules

24

Basket

100

pHs 1.2 and 7.4

268

HMM S30INM (un-foamed and foamed disks)

24

Basket

100

pHs 1.2 and 7.4

268

INM in capsules

24

Basket

100

pHs 1.2 and 7.4

268

HME S30INM (un-foamed and foamed disks)

72

Paddle

50

pH 7.4

319

HME S30INM (un-foamed and foamed disks)

35

Paddle

50

pH 7.4

319

INM in capsules

25

Paddle

50

pH 7.4

319

Milled HME S30INM in capsules

25

Paddle

50

pH 7.4

319

Milled foamed extruded S30INM

25

Paddle

50

pH 7.4

319

HME S15CBZ (un-foamed and foamed disks)

16

Paddle

50

Deionized water

284

33

Paddle

50

pHs 1.2 and 7.4

319

PVCap-PVAc-PEG (un-foamed and foamed
disks)

HME EPO30INM (un-foamed and foamed
disks)

*Reported weight corresponds to PVCap-PVAc-PEG’s not to API. ** pH 1.2 corresponds to a hydrochloric acid buffer solution and pH 7.4 to a phosphate buffer
solution.
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3.3.10 Extrudate Content Uniformity
Content uniformity of the extrudates was evaluated by determining the concentration of
INM in five randomly collected samples of each particular extrudate.

Samples of

16 - 30 mg were placed in a 100-mL volumetric flask containing 10 mL of methanol and
shaken until the extrudate was completely dissolved. Then the solution was diluted to the
100 mL volume with a pH 7.4 phosphate buffer solution. The API loading in the
extrudates was calculated based in the concentration of INM in the solution. The latter
was determined by UV spectroscopy at 319 nm using an absorbance calibration curve as
mentioned in section 3.3.9 above.

3.3.11 Solubility of CO2 in S30INM
Solubility measurements of CO2 in S30INM were performed using HME and
compression molded samples of 25.4 x 1mm. Two high pressure steel vessels with
45 cm3 cavities, as shown in Figure 3.7, were used to saturate the samples with CO2 for
24 h at different pressures and temperatures. The vessels were heated in an oven; oven
temperature and pressure in each vessel were measured and recorded continuously during
gas saturation. Samples were weighed and placed inside vessels preheated to the test
temperature; air in the system was evacuated using a vacuum pump for 4 min. Following
the application of vacuum, CO2 was injected into the vessels’ cavities and the system was
pressurized. After 24 h of saturation, the vessels were depressurized and the samples
extracted and weighed immediately. It should be mentioned that samples did not foam at
any of the temperatures and pressures used, otherwise excessive gas loss would have
occurred due to diffusion.
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Figure 3.7 Drawing of the high pressure vessels used for the CO2 solubility
measurements (Faridi and Todd 2007).

3.3.12 Long Term Physical Stability of the S30INM Binary System
The six month stability of the binary system S30INM was determined in open containers
at 75 % RH and room temperature.

Un-foamed compression molded disks of

16 x 1 mm and the corresponding foamed samples produced with dwelling times of 15,
30 and 60 min (F15, F30 and F60, respectively) were evaluated.

CHAPTER 4
RESULTS AND DISCUSSION

4.1 Solubility of INM in PVCap-PVAc-PEG
One of the objectives of this research is to gain fundamental understanding of the effects
of the foaming process and cellular structure on the performance of amorphous solid
solutions. Therefore, it is important to have a good understanding of the miscibility and
solubility of the API in the polymer excipient, in order to assure that the binary system
evaluated is a solid solution and not a solid dispersion.
The binary system comprising INM and PVCap-PVAc-PEG is expected to be
miscible. The solubility parameter approach and criterion, although it has its limitations,
suggests that this system is likely to be miscible. The difference in solubility parameters
(Δδ) between INM and PVCap-PVAc-PEG is 2.7 MPa1/2. In general the smaller this
difference the higher the probability for a given API-polymer pair to be miscible.
Specifically, Greenhalgh et al. (Greenhalgh et al. 1999) proposed that miscible systems
have a Δδ between 1.6 and 7.5 MPa1/2, Forster et al. (Forster et al. 2001) on the other
hand stated more conservatively that Δδ has to be less than 2.
In addition to the solubility parameter approach, by analyzing the chemical
structures of INM and PVCap-PVAc-PEG [see Figures 3.1 (a) and 3.2 (b)] it is evident
that these two molecules are capable of forming hydrogen bonds. The possibility of
specific interactions between API and polymer could potentially facilitate drug
dissolution in the polymer and furthermore provide shelf life stability to the binary blend.
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INM has one proton donor (a hydrogen atom) and two proton acceptors (two oxygen
atoms) in the carboxylic group. PVCap-PVAc-PEG has several proton acceptors capable
of forming hydrogen bonds; oxygen atoms are available along the PEG backbone (see
Figure 4.1 a) as well as along the branches of PVAc and PVCap (see Figures 4.1 b and c,
respectively). Additionally, a nitrogen atom is also present on the PVCap braches but is
most likely not accessible due to steric hindrance. In addition, by comparing the dipole
moments of the bonds containing the proton acceptor atoms in the polymer (see Table
4.1) it is evident that the most favorable sites are the oxygen atoms forming double bonds
with carbon (C=O) along the branches of PVCap and PVAc, followed by the other
oxygen atoms in the PVAc branches and along the PEG backbone. A bond with larger
dipole moment has a higher polarity and is thus more prone to donate or accept the
positive charge or proton. This will also result in stronger hydrogen bonding. The effect
of hydrogen bonding between INM and PVCap-PVAc-PEG on API release is presented
in section 4.2.1.
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Figure 4.1 Possible hydrogen bonds between INM and the different blocks of PVCapPVAc-PEG terpolymer. (a) INM and PEG backbone, (b) INM and PVAc branch, and (c)
INM and PVCap branch
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Table 4.1 Dipole Moments of Bonds of the Proton Donors and Acceptors in INM and
PVCap-PVAc-PEG
Bond
Bond Dipole Moment [D]
C=O

2.4

C-O

0.86

C-N

0.22

H-O

1.53

Source: (Wade 1993)

The solubility of INM in PVCap-PVAc-PEG is evaluated through binary blends
with drug loadings of 10, 30, 50 and 75 wt% prepared through HME and designated
S10INM, S30INM, S50INM and S75INM, respectively. The morphological state of the
API in the extrudates is determined by combining three characterization techniques
described in the previous Chapter: POM, DSC and FT-IR. Since each technique has its
own limitation and/or level of sensitivity in detecting the crystalline content, several
techniques are combined in order to have a higher level of confidence regarding the
morphological state of INM after HME. For example: POM is limited by the resolution
of the microscope, which is diffraction-limited and thus features smaller that light’s
wavelength cannot be detected using this technique (Campbell et al. 2000). In the case of
DSC, Leuner and Dressman (Leuner and Dressman 2000) observed the lowest detection
limit for residual crystallinity is ~2 %.
POM allows detecting the presence of crystals in a sample through birefringence.
Through this technique a specimen is placed between two polarizing plates oriented
perpendicularly to each other resulting in no light transmission and a dark field.
However, in the presence of a preferential orientation of the polymer chains, residual
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stresses or two or more phases with different refractive indices, the light is scattered and
bright spots or color fringes are evident (Campbell et al. 2000). Figure 4.2 shows the
POM images of the extrudates containing 10, 30, 50 and 75 wt% of INM loading.
Among all the samples bright particles are only visible throughout the highest API
concentration sample, i.e. the S75INM.

These bright particles correspond to INM

crystals, suggesting that only S75INM extrudates have residual crystallinity after HME.
In other words, INM was fully dissolved in PVCap-PVAc-PEG in the S10INM, S30INM
and S50INM extrudates, but not in S75INM.

(a)

(b)

(c)

(d)

Figure 4.2 POM images of four HME extrudates: (a) S10INM, (b) S30INM, (c)
S50INM and (d) S75INM
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FT-IR spectroscopy has been widely used to differentiate between drug
polymorphs with high precision (Matsuda et al. 1994; Taylor and Zografi 1997; Otsuka et
al. 1999; Rustichelli et al. 2000; Brittain 2009). As other spectroscopic techniques FT-IR
allows the identification of different API polymorphs through shifts in the absorption
frequency of specific functional group within the compound. These changes are caused
by the intra-molecular coupling effect (i.e. interaction between vibrating groups)
(Campbell et al. 2000). Packing or spatial arrangement of the API molecules differs
among crystalline polymorphous and amorphous state, resulting in slight changes in the
environment of a given functional group. Thus, the interactions between vibrating groups
differ and hence the position of the absorption peak varies. In the case of INM, as
summarized in Table 4.2, the locations of the absorption peaks of C=O in the carboxylic
and benzoyl groups allow to clearly differentiate between amorphous, γ-INM and α-INM
(Taylor and Zografi 1997).

Table 4.2 FT-IR Positions and Assignments of INM Characteristic Absorption Peaks
Position of the Absorption Peaks [cm-1] for
Assignment
γ-INM
α-INM
Amorphous INM
Asymmetric stretching of hydrogenbonded acid C=O in a cyclic dimer
Asymmetric stretching of hydrogen
bonded hydrogen-bonded acid C=O
Stretching of non-hydrogen bonded acid
C=O
Stretching of benzoyl C=O

1717 s
-

1681 sh
1649 w

1710 sh
-

-

1735 w-m

1735 sh

1692 s

1688 s

1684 s

s = strong, m = medium, w = weak, sh = shoulder. Source: (Taylor and Zografi 1997)
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Figure 4.3 shows the FT-IR spectra of the four physical mixtures (PM) and the
corresponding extrudates of S10INM, S30INM, S50INM and S75INM. By comparing
the spectra of crystalline INM (γ-INM) with those of the physical mixtures
[Figure 4.3 (a)], it is evident that in all cases INM is crystalline and in its γ-form. In all
PMs, two sharp peaks can be clearly observed at 1692 and 1718 cm-1. These peaks
correspond to the benzoyl group stretching vibration and asymmetric stretching vibration
of hydrogen-bonded acid C=O in a cycle dimer, respectively (see Table 4.2). In addition,
the intensity of the peaks associated with INM increases with respect to the peaks
associated with PVCap-PVAc-PEG as APIs concentration is increased. In S50INM and
S75INM the absorption peaks of the polymer are no longer visible.
(a) Physical Mixtures
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Figure 4.3 Comparison of the FT-IR spectra of the binary systems S10INM, S30INM,
S50INM and S75INM: (a) Physical mixtures and (b) HME extrudate samples. Spectra of
pure PVCap-PVAc-PEG and INM (in its γ-form and amorphous state) are shown as
reference.
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In the case of the HME samples [see Figure 4.3 (b)], the peak at 1692 cm-1
associated with γ-INM is no longer present in S10INM, S30INM and S50INM; but a new
peak appears at 1683 cm-1. This is a clear indication that INM is amorphous in these
samples. The peak at 1683 cm-1 can be observed in the spectrum of amorphous INM in
Figure 4.3 and as indicated in Table 4.2 it corresponds to benzoyl group’s stretching
vibration in amorphous INM.
On the other hand, the spectrum of the S75INM extrudate shows evidence of the
presence of both amorphous as well as crystalline INM. The characteristic peak of
γ-INM at 1692 cm-1 can be clearly seen. In contrast, the peak associated with asymmetric
stretching vibration of hydrogen-bonded acid C=O in a cyclic dimer is observed at
1715 cm-1, which is between the normal wavelengths of amorphous and γ-INM. This
shift is due to the contribution of both forms.
Table 4.3 shows a summary of the DSC-determined thermal properties of the
HME extrudates of the four binary systems. The properties of pure INM and PVCapPVAc-PEG are also shown as reference. Figure 4.4 shows characteristic first heating
thermograms of PVCap-PVAc-PEG and the HME samples S10INM, S30INM, S50INM
and S75INM. In the case of INM, both first heating and second heating thermograms are
shown. From the DSC analysis of the extrudates it is evident that S10INM, S30INM and
S50INM have only one thermal transition during their first heating, corresponding to
their glass transition temperatures. On the other hand, the S75INM extrudate showed two
thermal transitions: a glass transition and endothermic peak in the high temperature
region. These can be seen as an evidence of the presence of two phases, as observed
through POM [see Figure 4.2 (d)].
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Table 4.3 Summary of the Thermal Transitions Determined from DSC First Heating of
the Extrudates (DSC Thermal Analyses Were Performed in Triplicate).
Tedotherm,onset Tedotherm,peak ΔHendotherm
INM loading
Sample
Tg [°C]
[wt%]
[°C]
[°C]
[J/g]
PVCap-PVAc-PEG

0

73 ± 2

-

-

-

S10INM

10

68 ± 1

-

-

-

S30INM

30

62 ± 1

-

-

-

S50INM

50

61 ± 2

-

-

-

S75INM

75

53.0 ±0.2

147.4 ± 0.3

159 ± 1

6.7 ± 0.9

INM

100

46.33 ± 0.07* 159.5 ± 0.2 161.0 ± 0.3

109 ± 5

*Value determined through DSC second heating

Besides S75INM, the only other sample that shows an endothermic peak during
DSC first heating is INM (see Figure 4.4). These endothermic regions correspond to the
melting of crystalline INM.

In the case of pure INM [see Figure 4.4 (g)], the

experimentally determined peak melt temperature is 161.0 ± 0.3 °C, which is in very
good agreement with literature reported values for γ-INM (Otsuka et al. 2001). On the
other hand, during INM melting in the S75INM extrudate, a depression in melting point
is observed (12° and 2 °C depression in the onset and peak melting temperatures,
respectively), as well as lower melting enthalpy compared to pure INM melting (see
Table 4.3). Making the experimentally supported assumption that during the HME
process the solubility limit of INM in the excipient was exceeded, then the depression in
melting point may result from a reduction in size and or quality of the crystalline particles
during HME, as a consequence of INM’s partial dissolution. The lower melting enthalpy
results from a smaller amount of crystalline INM in the samples. It should be noted that
although enthalpy values are normalized by weight, this normalization corresponds to the
total weight of the samples placed in the DSC pans, thus in the case of S75INM, out of
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the total weight of the samples only 75 wt% corresponds to INM and not all of this
amount is in crystalline form after the HME process; at least 66.67 % of INM was
dissolved during processing (which corresponds to 50 wt% of INM loading).
In the case of S10INM, S30INM and S50INM the absence of an endothermic
peak is indicative of the fact that the API was completely dissolved during the HME
process. In addition, the results shown in both Figure 4.4 and Table 4.3 indicate that all
HME extrudate samples have a single glass transition region with Tg values between that
of the polymer and the API. Lower Tg of the extrudates than that of the pure polymer
suggests that INM has been dissolved into the PVCap-PVAc-PEG during melt mixing,
and that it acts as a plasticizer. Additionally, a single glass transition suggests one phase,
thus, an amorphous solid solution.
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Figure 4.4 Characteristic 1st heating thermograms (unless otherwise indicated) of: (a)
PVCap-PVAc-PEG, (b) S10INM, (c) S30INM, (d) S50INM, (e) S75INM, (f) INM (2nd
heating), and (g) INM.
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The effects of incorporating low molecular-weight APIs on a polymer’s Tg have
been widely studied and can be found in the literature (Chokshi et al. 2005; Chokshi et al.
2008; Guo et al. 2010; Liu 2010; Yang et al. 2011). In general, a shift in Tg is expected
when the API is dissolved into the polymeric excipient: on the other hand the polymer’s
Tg will not change if the two compounds are not in one phase and the API remains
crystalline. The effect of dissolved API molecules on a polymer’s Tg can be viewed in
terms of molecular interactions or free volume. The free volume theory assumes that
there is “free space” distributed between polymer molecules and that the free volume
increases with molecular mobility. When a small molecule such as INM dissolves into
the polymer, it increases the free volume among the polymer chains and, thus, the glass
transition temperature of the system decreases (Sears and Touchette 1985; Crowley et al.
2007). From the intermolecular interaction perspective, by dissolving a low molecularweight compound in a polymer, its inter-chain interactions are disrupted and replaced by
new secondary bonds, such as the API-polymer interactions. The mobility of the systems
is altered due to the change of intermolecular interactions, resulting in either an increase
or depression of the Tg (Chokshi et al. 2005; Zhang et al. 2005; Andrews et al. 2008). In
some cases, as observed in the present case for the binary systems of INM and PVCapPVAc-PEG, the glass transition temperatures of the mixtures are lower than that of the
pure excipient (Chokshi et al. 2005; Huang et al. 2006; Chokshi et al. 2008; Qi et al.
2008) (a phenomenon often referred to as plasticization effect). In other cases (often
referred to as anti-plasticization effect), the Tg of the system may be higher than that of
the pure excipient (Guo et al. 2010; Yang et al. 2011) or even higher than both
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components in the formulation (Chokshi et al. 2005; Chokshi et al. 2008; Liu 2010). The
last case may occur when the API-polymer interactions are very strong.
Since DSC results show that INM acts as a plasticizer for PVCap-PVAc-PEG, it
is then expected that as a larger amount of INM is dissolved in the polymer, then the Tg
of the solid solution will decrease further. And as it can be seen in Table 4.3 and
Figure 4.4, as INM’s loading is increased, the Tg of the solid solution is decreased
correspondingly. It is interesting to note that even though 75 wt% of INM is not fully
dissolved during HME, S75INM has a lower Tg than S50INM. This suggests that the
solubility limit of INM in PVCap-PVAc-PEG is between 50 and 75 wt%.
Using the Gordon-Taylor model (see equation 4.1) and Tg values reported in
Table 4.3, it is possible to estimate the solubility if INM in PVCap-PVAc-PEG. This
model has been used to describe and predict the dependence of Tg with composition of
random copolymers, polymer blends (Schneider et al. 1997) and in API-polymer solid
solutions (Chokshi et al. 2005; Chokshi et al. 2008; Malaj et al. 2010).

T

,

=

w T + Kw T
w + Kw

K=

ρ ∆α
ρ ∆α

(4.1)

(4.2)

Where sub-indexes 1 and 2 refer to the components of the blend, Tgi is the glass
transition, wi the weight fractions of component 1 and 2, K is a system specific constant
defined in equation 4.2, ρi is the density at Tg, and Δαi=αmelt-αglass the increase of the
thermal expansion coefficient at Tg.
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Since the Gordon-Taylor model is based on an ideal solution behavior, and, thus,
any kinds of interaction between components are neglected, deviation from the model are
often seen (Schneider et al. 1997; Chokshi et al. 2005; Liu 2010; Malaj et al. 2010).
Therefore the value of K for this system was determined as 1.2 by fitting the
experimentally determined Tgs of pure materials and those of the solid solutions
(S10INM, S30INM and S50INM) in equation 4.1, instead of using equation 4.2. This
approach was also used by Schneider et al. (Schneider et al. 1997), to correct for the ideal
solution assumption. Figure 4.5 shows the experimental data together with the GordonTaylor fitting. Then using equation 4.1 with K = 1.2 and Tg1,2= 53.0 – which corresponds
to the experimentally determined Tg for the S75INM extrudate – the amount of INM
dissolved in this sample is determined to be 71 wt%.
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Figure 4.5 Tg vs. composition of the binary system INM/PVCap-PVAc-PEG. Points
represent experimentally determined Tg values and the dashed line represents the “fit” by
Gordon-Taylor model with K = 1.2.
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In summary, all three characterization techniques (POM, DSC and FT-IR)
indicate that the solubility of INM in PVCap-PVAc-PEG is between 50 and 75 wt%
(most likely 71 wt% as estimated by the Gordon-Taylor equation). In all cases INM was
not fully dissolved in S75INM while in S50INM the API was fully dissolved.

4.2 General Properties of the Binary System S30INM

4.2.1 Effect of pH on INM’s Release
The release profiles of INM from three different dosage forms containing an average of
24 mg of drug loading are presented in Figure 4.6. As described in Chapter 3 (Table
3.10) pure INM and the physical mixture (PM) S30INM are analyzed by filling the
powder into Hydroxypropyl Methylcellulose (HPMC) capsules, while HMM S30INM
samples are analyzed as compression molded disks of 5∅ x 1 mm. In addition, it is
important to note that the INM loaded into the capsules is crystalline – in its γ-form. On
the other hand in the HMM samples INM is amorphous, forming a solid solution with the
polymer excipient. The in vitro dissolution tests are conducted in a pH 7.4 phosphate
buffer solution and in a pH 1.2 hydrochloric acid buffer solution.

The results are

discussed first in terms of the pH and then in terms of the type of sample used.
It can be seen from Figure 4.6 that the release rate of INM is pH-dependent.
Regardless of the type of sample, higher pH leads to faster release rate and a greater
amount of INM been released. In the case of pure INM and PM, the pH-dependence is
due to the ionizable character of the carboxylic group.

Higher percentage of the

carboxylic groups was ionized when pH increases from 1.2 to 7.4.
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Figure 4.6 Release profiles of pure INM in capsules (black circles), physical mixture
(PM S30INM) in capsules (pink triangles), and HMM S30INM sample (green squares) at
pH 7.4 (continuous lines) and at pH 1.2 (dashed lines). Dissolution tests obtained using a
USP apparatus 1, and tests were performed in triplicate.
Similarly to pure INM and the physical mixture, the release profile of INM from
the HMM-prepared samples also shows pH-dependency.

The percentages of INM

released within 1 h at pH 7.4 and 1.2 are 90 % and 0.02 %, respectively. There was no
evident erosion or gel formation at pH 1.2, except for the 5 % weight increase due to
water absorption, after 1.5 h in the buffer solution. It should be mentioned that pure
PVCap-PVAc-PEG is soluble at both pHs. The apparent insolubility of the polymer in
the HMM sample is due to hydrogen bonding between the carboxylic group in INM and
the oxygen atoms in the polymer. The effect of hydrogen bonds on the polymer’s
solubility has been studied for mixtures comprising Polyethylene Oxide and another
polymer that has carboxylic acid functional groups (such as polycarboxylic acid and
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polymethacrylic acid) (Smith et al. 1959; Hemker and Frank 1990; Doseva et al. 1997;
Ozeki et al. 1998; Lele and Hoffman 2000). Both polymers are individually soluble in
deionized water but become insoluble due to hydrogen bonding (Smith et al. 1959; Ozeki
et al. 1998; Lele and Hoffman 2000) once mixed together. However, by increasing the
pH of the aqueous solution, the acid functional groups are ionized and the complex
becomes unstable and the mixture becomes soluble (Smith et al. 1959; Hemker and Frank
1990; Doseva et al. 1997; Ozeki et al. 1998; Lele and Hoffman 2000).
Therefore, as reported for some polymer blends, hydrogen bonding between INM
and PVCap-PVAc-PEG hinders the dissolution of the polymer at pH 1.2. However, once
the pH of the solution is increased above the INM’s pKa (which is 4.5 (Yazdanian et al.
2004)), as is the case at pH 7.4, the interactions between API and polymer are reduced by
ionization of the INM’s carboxylic groups, allowing the dissolution of the system. In
more detail, by describing the ionization of INM in aqueous solution by the reaction
below.
O
R
OH

H2O

O

+

R

O

H

+

-

(4.3)

The acid dissociation constant (ka) can be defined by equation 4.4. Rearranging
equation 4.4, the relationship between pH and the concentrations of INM in various
forms can be obtained according to equation 4.5.

k =

RCOO H
RCOOH

pH = pk + log( RCOO ) − log( RCOOH )

(4.4)

(4.5)
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Where, [RCOO-] and [RCOO] are the molar concentrations of ionized INM and
non-ionized INM, respectively.
Finally, since INM cannot be released from the solid solution until its carboxylic
group is ionized, and thus reducing the polymer-API interaction allowing dissolution of
both components, equation 4.5 is used to estimate the amount of INM that can be
released from the solid solution (i.e. HMM-prepared S30INM) as a function of pH of the
solution. As shown in Figure 4.7, at pH 1.2 only 0.05% of INM can be released, while at
pH 7.4 99.9% INM can be released, which is in agreement with the results presented in
Figure 4.6 for the melt mixed samples.
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Figure 4.7 Expected amount of INM to be released from a solid solution such as the
HMM S30INM sample as a function of pH.
It should be mentioned that strong physical interactions between a drug and a
polymer are in general desirable in HMM/HME products because they help to stabilize
the API in the amorphous state during the shelf life of the product. However, in this case,
the strong physical interactions make it difficult for the polymer to dissolve in acidic
conditions, although the API has been transformed into its amorphous form.
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In addition to the pH effect, Figure 4.6 also shows the impact of different oral
delivery forms. At pH 7.4, the fastest release rate of INM is observed from the HMMprepared compression molded samples, followed by γ-INM in capsules, and then the PM
in capsules. The percentage of INM released in 1 h is 91 ± 3 % from the HMM sample,
65 ± 7 % for γ-INM in capsule, and 37 ± 8 % for the PM in capsule. The fastest release
rate associated with the HMM sample is due to INM been in its amorphous state.
Dissolution of a material in the amorphous state, compared to its crystalline counterpart,
is facilitated by the lack of lattice structure. In the amorphous state the lattice energy
does not have to be overcome in order to dissolve the API (Leuner and Dressman 2000).
In addition, also due to the lack of lattice structure, an amorphous API has a higher free
energy compared to its crystalline counterpart (Bhugra and Pikal 2008), facilitating
dissolution is the former case.
It is important to mention that INM concentration determined through UV
analysis most likely corresponds to only truly dissolved API, since micellar INM was
probably blocked during filtration. When studying the dissolution behavior of PVCapPVAc-PEG, no UV signal of the polymer was observed when the PVDF filters with pore
size of 0.45 μm were used, even though the PVCap-PVAc-PEG is a chromophore. The
dissolution profiles of pure PVCap-PVAc-PEG are presented in section 4.6.2, were
obtained through UV analysis without filtration. This observation suggests that the
PVCap-PVAc-PEG micelles cannot pass through the filter.
In the case of crystalline INM at pH 7.4, after 1.5 h, complete dissolution is not
obtained even though the amount used is significantly below its solubility limit. The
maximum amount of INM dissolved is 18 ± 3 mg/L, while its solubility has been reported
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to be 1300 mg/L at pH 7.4 (Yazdanian et al. 2004). This is due to the slow dissolution
rate of crystalline INM. The remaining un-dissolved INM particles precipitated to the
bottom of the dissolution vessel.
Surprisingly, at pH 7.4 INM release rate from the physical mixture is slower than
that of the pure crystalline INM. Because the PVCap-PVAc-PEG is a surfactant, an
opposite result was expected.

INM is a crystalline powder in both cases and its

difference in the release rate can be attributed to the presence of the polymer. This
phenomenon can be explained through a combination of two factors: polymer gelation
and a low pH micro-environment. Once the physical mixture is wetted by the aqueous
solution, the polymer rapidly forms a gel which encapsulates the crystalline INM
particles.

Because the polymer gel has a much higher viscosity than the aqueous

solution, it slows down the diffusion rates of the solvent and API. In addition, the
microenvironment surrounding the INM particles probably has a slightly lower pH than
the bulk solution. Information appearing in PVCap-PVAc-PEG data sheet from the
manufacturer states that the polymer solution has a pH of 3~5.5. It should be mentioned
that other researchers have incorporated pH controlling additives into their formulations
to generate a specific micro-environment around the API to control its release rate
(Doherty and York 1989; Govindarajan et al. 2006). In some cases the chemical nature
of the API itself is responsible for the slightly different pH of the micro-environment
from that of the dissolution medium (Bruce et al. 2005). In this study, the acidic
microenvironment and the gel caused by the presence of the polymer slowed down the
INM’s release rate. The 5 min delay in the dissolution curves of pure INM and PM
corresponds to the dissolution time of the HPMC capsules.
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4.2.2 CO2 Solubility in the S30INM Binary System
The solubility of physical blowing agents in a polymer is of great importance during
foaming operations. Gas solubility has also a direct impact on the rheological properties
of the material, and thus the morphology and final properties of the foamed product.
Various in-line and off-line methods have been used to measure the solubility of PBA in
polymers.

In-line gas solubility determination techniques are generally based on

viscosity measurements (Todd et al. 1998; Lee et al. 1999; Choudhary et al. 2005) and
optical methods (Zhang and Xanthos 2004; Faridi and Todd 2007). Pressure decay and
gravimetric methods are the most commonly used off-line measurement techniques (Sato
et al. 2001; Tomasko et al. 2003; Faridi and Todd 2007). These methods provide
between 5-7 % accuracy in the solubility determination (Tomasko et al. 2003).
In this study a gravimetric method is used to determine the solubility of CO2 in
the HME-produced binary system S30INM, wherein the amount of gas dissolved is
determined by weight difference of the samples before and after 24 h gas saturation at
various pressures and temperatures. It is important to note that samples are weighed
under ambient conditions, after removing them from the high pressure vessel, in order to
avoid gas loss due to diffusion; thus bubbles are not observed at any of the conditions
evaluated. This methodology has been used by other authors to successfully measure the
solubility of PBAs in different polymers (Faridi and Todd 2007; Brown et al. 2011).
Figure 4.8 shows the measured CO2 solubility in S30INM as a function of
pressure and at three different temperatures.

Two of the temperatures tested are

significantly below the Tg of the binary system, while the third corresponds to the
measured Tg value of the S30INM system (i.e. 62 ± 1 °C, as reported in Table 4.3).
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However, it should be noted that the Tg of the ternary system S30INM containing CO2 is
expected to be lower than that of the binary system S30INM, since it is known that CO2
acts as a plasticizer for many polymers lowering their Tg (Tomasko et al. 2003). Thus, it
can be assumed that these measurements are performed at both above and below of the
system’s Tg.
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Figure 4.8 CO2 solubility (S) in S30INM as a function of CO2 pressures (PCO2) at
different temperatures:  39.6 °C,  52.2°C and  62.9 °C.
Results presented in Figure 4.8 indicate that the solubility increases as the
pressured increases, but decreases as the temperature is increased. The latter is due to
increased mobility of both the gas and solid phases, making it more difficult for the gas to
remain within the solid phase. On the other hand, the pressure dependence of solubility
of gases in polymers is known to follow Henry’s law (Lee et al. 1999; Zhang and
Xanthos 2004; Faridi and Todd 2007; Brown et al. 2011), through the following
expression:

=

(4.6)
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Where S is the volume of gas dissolved at STP (standard temperature and pressure
– 237 K and 1 atm) conditions per unit weight of the S30INM disk [cm3(STP)/g], kp is the
Henry’s Law constant, and

is the saturation pressure.

Values of Henry’s law constant for the CO2 - S30INM ternary system are
calculated by fitting the solubility data with equation 4.6 and are reported in Table 4.4.
These calculated values are of the same order of magnitude with those reported in the
literature for other CO2 - polymer systems not containing APIs (Faridi and Todd 2007;
Brown et al. 2011).

Table 4.4 Calculated Henry’s Law Constant Values for CO2 - S30INM Ternary System
kp [cm3(STP)/g MPa]
Temperature [°C]
39.6 ± 0.9

5.9 ± 0.1

52.2 ± 0.5

4.9 ± 0.1

62.9 ± 0.3

4.17 ± 0.01

Furthermore, the temperature dependence of kp follows an Arrhenius expression
as follows:
=

−

(4.7)

Where kpo is the temperature independent Henry’s law constants, Es is the heat of
solution, T is the absolute temperature and R is the universal gas constant.
Using equation 4.7 to fit the kp values reported in Table 4.4, it is determined that
kpo and Es for CO2 - S30INM are 0.04 cm3(STP)/g MPa and -128.2 L atm/mol K,
respectively. Finally, by combining equations 4.6 and 4.7 the solubility of CO2 in
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S30INM at different temperatures and pressures relevant to foaming processing
conditions can be estimated.

4.3 Crystallization of Amorphous INM in the Presence of ScCO2
As mentioned in Chapter 2, supercritical fluids and especially supercritical CO2 (ScCO2)
have been used to induce polymorphic transitions in APIs (Edwards et al. 2001; Moribe
et al. 2008; Brittain 2009) and as processing aids during manufacture of solid
solution/dispersions by different techniques (Sethia and Squillante 2004; Verreck et al.
2006a; Lyons et al. 2007; Moribe et al. 2008; Nagy et al. 2012). Given that it has already
been established in the literature that ScCO2 is capable of inducing polymorphic changes
in an API, it is relevant to this work to study its effect on the morphology of INM. To
accomplish this, the batch foaming apparatus and process are used to evaluate the
crystallization of INM from its amorphous state. Samples of amorphous INM were
prepared by compression molding at 165°C, and a picture of an amorphous INM sample
can be seen in Figure 4.9 (a).
Amorphous INM samples were heated with and without ScCO2. The samples
heated without ScCO2 were intended to be control samples. Figures 4.9 (a) and (b) show
the effect of temperature on amorphous INM. At 25°C, the samples remain amorphous,
being transparent glasses. But when heated for 15min at 100°C the sample partially
crystallizes.

In contrast, in the presence of ScCO2 the crystallization process is

accelerated as is shown in Figures 4.9 (c) and (d). Even at 25°C, temperature at which
INM can remain amorphous for several weeks (Andronis and Zografi 2000) the sample
became opaque, a strong indication of recrystallization.
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(a)

(b)

(c)

(d)

Figure 4.9 Photographs of INM samples: (a) Initial amorphous INM sample at 25 °C,
(b) sample after heating amorphous INM to 100 °C for 15 min, (c) sample after treating
amorphous INM with ScCO2 at 25 °C and 10.34 MPa for 15 min, and (d) sample after
treating amorphous INM with ScCO2 at 100° C and 10.34 MPa for 15 min.
FT-IR is used to study in more detail the state of INM on each of the samples
shown in Figure 4.9. The spectra for all the samples appear in Figure 4.10. The
spectrum of the sample treated with ScCO2 at 25°C [Figure 4.10 (c)] is a mixture of all
three forms (i.e. amorphous, α-INM and γ-INM). The shoulder observed at 1736 cm-1
and the peak at 1692 cm-1 belong to the amorphous and γ-INM, respectively [see
Table 4.2 and Figures 4.10 (a) and (b)]. The weak band at 1650 cm-1 is due to the
asymmetric stretching of hydrogen-bonded acid C=O in α-INM.

The other peaks

observed correspond to coupling of two forms. For example the one at 1715 cm-1
corresponds to the asymmetric stretching hydrogen-bonded acid C=O in a cyclic dimer
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(see Table 4.2) and is observed between the normal position for the amorphous and
γ-forms; the shift is due to the presence of both species in the sample.
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Figure 4.10 FT-IR spectra of INM: (a) γ-INM, (b) amorphous sample prior to thermal
treatment, (c) INM after treating the amorphous sample at 25 °C with ScCO2 for 15 min,
(d) INM after heating the amorphous sample at 100 °C for 15 min, and (e) INM after
treating the amorphous sample at 100 °C with ScCO2 for 15 min.
Since the sample treated at 100 °C for 15 min [see Figure 4.10 (d)] also resulted
in a mixture of the three forms (amorphous, γ-INM and α-INM), its spectrum is very
similar to the one of the sample treated with ScCO2 at 25 °C [Figure 4.10 (c)]. However,
the relative intensity of the peak is affected and the influence of α-INM becomes more
dominant.

For example: the shoulder at 1736 cm-1 associated with the stretching

vibration of the non-hydrogen bonded acid C=O in amorphous INM, becomes a welldefined peak at 1735 cm-1, which corresponds to the same vibration in α-INM. Another
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change observed is the reduction in intensity of the 1692 cm-1 peak of γ-INM. The
predominance of α-INM in this sample is due to the significantly faster crystal growth
rate of α-INM compared to γ-INM at 100 °C (Andronis and Zografi 2000).
Finally, the sample treated for 15 min at 100 °C with ScCO2 [Figure 4.10 (e)] is
completely crystalline and composed of γ and α-INM. The disappearance of the peak at
1715 cm-1 is evidence of the absence of amorphous INM and predominance of α-INM.

4.4 Foam Extrusion of S30INM Binary System
As mentioned in section 2.3, one of the primary interests of the pharmaceutical industry
in foam extrusion technology is to facilitate the milling operation of HME products.
Currently, the HME process is mainly used to produce intermediate drug products;
however final dosage forms are seldom in the form of an extrudate. In general, the HME
product (i.e. the extrudate) in the vast majority of the cases has to be milled and blended
with other excipients to tailor the product performance and/or to improve tableting
operations. Few exceptions can be found where the final drug product is an HME
extrudate. Only few examples include: NuvaRing, Implanon and Lacrisert® (Zhang and
DiNunzio 2010; DiNunzio 2011). However, these drug products are not oral dosages but
implants or medical devices. Therefore, the objective of this section is to understand the
effect of the morphology of the cellular structure on the milling efficiency of extrudates,
as well as, hopefully, improve the quality of the milled products. By varying the foam
extrusion conditions two foam morphologies were produced and their performance (in
terms of milling efficiency and release rate) was compared to the un-foamed extrudate of
the same composition.
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4.4.1 Cellular Morphology in Foamed Samples
Prior to analyzing and discussing the cellular morphology of the foam-extruded samples
it is important to bear in mind that it was not the objective of this work to perform a
detailed parametric study of the effect of the processing variables on the foam
morphology, which has already been studied by other researchers (Han et al. 2002; 2003;
Kaewmesri et al. 2006; Nagy et al. 2012). However, it is of interest to use the already
existing knowledge to produce different cellular morphologies in order to evaluate the
effect of the cellular morphology on the performance of HME products.
A summary of the properties of un-foamed and foamed extrudates is presented in
Table 4.5. Figures 4.11 and 4.12 show pictures of the extrudates and SEM images of
their cross-sectional surfaces, respectively. The un-foamed samples are designated as
HME, and were produced without injecting CO2 during the HME process. On the other
hand, foamed extrudates (referred to as fHME) were produced by injecting CO2 as PBA
into the extruder during the HME process. As can be seen in Table 4.5, by varying the
concentration of CO2 injected during the foam extrusion process it was possible to
produce foamed extrudates with different densities, and in particular one high density
foamed extrudate (HD-fHME) and a low density foamed extrudate (LD-fHME).

Table 4.5 Summary of the Characteristics of the Un-foamed and the Foamed Extrudates
(HME and fHME, Respectively)
Cell Size
Wall Thickness
CO2 concentration
Density
Sample
[w/w %]
[g/cm3]
[μm]
[μm]
HME

0

1.01 ± 0.05

-

-

HD-fHME

12

0.24 ± 0.05

774-2165

9.8-153.5

LD-fHME

4

0.071 ± 0.004

27-320

0.4-7.7
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(a)

(b)

(c)
Figure 4.11 Photographs of the S30INM extrudates: (a) un-foamed extrudate – HME –
(b) HD-fHME extrudate, and (c) LD-fHME extrudate.
As can be seen in Figures 4.11 (a) and 4.12 (a) the un-foamed extrudates (HME
sample) are non-porous. On the other hand, extrudates produced by foam extrusion (HDfHME and LD-fHME) are porous, as seen in Figures 4.12 (b) and (c). The densities of
the foamed extrudates are 4 and 14 times lower than the density of the un-foamed
extrudates, which corresponds to reduction in density of 76 and 93%, respectively (see
Table 4.5). These reductions in density resulted from the creation of closed cells in both
HD-fHME and LD-fHME extrudates as shown in Figures 4.12 (b) and (c).
Based on the mass flow rates of polymer, API and CO2 fed to the extruder it is
possible to determine a theoretical or minimum density that could be achieved for the
foamed samples. The values reported in Table 4.6 (see Appendix C for the detailed
calculations) allow to give a semi-quantitative understanding of the morphologies of the
extrudates. As can be seen in Table 4.6, in both cases the theoretical density is lower
than the measured density. While in the case of the HD-fHME extrudate the theoretical
density is two orders of magnitude lower than the experimental density; in the case of the
LD-fHME sample the densities are within the same order of magnitude. The latter is
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most likely due to small CO2 losses as the melt flows through the die. In the case of the
HD-fHME sample a significant amount of gas is lost due to flow instabilities as will be
discussed below.

(a)

(b)

(c)
Figure 4.12 SEM images of a cross-sectional surfaces of the S30INM extrudates (100X
in the left column and 500X in the right): (a) un-foamed extrudate – HME –, (b) HDfHME extrudate, and (c) LD-fHME extrudate.
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Table 4.6 Comparison Between the Calculated Ideal Densities and Experimentally
Determined Densities for Foamed Samples
Theoretical
Experimental
QCO2
QS30INM
S30INM
CO2
Density
Density
Sample
[kg/h] [g/min] [cm3/h]* [cm3/h]**
[g/cm3]
[g/cm3]
HD-fHME

1

2

990

120000

LD-fHME

1.5

1

1485

60000

0.008

0.24 ± 0.005

0.024

0.071 ±0.004

3

*Calculations carried out used a density of S30INM as 1.01 g/cm
**Calculations carried out using the density of CO2 at measured melt temperature and 0.101MPa in both
cases it is 0.001 g/cm3 (NIST 2011).

The results summarized in Table 4.5 and the SEM images shown in Figure 4.12
clearly indicate that increasing the concentration of CO2 from 4 to 12 w/w% resulted in a
cellular structure with higher density, bigger cells and thicker cell walls. However, these
results are counterintuitive, since homogenous nucleation theory predicts that higher PBA
concentration leads to higher number of nuclei and therefore more and smaller cells
(Colton and Suh 1987; Han et al. 2002). The opposite trend is observed in the present
case because the gas concentrations utilized are above the estimated solubility limit of
CO2 in the S30INM system (see Table 4.7). It is important to point out that process
instabilities commonly occur when gas concentrations exceed its solubility; as will be
discussed in more detail below.
Figure 4.13 schematically represents the physical aspects of cell nucleation and
growth during a typical foam extrusion process along a capillary die. As shown, the
pressure drop between the die entrance and its exit can be approximated by a linear
pressure drop along the die (Lee 2000). Ideally the gas is fully dissolved in the melt
forming a single phase with the molten polymer as it enters the die. As a result of this
rapid depressurization cell nucleation is triggered, by a drop in gas solubility in the melt
with decreasing pressure. The onset point for nucleation occurs when a critical pressure
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(Pc) is reached; at Pc the gas-polymer systems becomes oversaturated (Han et al. 2002;
2003). Then, once the nuclei reach a critical size (which has been found to be in the
order of 0.3 μm in radius for polystyrene (Lee 2000)) cellular growth takes place through
diffusion of the gas in the bulk toward and into the CO2 bubbles. For a stable process,
nucleation should occur as close as possible to the die exit.

Figure 4.13 Schematic representation of the pressure profile in a capillary die and the
foaming mechanism during a foam extrusion process. Nucleation starts at a critical
pressure (Pc) where the system becomes oversaturated with CO2.
As mentioned above, the processing conditions used lead to gas loadings most
likely above its solubility limit. The estimated solubility values of CO2 in the S30INM
system presented in Table 4.7 are calculated using Henry’s law, with the parameters
determined in section 4.2.2 for the ternary system CO2 – S30INM. The temperature and
pressure values used to calculate the gas solubility correspond to the experimentally
measured values of melt temperature and the die pressure, which are also reported in
Table 4.7. It is important to point out that this estimated solubility values may have
underestimated the gas solubility at the processing conditions, due to higher free space in
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the molten state compared to the “semi-solid” state at which solubility measurements
were performed (at the highest measured temperature the samples were softened but did
not show flow).
Table 4.7 Calculated Solubility of CO2 in the S30INM System at the Processing
Conditions Used
Estimated CO2
CO2 Concentration
Sample
Padie [MPa]
Tmelt [°C]
[w/w %]
Solubility b [w/w %]
HD-fHME

12

102

3.65-3.72

1.85 - 1.88

LD-fHME

4

97

3.03-3.50

1.63 – 1.88

a
b

Maximum and minimum experimental die pressures measured during foam extrusion runs.
Upper and lower solubility limit were calculated using maximum and minimum die pressure values.

In the case of the HD-fHME sample, the amount of gas injected was 12 w/w%,
which exceeds the estimated gas solubility in the S30INM system (1.85 – 1.88 w/w%, see
Table 4.7) at the processing conditions used for this sample. In the case of the LD-fHME
sample, the difference between the amount of gas injected (4 w/w%) and the estimated
solubility is not as significant; the estimated solubility of CO2 at the processing
conditions is 1.63 – 1.88 w/w% (see Table 4.7). Therefore, before depressurization along
the die (which is the driving force for cell nucleation during the foam extrusion process
(Han et al. 2002; 2003)), the gas was not fully dissolved in the melt. Thus, two phases
were most likely present, namely: (1) a homogenous continuous phase foamed by CO2
and S30INM melt, and (2) a dispersed phase containing the CO2 that was unable to
dissolve.

In other words, gas bubbles were already present in the melt prior

depressurization.

As the melt flowed through the die and the pressure drops to

atmospheric conditions (~0.101 MPa) the gas bubbles that were already present in the
melt expanded. Consequently, cellular growth takes place along the die without the need
to go through the nucleation step.
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Carrying out calculations similar to those used for the estimation of the theoretical
densities of the extrudates, it is possible to roughly estimate the volume fraction occupied
by un-dissolved CO2. As shown schematically in Figure 4.14, in the case of HD-fHME
with 12 w/w% of CO2 injected, 10 w/w% remains most likely un-dissolved and, at the
pressure and temperature at the capillary die entrance it occupies 64 % of the volume of
the two phase stream. As the pressure decreases along the die these un-dissolved gas
regions of complex morphology expand, increasing the volume fraction occupied by
them. Moreover, dissolved CO2 will tend to diffuse into these gas regions, due to further
reduction of its solubility in the melt. For example, at a pressure of 1.8 MPa (which
corresponds to approximately half-length of the die – when assuming linear pressure
drop), the amount of un-dissolved CO2 is estimated to be 11 w/w% which corresponds to
81 % of the volume.

The presence of the expanding gas phase promotes axial

acceleration of the melt / CO2 two-phase stream and, because of the very large difference
in viscosities between the melt and the dispersed gas phase, the morphology of the
“blend” is very complex leading to flow instabilities. These favor the escape of CO2
before the stream exits the die, for example, through CO2 “channeling” forming a
continuous streak of CO2 from an upstream location of the capillary die to the exit. Such
“channels” most likely appear at the die-melt stream interphase, since the number of
nuclei per unit volume tends to be much higher toward the extrudate “skin” than along its
core during the foam extrusion process (Lee 2000). As shown in the Optical Microscope
images of HD-fHME in Figure 4.15 open cells can be seen along the edges of the crosssectional surface and on the surface of the extrudates.
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Figure 4.14 Schematic representation of the pressure profile and two-phase melt stream
morphology along the die during foam extrusion of HD-fHME sample. Point A indicates
the entrance to the capillary and point C the capillary exit (or opening of the die to
atmosphere).

(a)

(b)

Figure 4.15 Optical Microscope images of a HD-fHME extrudate: (a) extrudate surface,
and (b) cross-sectional surface.
It should be noted that although the pressure profiles along the die can be
considered linear, during foam extrusion process a positive deviation, as shown by the
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dashed line is Figure 4.14, may prevail. This deviation may be due to two factors: (1)
increase in melt viscosity as the gas diffuses from the melt into the bubble, and (2) higher
gas pressure inside the bubble compared to the melt and local pressure build up,
sometimes referred to in literature as “superheat” (Lee 2000).
In the case of the LD-fHME sample, some of this flow instabilities may also
occur but to a lesser degree. Performing the same calculations described above it was
found that before entering the die only 2.1 w/w% CO2 remains un-dissolved, and this
would correspond to only 29 % of the volume of the melt stream.

Again at

approximately half the length of the die, the amount of un-dissolved gas is expected to be
2.3 w/w% (48 % of the volume). However, as mentioned above, local pressures along
the die are most likely higher than predicted by the linear approximation; thus, the gas
expansion inside the die should be less than estimated. Having this in mind and knowing
that critical nuclei sizes are in the submicron level (Lee 2000), significantly lower gas
losses are expected through the die due to the flow instabilities in the case of LD-fHME
compared to the processing conditions used for the HD-fHME sample, as the semiempirical analysis on the densities also suggests.

In addition, open cells were not

observed along the surface of the LD-fHME extrudates using both SEM and Optical
Microscopy (see Figure 4.16).
Based on the discussion above then it is evident that due to the flow instabilities
which most likely result in extensive gas loss along the die at the processing conditions
used for HD-fHME extrusion, the foam structure resulted in the formation of few and
very big cells ranging from 0.77 to 2.2 mm, as seen in Table 4.5 and Figures 4.12 (b) and
4.15 (b).
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Figure 4.16 Optical Microscope image of the cross-sectional surface of a LD-fHME
extrudate.
Conversely, the processing conditions used to produce the LD-fHME sample
resulted in a more stable process with minimal gas loss.

Therefore, in this case

significantly smaller cells were produced, with sizes in the rage between 27 – 320 μm. In
addition, by comparing Figures 4.12 (c) with (b) it is evident that the LD-fHME sample
has a significantly higher number of cells per unit area than the HD-fHME sample.
It should be mentioned that a foam extrusion condition where the PBA content
exceeds its solubility in the melt would not be used in an industrial manufacturing setting,
since it results in process and product variability. However, further optimization of the
processing conditions used for the LD-fHME samples were not possible due to
equipment and material limitations. On the other hand, HD-fHME samples were used –
notwithstanding the limitations associated with the process – since it provided the
opportunity to compare the performance of a drastically different morphology with
respect to the LD-fHME extrudates, and, therefore, making it possible to observe tangible
differences between the milling and dissolution performance of the two foam
morphologies, as will be discussed below.
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The differences in morphology observed among the extrudates are expected to
affect their milling efficiency, as well as the morphology of the particles produced, and
therefore the in vitro dissolution/release performance of the S30INM system. These
aspects are discussed in detail in the next sections.

4.4.2 The State of INM and Content Uniformity in Foamed Extrudates
Since two independent feeders were employed during the foam extrusion process it is
important to confirm that the drug loading after compounding was in fact 30 wt%. In
addition, by determining the concentration of INM in randomly collected samples for
each condition, it would be possible to detect variability on the drug loading as a function
of time due to either feeding non-uniformities or poor axial mixing by the extruder. As
can be seen in Table 4.8, the experimentally determined amount of INM in the extrudates
is between 28 and 30.4 wt% (30 wt% was the intended and nominal drug loading). In
addition, variability within each processing condition is less that 3.4 % in all cases.
These results reflect good content uniformity and are within the requirements established
in USP Monograph for the different INM’s dosage forms (i.e. capsules, suppositories and
oral suspensions). The monograph states that the content of INM in a dosage form can
not be less than 90.0 % and no more than 110 % with respect to the theoretical amount.

Table 4.8 Determined Drug Loading in the Extrudates Through Content Uniformity
Analysis
Sample
CO2 Concentration [w/w%] INM Concentration [wt %]
HME

0

29 ± 1

HD-fHME

12

28.7 ± 0.6

LD-fHME

4

29.8 ± 0.6
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In section 4.1 it was shown that solubility limit of INM in PVCap-PVAc-PEG is
significantly higher than 30 wt% (with INM’s estimated solubility being 71 wt%).
Additionally, in the same section it was also shown that the S30INM system compounded
in a twin screw extruder is an amorphous solid solution, that is, all of the INM has been
dissolved. However, it is known that gases injected during the extrusion process affect
the properties of the melt. For example, the melt viscosity and surface tension tend to
decrease (Goel and Beckman 1994a; Elkovitch and Tomasko 2000; Lee 2000; Tomasko
et al. 2003; Sauceau et al. 2011). These changes in material properties could potentially
affect the dissolution process of the API in the polymer, because they are translated into
changes in the capillary number of the melt and in the viscosity ratio between materials
been blended; these critical parameters during melt compounding with polymers
(Tomasko et al. 2003; Tadmor and Gogos 2006). For example, Elkovitch and Tomasko
(Elkovitch and Tomasko 2000) observed significant changes in the morphology of a
blend of two immiscible polymers by injecting CO2 during melt compounding. Verreck
et al. (Verreck et al. 2007) observed for some conditions incomplete dissolution of
Itraconazole in Ethyl Cellulose during foam extrusion while complete dissolution was
observed by conventional HME. Another factor that may affect API dissolution is
associated with the necessary changes which have to be made in the process variables to
have successful foam extrusion. Compared to the conventional HME process, during
foam extrusion the melt temperatures needs to be lower in order to provide the necessary
melt strength needed to prevent rupture of the expanding cells during foaming or
consequent collapse of the cellular structure. This reduction in temperature may also be
beneficial and sought when working with thermally sensitive APIs. On the other hand it
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may be detrimental to the dissolution rates and solubility of the API in the excipient.
Additionally, as mentioned before in Chapter 2 in section 2.4, CO2 it is known to act as
anti-solvent for some APIs and also to promote polymorphic transformation of some
APIs.

Specific to INM, in section 4.3, it was shown that CO2 facilitates INM’s

recrystallization from the amorphous state. Therefore, it is important to establish if the
presence of CO2 during HME process, where foamed S30INM extrudates were produced,
affected the dissolution of INM in the excipient. The state of INM in the S30INM binary
blends was analyzed through FT-IR, and the spectra obtained are shown in Figure 4.17.
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Figure 4.17 Comparison of the FT-IR spectra of the un-foamed and the foamed S30INM
systems produced by HME and foam extrusion. Spectra of pure PVCap-PVAc-PEG,
INM (in its γ-form and amorphous state), and physical mixture (PM) are shown as
reference.
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As discussed in detail before in section 4.1, FT-IR allows to accurately
differentiate between amorphous INM, γ-INM and α-INM. In the case of the S30INM
systems, the shifts in the peak associated with the stretching vibration of the C=O bond in
the benzoyl group has shown to be the best indicator to identify the state of INM in the
blends. This peak is not overlapped or affected by peaks associated with the excipient
and it has a strong intensity.
By comparing the location of the benzoyl peak in the extrudates with its location
in the PM and γ-INM, it is evident that in all the extrudates (foamed and non-foamed) the
drug was in amorphous state. This peak is located at 1683 cm-1 in all the extrudates,
while in the samples were INM is crystalline is seen at 1692 cm-1. The first peak
corresponds to amorphous INM while the latter to the crystalline γ-INM (see Table 4.2
and Figure 4.17).

4.4.3 Effect of Foam Cellular Structure on Milling
As described in Chapter 3, milling of the extrudates was carried out in batches of 25 g for
20 s in a laboratory coffee grinder. Figure 4.18 shows the particle size distribution (PSD)
obtained by milling the un-foamed and foamed extrudates. From these results it is
evident that milling of the foamed extrudates lead to narrower PSDs. The PSD of the
ground un-foamed extrudates presented in Figure 4.18 (a) clearly shows a tail of very big
particles, lager than 1.8 mm, which is above the maximum detection limit of the
instrument. A summary of the characteristics of the milled extrudates is shown in Table
4.9. In addition, the morphology of the particles produced can be seen in the SEM
images presented in Figure 4.19.
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Figure 4.18 Particle size distribution (PSD) of the three milled extrudates: (a) ground
HME sample, (b) ground HD-fHME sample, and (c) ground LD-fHME sample.
Combining the results presented in Figure 4.18 and Table 4.9 it is clear that the
smallest particles with the tightest PSD were produced by milling the LD-fHME
extrudate, followed by the HD-fHME extrudate and finally the HME extrudate. As
expected the bulk density of the milled samples follows the same trend as the particle
size, that is, lower bulk density as the particles become smaller with narrower PSD.

Table 4.9 Summary of the Properties of the Milled Extrudates
Sample
Property
HME
HD-fHME
CO2 concentration [w/w%]

LD-fHME

0

12

4

0.69 ± 0.01

0.55 ± 0.01

0.21 ± 0.01

d10 [μm]

72 ± 1

50 ± 6

16.4 ± 0.2

d50 [μm]

296 ± 7

206 ± 10

67 ± 1

d90 [μm]

864 ± 4

574 ± 56

256 ± 13

Bulk density [g/cm3]
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It is interesting to note that the size of the particles produced by milling the LDfHME extrudate tends to be bigger that the cell wall thicknesses measured from the SEM
images of the cross-section of the extrudates. The median particle size was determined to
be 16.4 ± 0.2 μm, while the cell wall thicknesses are in the range 0.4 – 7.7 μm (see
Tables 4.9 and 4.5, respectively). This result suggests that even after milling some of the
cellular structure was retained in the particles. Evidence of this can be seen in Figures
4.19 (e) and (f) where some of the cellular structure is still present although now, after
milling, with open cells; this was also observed by Nagy et al. (Nagy et al. 2012). The
incomplete destruction of the cellular structure could bring additional benefits to the drug
product. On one hand, the presence of cells can potentially aid tableting operations of the
product by facilitating particle deformation during compression of otherwise tough and
brittle particles, and on the other hand, the remaining cellular structure results in particles
with higher surface area thus dissolution rate enhancement is possible.

The higher

surface area of the particles produced by milling foamed extrudates compared to unfoamed ones has also been observed in other HME products (Verreck et al. 2005;
Verreck et al. 2006b; Verreck et al. 2007).
Results shown in Figure 4.18 and Table 4.9 indicate that even though the milled
HD-fHME sample has a “tighter” PSD, at least up to the mean particle size, its
distribution (although with a slight shift to smaller particles) is comparable to the one
obtained for the un-foamed extrudate characterized by a larger particulate size tail, as
seen in Figures 4.18 (a) and (b). In addition, by comparing the SEM images of the
particles obtained from these two samples in Figures 4.19 (b) and (d) it can be seen that
the particles have similar shapes.
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(a)

(b)

(c)

(d)

(e)

(f)

Figure 4.19 SEM images of milled S30INM extrudates. Ground HME sample: (a)
1.00kX and (b) 500X; ground HD-fHME: (c) 1.00kX and (d) 500X; and ground LDfHME: (e) 1.00kX and (f) 500X.
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The improvement in milling efficiency observed for the S30INM system by
utilizing the foam extrusion technology has also been observed for pure excipients and
solid solutions (Verreck et al. 2005; Verreck et al. 2006b; Verreck et al. 2007).
Milling of an extrudate becomes easier upon foaming due to the void fraction in
the foam, which affects the stress levels acting on the material during milling. In a
foamed extrudate the effective area on which an applied force is acting is very small
compared to the same force acting in an un-foamed extrudate. Thus, the effective stress
acting on the extrudate is higher in a foamed sample than in a un-foamed one. In
addition, if the cells are small enough to act as stress concentrators, then the milling
efficiency can be further increased. The same reasoning can be used to understand the
change in milling efficiency between the two foamed samples. On one hand, the LDfHME samples have thinner walls than the HD-fHME samples (two orders of magnitude
difference in the thickest walls, see Table 4.5). On the other hand, the density of the LDfHME extrudate is one order of magnitude lower than in the HD-fHME sample, thus the
former has a significantly higher void fraction. Therefore, the LD-fHME extrudate will
be subjected to much higher stress levels during milling than the HD-fHME extrudates.
Another approach that can be used to understand the effect of foaming and
cellular morphology on the change in milling efficiency is through understanding the
changes in their mechanical properties due to cell morphology. The type of cells (i.e.
open vs. closed cells), cell size, and foam density are known to affect the mechanical
properties of a foam (Shutov 1991; Sun et al. 2002; Wolff et al. 2011). In general, as the
density of the foam decreases, the elastic modulus and the strength of the foam tend to
decrease, thus a foam with lower density is easier to fracture.
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In summary, it is found that the milling efficiency of HME extrudates is increased
through cellular structures.

Foamed extrudates compared to un-foamed extrudates

allowed, under the same milling conditions, to produce smaller particles with a narrower
particle size distribution and lower bulk density. However, by simply introducing some
degree of porosity in the extrudate without actually producing a foamed structure with
closely packed cells and thin walls, the particles produced by milling the extrudate are
very similar to the ones produced by milling an un-foamed extrudate.

4.4.4 Release of INM from Milled Extrudates
The release profiles of INM from HPMC capsules containing an average of 25 mg of
drug are presented in Figure 4.20. While the API in the capsules containing pure INM is
in its crystalline γ-form, in the ones containing the milled extrudates INM is amorphous
having formed a solid solution with the excipient during extrusion, as was shown in
section 4.4.2. The in vitro dissolution tests are conducted in a phosphate buffer solution
with pH 7.4. The release profiles in Figure 4.20 clearly indicate that INM is released
faster from the milled extrudates in capsules, than from capsules containing pure
crystalline INM. In 30 min the amount of INM released from capsules containing pure γINM is 50 ± 5 %, while from the milled extrudates it is 95 ± 3 % for ground HME
sample, 97 ± 1 % for ground HD-fHME and 96 ± 2 % for ground LD-fHME. Since INM
is amorphous in the milled extrudates its release is faster compared to the crystalline
samples.

As mentioned before in section 4.2.1, dissolution of a material in the

amorphous state, compared to its crystalline counterpart, is facilitated by the lack of
lattice structure and higher free energy (Leuner and Dressman 2000; Bhugra and Pikal
2008).
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Figure 4.20 Release profiles from HPMC capsules of pure INM (▼), ground HME
sample (), ground HD-fHME sample (), and ground LD-fHME sample () in
phosphate buffer solution with pH 7.4. Dissolution tests obtained using a USP apparatus
2. Tests were performed in triplicate.
From a general perspective, it can be seen that the release profile of pure INM is
characterized by a delay in API’s release of approximately 5 min. During this time no
API was detected by the UV analysis.

In section 4.2.1 this was attributed to the

dissolution of the HPMC capsule. However, in this case all the samples were analyzed
by placing the powder in the capsules, since the milled extrudates also showed a delay in
the API release, although shorter of ~2min, then, it can be concluded that for the pure
INM this delay is not only due to the dissolution of the capsule, but also results from
slower wetting of the crystalline API compared to the amorphous solid solution particles.
In the latter case, the amorphous API was embedded in a polymer which is highly
hydrophilic and soluble in the buffer solution, thus wetting was favored in the solid
solutions compared to γ-INM.
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Up to this point, the release profiles of milled extrudates have been compared to
the release profile for pure crystalline INM, and as expected the release rate of the API
was accelerated through the formation of an amorphous solid solution during extrusion
processing. .
By comparing the release profiles of milled extrudates shown in Figure 4.20 it is
clear that ground LD-fHME leads to the fastest INM release, while the release profiles of
ground HME and HD-fHME samples are very similar and their release profiles overlap.
The amount of INM released in 10 min from ground LD-fHME sample is 93 ± 4 %, from
ground HD-fHME sample is 51 ± 5 % and from ground HME sample 42 ± 2 %. These
results suggest that there is a direct correlation between release rate and particle size.
Other reports can be found in the literature, where it has been shown that solid solution
particles produced from milling foam extrudates lead to faster dissolution/release rate
than particles produced by milling un-foam extrudates (Lyons et al. 2007; Verreck et al.
2007; Nagy et al. 2012), the same results have also been reported for placebo
formulations (Verreck et al. 2006b).
In the literature, numerous mathematical models have been proposed to describe
API release/dissolution (Higuchi et al. 1965; Nogami et al. 1970; Ritger and Peppas
1987a; b; Peppas and Sahlin 1989; Narasimhan 2000; Costa and Sousa Lobo 2001). All
these models, regardless of the API release mechanism, show a correlation between
dissolution/release rate and either a characteristic dimension or the surface area of the
particles. In general, a reduction in particle size or an increase in surface area is expected
to result in faster release/dissolution rates. As shown in section 4.4.3, the smallest
particles were produced by milling the LD-fHME extrudate (see Figure 4.18 and
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Table 4.9) and thus this sample showed the fastest API release. On the other hand, the
ground HME and HD-fHME samples have very similar particle size distributions, and
thus their release profiles are also very similar. However, the release from ground HDfHME is slightly faster than from the milled un-foam extrudates, because the former has
slightly smaller particles and higher surface area. Similar results were obtained by Nagy
et al (Nagy et al. 2012) for the solid solution of Carvedilol with EPO, with 20 wt% of
drug loading. Andrews et al. (Andrews et al. 2010), on the other hand, did not observe
any difference between the release profiles from milled foamed and un-foamed samples;
the systems evaluated being also solid solutions comprising Celecoxib and Polyvinyl
pyrrolidone with 30wt% of drug loading.

4.5 Impact of Foamed Structure and Morphology on API Release Rates from
Binary Systems with Different API Release Mechanisms
The impact of foamed structures on the release rate of several API has been reported in
the literature, where publications have shown two main trends: in the majority of cases it
has been reported that the API release rate is increased upon foaming (Fukuda et al. 2006;
Lyons et al. 2007; Verreck et al. 2007; Andrews et al. 2010); on the other hand, few
reports indicate that the cellular structures have very little influence or do not affect the
API release rate (Fukuda et al. 2006; Lyons et al. 2007; McKelvey et al. 2010).
Therefore, it is natural to question if there is some degree of system specificity regarding
the impact of a cellular morphology on API release. Therefore the main objective of this
section is to study the impact of foaming on the API release profile from different binary
systems, and more specifically, examine if a correlation exists between API release
mechanisms and the impact of foaming on its release rate.
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In order to do this three binary systems are evaluated: PVCap-PVAc-PEG loaded
with 30 wt% of INM (S30INM), PVCap-PVAc-PEG loaded with 15 wt% of CBZ
(S15CBZ), and EPO loaded with 30 wt% of INM (EPO30INM).

4.5.1 Characterization of the Binary Systems: S30INM, S15CBZ and EPO30INM
The state of the API in the three binary systems is characterized combining thermal
analysis, FT-IR and XRD. A summary of the glass transitions of S30INM, S15CBZ and
EPO30INM obtained by DSC and MTDSC is shown in Table 4.10.
Thermal analyses indicate that in all cases the API is in the amorphous state; no
endothermic peaks are observed due to melting and/or API dissolution in the polymeric
excipient during the first heating of the HME-prepared samples (see Figure 4.4 in
section 4.1, and Figures 4.21 and 4.22 below).

Table 4.10 Summary of the Glass Transition Temperatures (Tg) of the HME-Prepared
Binary Systems: S30INM, S15CBZ and EPO30INM
System
Tg [°C]
S30INM*

62 ± 1

S15CBZ*

72 ± 1 and 63 ± 1

EPO30INM**

47.8 ± 0.5

Thermal analyses performed by *DSC and **MTDSC

The S30INM and EPO30INM systems showed a single glass transition
temperature (Tg). This indicates that an amorphous solid solution is produced through the
HME process. In other words, the API was fully dissolved in the excipient during
compounding and both materials are in amorphous state forming a single phase.
Additionally, in both cases a Tg shift with respect to the polymer’s glass transition
temperature is observed. As mentioned before in section 4.1, in the case of S30INM the
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resulting Tg is ~11°C lower that PVCap-PVAc-PEG due to the plasticizing effect of INM
on the excipient. Conversely, the Tg of the EPO30INM systems is ~ 3°C higher than
EPO’s, which has also been reported by other authors and results from very strong
interactions between INM and EPO (Chokshi et al. 2005; Liu 2010).
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Figure 4.21
Characteristic 1st heating MTDSC thermogram of HME-prepared
EPO30INM binary system.
On the other hand, S15INM showed two glass transition temperatures one at
63 ± 1 °C and the other at 72 ± 1 °C; thus a two phase amorphous system is produced
through HME process (i.e. an amorphous solid dispersion). The latter is within the range
of PVCap-PVAc-PEG (i.e. 73 ± 2 °C) and the former is between the Tgs of the excipient
and CBZ. The Tg of CBZ has been reported by other authors to be in the range between
53° and 56 °C (Li et al. 2000; Patterson et al. 2005). These results suggest that CBZ
dissolved in the polymer during the HME process, but it is not homogeneously
distributed along the matrix. However, this is not indicative of incomplete mixing;
content uniformity analysis indicated good content uniformity (14.3 ± 0.5 wt% in the
extrudates), which attests to good distributive mixing. Therefore the two Tgs most likely
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reflect that CBZ is being dissolved within preferential sites within the terpolymer. Since
PVCap-PVAc-PEG is a graft terpolymer, then CBZ may be driven to dissolve
preferentially in one of the blocks giving rise to two Tgs.
While the S30INM system was already analyzed in detail in sections 4.1 and 4.2
and the system EPO30INM was studied in detail by Liu (Liu 2010), the S15CBZ systems
has not been studied before. Therefore this discussion is mostly concerned with the
properties of this last blend.
Characteristic 1st heating thermograms of CBZ, HME-prepared S15CBZ, and
PVCap-PVAc-PEG are shown in Figure 4.22. The two glass transition temperatures for
the HME-prepared S15CBZ are clearly shown in the low temperature region of the
thermograms in Figure 4.22 (a). In the high temperature region of the thermograms – see
Figure 4.22 (b) – it is evident that the HME sample does not have any thermal transitions
in this region. On the contrary, pure CBZ shows two endotherms and one exotherm
during its 1st heating. The first endoderm corresponds to the melting of p-Monoclinic
CBZ, with onset and peak temperatures of 174.5 ± 0.3° and 175.6 ± 0.2 °C, respectively.
Following this endotherm, CBZ immediately crystallizes as Triclinic CBZ (peak
crystallization temperature of 176.5 ± 0.4 °C). The melting peak for this form is seen as a
second endotherm with onset and peak temperatures of 190.4 ± 0.2° and 191.5 ± 0.2 °C,
respectively.

Similar behavior has been reported extensively in the literature for

commercially available CBZ (Otsuka et al. 1999; Rustichelli et al. 2000; Sethia and
Squillante 2004; Ugaonkar et al. 2007).
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Figure 4.22 Characteristic 1st heating DSC thermograms of PVCap-PVAc-PEG,
HME-prepared S15CBZ, and CBZ. (a) Low temperature region, and (b) high
temperature region
Another commonly used characterization technique to assess the state of the APIs
in the samples is FT-IR. In the case of INM, FT-IR has been shown to be a very accurate
characterization technique to differentiate between its three forms. Figure 4.23 shows the
characteristic spectra for both systems containing INM (i.e. S30INM and EPO30INM).
As can be seen in Figures 4.23 (a) and (b) in both S30INM and EPO30INM, respectively,
the API is in its amorphous state in the extrudates and it remains amorphous after
foaming (spectra f-S30INM and f-EPO30INM). As mentioned above, the peak for the
stretching vibration of the benzoyl group is seen at 1683 cm-1 which corresponds to
amorphous INM (see Table 4.2 in section 4.1 and Figure 4.23 below). On the other hand,
in the physical mixtures and γ-INM this peak can be seen at 1692 cm-1, since the API is
crystalline and in its γ-form in both samples.
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Figure 4.23 FT-IR spectra of the binary systems: (a) S30INM and (b) EPO30IM. The
prefices PM, HME and f are used to indicate the physical mixture, the HME-prepared and
foamed samples, respectively. Spectra of the pure excipients PVCap-PVAc-PEG and
EPO as well as INM (in its γ-form and amorphous state) are shown as reference.
FT-IR has also been widely used to identify the different polymorphic forms of
CBZ (Matsuda et al. 1994; Otsuka et al. 1999; Rustichelli et al. 2000; Kipouros et al.
2006). The region between 3400 – 3600 cm-1 shows the most characteristics differences
between the different forms of CBZ (Kipouros et al. 2006). In this region the peaks
associate with the stretching vibration of N-H bond in the primary amide group in CBZ
can be found (Rustichelli et al. 2000; Sethia and Squillante 2004; Kipouros et al. 2006).
In the case of p-Monoclinic this peak appears between 3464 - 3466 cm-1 (Rustichelli et al.
2000; Kipouros et al. 2006).
As can be seen in Figure 4.24 (a), crystalline CBZ and the physical mixture
(PM_S15CBZ), show a strong and sharp peak at 3466 cm-1. Since in both these samples
CBZ is in the crystalline state, it can be concluded that the crystalline form of the API is
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p-Monoclinic. This finding is in agreement with the DSC results presented above. It is
interesting to note that the peak at 3466 cm-1 is no longer present in the spectra of the unfoamed and foamed S15CBZ samples (HME_S15CBZ and f-S15CBZ, respectively).
The absence of this peak indicates that CBZ’s amide group is no longer forming
hydrogen bonds with itself but with PVCap-PVAc-PEG. The same has been reported for
dihydrate CBZ where the CBZ-CBZ hydrogen bonds are replaced with CBZ-H2O
hydrogen bonds (Otsuka et al. 1999), as well as when solid solutions of CBZ and
Polyvinyl pyrrolidone (PVP) have been produced (Nair et al. 2001; Sethia and Squillante
2004).
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Figure 4.24 FT-IR spectra of the binary system S15CBZ, (b) shows a detail of (a). The
prefices PM, HME and f are used to indicate physical mixture, HME-prepared and
foamed samples, respectively. Spectra of the pure PVCap-PVAc-PEG as well as
crystalline CBZ are shown as reference.

102
As described in section 4.1 for the pair INM / PVCap-PVAc-PEG CBZ and
PVCap-PVAc-PEG are also capable of forming hydrogen bonds. The amide group in the
API has two proton donors (–NH2) capable of participating in hydrogen bonding.
However, hydrogen bonds formed between CBZ and PVCap-PVAc-PEG are expected to
be weaker than those formed between this excipient and INM. The dipole moment of the
O-H bond in INM is 1.53 D while the N-H bond in CBZ has a dipole moment of 1.31 D
(Wade 1993).
As described also in section 4.1, the most favorable site for CBZ to be hydrogenbonded with the excipient are the oxygen atoms double bonded with carbon (C=O) along
the branches of PVCap and PVAc, followed by the oxygen atoms in the PVAc branches,
and along the PEG backbone. The characteristic FT-IR peaks for these functional groups
are indicated in the spectrum of PVCap-PVAc-PEG in Figure 4.24. The peaks seen at
1738 cm-1 and 1246 cm-1 are characteristic to PVAc, the former corresponds to the C=O
stretching vibration and the second one is due to the asymmetric stretching of the acetate
(C-O-C) group. The band seen at 1638 cm-1 is characteristic of the C=O stretching
vibration in the PVCap. Finally, the band at 1110 cm-1 results from the asymmetric
stretching vibration of the C-O-C in PEG (Socrates 2000). Shifts in these peaks are
expected, as hydrogen bonds between CBZ and the polymer are formed. However, in
Figure 4.24 (a) it is only in the region between 1710 and 1500 cm-1 that appreciable
differences can be seen between the spectra of the PM and solid dispersions. These
changes in the spectra can be seen more clearly in Figure 4.24 (b) where detail of the
spectra between 1900 and 1500 cm-1 are shown.
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The peaks observed in the spectrum of CBZ in Figure 4.24 (b) at 1676 cm-1
correspond to the stretching vibration of hydrogen bonded C=O (Otsuka et al. 1999;
Rustichelli et al. 2000). This peak is still detectable in the spectrum of the PM_S15CBZ.
After compounding this peak shifted to higher waive number; in the HME_S15CBZ and
f-S15CBZ samples this peak can be seen at 1689 cm-1. Since CBZ is now dissolved in
the polymer, its carbonyl group is no longer participating in hydrogen bonding and the
position of this characteristic peak is changed. Prior to compounding CBZ is forming
hydrogen bonds with itself through the primary amide group, where its oxygen atom (i.e.
oxygen in the carbonyl group C=O) is the proton acceptor and the hydrogen atoms (NH2). As mentioned before, after compounding the hydrogen bonds are formed between
CBZ’s proton donors and PVCap-PVAc-PEG’s proton acceptors, as a result CBZ’s
proton donor (C=O) is not involved in the newly hydrogen bonding between CBZ and the
polymer excipient.
Another evident change with respect to the spectra of CBZ and the physical
mixture is the disappearance of the double peak at 1606 and 1595 cm-1. These two peaks
are also associated with vibrations of the C=O and N-H bonds. Since the former does not
participate in hydrogen bonding after compounding and the latter now forms hydrogen
bond with the polymer, then these peaks are no longer clearly visible in the HME and fS15CBZ samples. Finally, with respect to the characteristic peak of PVCap at 1638 cm-1,
although a peak shift is not observed after the HME and foaming processes, this peak
appears narrower, probably due to interaction between the excipient and CBZ.
In addition to thermal and FT-IR analyses, XRD was also performed for the
system S15CBZ. XRD was only performed for this system since it has not been studied
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before.

Figure 4.25 shows the XRD diffraction patterns for crystalline CBZ, the

PM_S15CBZ, HME-prepared S15CBZ, and PVCap-PVAc-PEG. These results clearly
show sharp peaks associated with the presence of a crystalline phase only in the PM and
crystalline CBZ. However, in the former the peaks are less intense and the baseline is not
as flat as for pure CBZ due to the presence of 85 wt% of PVCap-PVAc-PEG which is an
amorphous material. In agreement with DSC and FT-IR results, the XRD pattern of the
HME-prepared S15CBZ sample indicates that this system is totally amorphous.
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Figure 4.25 XRD patterns of crystalline CBZ, S15CBZ samples – physical mixture
(PM_S15CBZ), and HME-prepared sample (HME_S15CBZ) – and PVCap-PVAc-PEG.
In summary, combining thermal and spectroscopic characterization techniques it
is shown that the S30INM and EPO30INM systems are amorphous solid solutions. On
the other hand, characterization of the S15CBZ system by DSC, FT-IR and XRD
indicates that it is an amorphous solid dispersion.
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4.5.2 Cellular Morphology in the Foamed Binary Systems: S30INM, S15CBZ and
EPO30INM
As described in section 3.2.3 in Chapter 3 following HME process, the extrudates are
ground and compression molded into disks of 19 ∅ x 0.3 mm. Since molding is carried
out above the glass transition temperature of the systems and under pressure, flow and
consolidation are possible and thus the resulting samples are continuous and lacking
porosity, as can be seen in Figure 4.26 (a) for the S30INM’s sample. Then, through batch
foaming process using ScCO2 as PBA, cellular structures were produced as shown the
one in Figure 4.26 (b). Foamed samples showed density reductions between 94.3 and
96.5 % (see Table 4.11) with respect to their original compression molded density (i.e.
un-foamed disks) due to the high degree of foaming expansion induced by the dissolved
ScCO2 coming out of solution with the sudden decompression.

(a)

(b)

Figure 4.26 SEM images of cross-sectional surfaces of the S30INM samples: (a) unfoamed disk of 19 ∅ x 0.3 mm, and (b) foamed disk.
All foamed samples have predominantly closed cell morphology, as can be seen
in all SEM images of the cross-sectional area of foamed samples (see Figures 4.27, 4.28
and 4.29). In other words, the cells (or bubbles) are not interconnected and the cross-
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sections of the foamed samples have honeycomb-like morphology. The foamed S30INM
and S15CBZ samples (f-S30INM and f-S15CBZ, respectively) have very similar cellular
morphologies. As can be seen in Table 4.11 their densities, cell size and wall thickness
are very similar.

Table 4.11 Summary of the Characteristics of the Foamed Binary System: S30INM,
S15CBZ, and EPO30INM
Binary System
Property
S30INM
S15CBZ
EPO30INM
Density of the un-foamed disk [g/cm3]

1.01 ± 0.05

1.09 ± 0.03

1.11 ± 0.02

Density of the foamed disks [g/cm3]

0.038 ± 0.001

0.038 ±0.005

0.06 ± 0.02

Density reduction after foaming [%]

96.2

96.5

94.3

Cell size range [μm]

16-130

14-128

7-215

Wall thickness range [μm]

0.4-1.7

0.8-2.1

0.5-10.6

(a)

(b)

Figure 4.27 SEM images of cross-sectional surfaces of a f-S30INM disk: (a) 20.00kX
and (b) 100X.

The foamed EPO30INM samples (f-EPO30INM) have slightly different
morphology than the systems containing PVCap-PVAc-PEG as the matrix.

In the
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summary presented in Table 4.11 it is evident that the f-EPO30INM samples have a
broader cell size and wall thickness distributions, with overall bigger cells and thicker
walls, which lead to a smaller reduction in density upon foaming than the other two
systems. In addition, in the high magnification SEM images of the cross-section of the
samples it is evident that the surfaces of the cells of the f-EPO30INM samples are
smooth, [see Figure 4.29 (a)], while the surfaces of the cells of the f-S30INM and fS15CBZ samples have regularly rough (ribbed) patterns [see Figures 4.27 (a)
and 4.28 (a), respectively].

(a)

(b)

Figure 4.28 SEM images of cross-sectional surfaces of a f-S15CBZ disk: (a) 5.00kX and
(b) 40X

(a)

(b)

Figure 4.29 SEM images of cross-sectional surfaces of a f-EPO30INM: (a) 5.00kX and
(b) 500X.
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In all three cases batch foaming is performed above the Tg of the systems (38 °C
in the case of S30INM and 47 °C in the other two cases). At these foaming temperatures
the materials are in a rubbery state, which is quite elastic and thus not capable of purely
viscous flow. During cellular growth the material is subjected to bi-axial tension and
deformation. Therefore the rough patterns observed in the f-S30INM and f-S15CBZ
samples can be attributed to the rheological properties of the excipient at the foaming
conditions. Since PVCap-PVAc-PEG has significantly higher viscosity than EPO – e.g.
at 170°C the zero shear rate viscosities are 3.5 x 103 Pa⋅s (see Appendix D) and 5 x 102
Pa⋅s (Liu 2010), respectively; then elongational flow is easier for EPO30INM than for
S30INM and S15CBZ, and thus smother surfaces without elastic instabilities are
generated during batch foaming.
As mentioned above, the f-EPO30INM samples have predominantly closed cells;
close inspection of the surface of the samples however showed the presence of open cells
or porosities along the face of the samples that is contact with the heated surface of the
mold during the batch foaming process, that is, the “bottom” face in Figure 4.30 (a). The
other surface – the “top” or free surface during the batch foaming process – has only
closed cells, with no open cells visible in Figure 4.30 (b). This fraction of open cells on
the bottom surface in the EPO30INM system is expected to have an impact in INM
release from the foamed samples, since it constitutes further increase in surface area.
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(a)

(b)

Figure 4.30 Optical microscope images of: (a) bottom face and (b) top face of a
f-EPO30INM disk.
4.5.3 Mathematical Models Describing API Release from Continuous Non-porous
Planar Polymer Sheet
From a general physical perspective, the release mechanism of an API from an
amorphous solid solution or dispersion into a “solvent” involves the following processes:
(1) surface wetting, (2) solvent penetration into the system, (3) polymer swelling, (4) API
diffusion, and (5) polymer dissolution (if polymer dissolution is possible) (Narasimhan
and Peppas 1997; Narasimhan 2001; Siepmann and Peppas 2001). The three mass
transfer processes involved (i.e. solvent penetration, API diffusion and dissolution) are
schematically presented in Figure 4.31.
All three mass transfer processes take place during the API release from any
delivery system where the API in imbibed in a polymeric matrix. However, one will be
the rate limiting step and thus the controlling mechanism.

There are three main

mechanisms that control API release, these are: (1) diffusion controlled, also known as
Fickian or Case I release; (2) relaxation-controlled, also known as Case II, swelling
controlled, zero order release or mass erosion; and (3) anomalous transport.

Well

established mathematical models have been used to describe API release from the first to
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controlling models and are discussed in more detail below. Additionally, empirical and
semi-empirical mathematical models can be used to identify the controlling release
mechanism for an API in a given formulation; one of which is discussed in detail in
section 4.5.4.

Figure 4.31 Schematic representation of the API release mechanism from solid solution.
On the left, the three mass transfer processes are indicated (i.e. solvent penetration, API
diffusion, and polymer dissolution). On the right, the difference between (1) the glassy
core region (dry region) and (2) the swollen surface layers are illustrated. The green dots
represent the API molecules dissolved in the polymer; the polymer chains are shown as
gray lines, and the solvent in blue.

4.5.3.1 Mathematical Model Describing API Release from a Thin Polymer Film
Through Fickian Diffusion. Equation 4.8 represents Fick’s second law in the case of a
thin film or slab, where one-dimensional diffusion in the x direction and constant
diffusion coefficient are assumed.
∂C
∂ C
=D
∂t
∂x

(4.8)
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Where C represents the API concentration, t represents time, and x the diffusional
direction.
Then, equation 4.8 can be solved considering the appropriate boundary conditions
for API release from a thin polymer sheet or slab of thickness 2L (with a symmetry line
at x=0). In the present case, initially the concentration of API in the slab is considered to
be uniform and constant and defined as C1, and the concentration of API at the surface is
maintained constant as Cs. These boundary conditions are summarized in expression 4.9,
and the corresponding exact solution of Fick’s second law is shown in equation 4.10.

t=0
t>0

=1−

8

-L < x < L
x= ± L

1
(2 + 1)

C=C1
C=Cs
− (2 + 1)

(4.9)

(4.10)

Where Mt denotes the amount of API released at time “t” and M∞ the
corresponding amount at infinite time.
It is well know that expression 4.10 can be a simplified for short times (i.e. for
Mt/M∞ ≤ 0.6) as shown in equation 4.11 (Crank 1975).

=4

(4.11)

4.5.3.2 Mathematical Model Describing Relaxation Controlled API Release from a
Thin Polymer Film. In the case of API release from a thin film described by Case II
transport (i.e. relaxation controlled system) the mathematical model was developed by
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Enscore et al. (Enscore et al. 1977) by combining a kinetic expression which describes
the rate at which the penetrant is absorbed by the systems and a mass balance expression.
The two principal assumption with a case II transport are: (1) the concentration profile of
the penetrant is step-like, and (2) both the dissolving front and the swollen-glassy
interphase (boundaries shown as XS and XG, respectively in Figure 4.31) move at a
constant velocity (Comyn 1985; Narasimhan and Peppas 1997). It should point out that
this model was developed to describe sorption of solvents into a glassy polymer.
However, this model is used to describe the release profile of drug delivery systems
where API release is said to be relaxation controlled, since the swelling and dissolution
kinetics of the polymer film control the release of the API.
Having the aforementioned assumptions in mind, then a mass balance for onedimensional transport can be defined by expression 4.12, and the kinetic expression is
given by equation 4.13.

=( − )

(4.12)

=

(4.13)

Where the product (L – x)YZ represents the volume of the swollen layer, in more
detail (L – x) is the thickness of the swollen layer, L the characteristic length of the film
(i.e. half it thickness) and 0 ≤ x ≤ L. The constants Co and ko represent the equilibrium
penetrant concentration and the relaxation constant respectively.
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Then, equation 4.14 is obtained by substituting the mass balance expression into
the kinetic expression (equations 4.12 and 4.13, respectively). This expression is used to
obtain a relationship between x and time.

( − )

( )

=

( )

(4.14)

Through differentiation and simplification expression 4.14 becomes:

=−

(4.15)

Then, the algebraic relationship for x as a function of time is given by equation
4.16, only for 0 ≤ t ≤ L ⋅ Co/ko; in other words, from the beginning of dissolution until the
“glassy” or dry region is completed depleted.

=

−

(4.16)

By substituting equation 4.16 in 4.12 and by further simplification results in
expression 4.17, this expression described the release of an API from a relaxation
controlled systems until the “glassy” region is completely depleted.

=

(4.17)
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4.5.4 Determination of API Release Mechanisms from Several API / Polymer
Excipient Binary Systems
In the present study the experimental data for the three binary systems: S30INM,
S15CBZ and EPO30INM are fitted using a semi-empirical mathematical model known as
the Power Law model shown in equation 4.18.

=

∙

(4.18)

Where Mt and M∞ are the masses of released API at time "t" and at infinite time,
respectively, k is a constant which accounts for structural and geometric characteristics of
the sample, t is the release time, and n is the release exponent which depends on sample
geometry and release mechanism.
In the literature this model is widely known as the Power Law, the KorsmeyerPeppas model or simply the Peppas model (Costa and Sousa Lobo 2001; Siepmann and
Peppas 2001), and can be used to identify the mechanism (i.e. Fickian diffusion,
relaxation-controlled or anomalous transport) controlling API release from a polymer
based system according to the values of the release exponent (n) in equation 4.18 as
summarized in Table 4.12. However, it should be mentioned that this approach was first
used by Enscore et al. (Enscore et al. 1977) to identify the mechanism of fluid sorption
and desorption (i.e. Fickian vs. Case II – relaxation controlled – transport) in polymer
microspheres. Latter this model was introduced by Ritger and Peppas. (Ritger and
Peppas 1987a; b; Peppas and Sahlin 1989) to describe drug release from polymeric
devices. Since then many researchers have used this model or variations of it to identify
the release mechanism from diverse drug delivery systems (Korsmeyer et al. 1983; Bruce
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et al. 2005; Huang et al. 2006; Andrews et al. 2008; Yang et al. 2010; Ha and Xanthos
2011).
In order to accurately use the Power Law model it is essential to understand the
assumptions associated with it as well as its limitations. First of all, equation 4.18 was
adapted from the short time solutions for Fickian and non-Fickian transport through a
thin film or slab (Ritger and Peppas 1987a). Therefore, when applying this model two
key conditions must be fulfilled: (1) one-dimensional transport must be assured, and (2)
the model is only valid up to 60% of drug released (Ritger and Peppas 1987a). While the
latter can be easily meet, it is harder to comply with the former as in reality threedimensional transport takes place. Nonetheless, certain geometrical consideration may be
used in order to approximate three-dimensional transport process to a one-dimensional
process. By considering a disk with diameter 2a and thickness l and defining the aspect
ratio of the samples as 2a/l, then three limiting conditions can be defined where the onedimensional transport can be assumed. These are: a thin film when 2a >> l, a sphere
when 2a ≅ l, and cylinder when 2a << l. In these cases transport in the longest path
(largest dimension) can be neglected with respect to the shortest path, thus the onedimensional approximation becomes valid.
Since the release exponent “n” in equation 4.18 depends not only on the API
release mechanism but it is also a function of the sample’s geometry (see Table 4.12), it
is also important to know the aspect ratio of the sample in order to do a correct
interpretation of the fitting results. This geometry dependence can be seen clearly in
Figure 4.32, which shows the correlation between the release exponent “n”, for a
diffusion controlled system, and the aspect ratio of the sample.
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Figure 4.32 Release exponent (n) in the Power law model for API release controlled by
Fickian diffusion as a function of the aspect ratio of the sample. Figure adapted from:
(Ritger and Peppas 1987a).
In the present study, the release mechanism of INM and CBZ from the amorphous
solid solutions and dispersion S30INM, EPO30INM and S15CBZ are determined using
compression molded samples of 19∅ x 0.3 mm which resulted in an aspect ratio of 63,
thus it can be considered a thin film geometry or slab.
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Table 4.12 Values of the Power Law Release Exponent “n” for Each API Release
Mechanism and Sample Geometry
Release Exponent (n) Values
Mechanism Controlling

Cylindrical Sample*

Spherical Sample*

Thin Film*

2a/l ≤ 0.2

1 ≤ 2a/l ≤ 2

2a/l ≥ 50

Fickian diffusion

0.45

0.43

0.50

Relaxation controlled

0.89

0.85

1

Anomalous transport

0.45<n<0.89

0.43<n<0.85

0.50<n<1

the API Release

*Limiting values for the aspect rations, 2a/l, were determined from Figure 4.32
Source: (Ritger and Peppas 1987a)

In vitro dissolution tests of the S30INM system are performed in a phosphate
buffer solution with pH 7.4 and containing an average of 35 mg of drug loading. The
S15CBZ system containing an average of 16 mg of drug loading is tested in deionized
water, which is the dissolution medium established for CBZ in its USP monograph.
Finally the EPO30INM system is tested in two solutions: a hydrochloric acid buffer
solution with pH 1.2 and a phosphate buffer solution with pH 7.4. In both cases the
samples’ drug loading is an average of 30 mg. These two buffer solutions were selected
because they provide two extreme scenarios. At pH 1.2 INM solubility is extremely low
(i.e. 1 mg/L (Yazdanian et al. 2004)) but the excipient is soluble. On the other hand, at
pH 7.4 the drug solubility is much higher (i.e. 1300 mg/L (Yazdanian et al. 2004)) but the
excipient is insoluble, it only swells as the solvent is absorbed.
Figure 4.33 shows the experimentally determined APIs release profiles under the
four in vitro dissolution conditions evaluated together with the Power law fittings. It
should be pointed out that in the case of S30INM, S15CBZ and EPO30INM in pH 1.2
only partial release profiles are shown – up to 60 % - since this is the range where the
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model can be applied.

As can be seen in Figure 4.33 the fittings, obtained using

OriginPro® software, are in very good agreement with the experimental data.

A

summary of the values of the release exponent (n) and the Power law constant (k)
determined for each system are shown in Table 4.13.

Table 4.13 Determined Values of the Release Exponent (n) and the Power Law Constant
(k) for the Binary Systems Using Samples of 19 ∅ x 0.3 mm (Thin Film Geometry).
EPO30INM
S30INM
S15CBZ
Parameter
pH 1.2
pH 7.4
n
k [min-n]
R2
Release
mechanism

1.02 ± 0.05

0.71 ± 0.01

1.0 ± 0.1

0.499 ± 0.008

0.040 ± 0.004

0.027 ± 0.001

0.06 ± 0.02

0.0030 ± 0.0001

0.998

0.998

0.974

0.998

Relaxation
controlled

Anomalous
controlled

Relaxation
controlled

Diffusion
controlled

As can be seen in Table 4.13 and Figures 4.33 (a) and (c), the API release rate of
two of the systems is independent of time, often referred to as zero order release
(Narasimhan 2000; Costa and Sousa Lobo 2001). The two systems that show this
behavior are S30INM and EPO30INM in pH 1.2; in both cases the release exponent
obtained is 1 (specifically 1.02 ± 0.05 and 1.0 ± 0.1, respectively), which corresponds to
relaxation-controlled API release in a thin film or slab. From a physical point of view the
release rate of INM from these systems is controlled by the swelling of the solid solution,
as the solvent is absorbed by the thin film, and its consequent dissolution.
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Figure 4.33 Comparison between experimentally determined API release from disks of
19 ∅ x 0.3 mm (), and the power law fitting (dashed lines) for the binary systems: (a)
S30INM in pH 7.4, (b) S15CBZ in deionized water, (c) EPO30INM in pH 1.2, and (d)
EPO30INM in pH 7.4. All dissolution tests performed using a USP apparatus 2 and in
triplicate.

In this liming case, a thin film geometry where the Power law release exponent
takes the value n = 1 the empirical constant (k) has physical meaning, and it is defined by
equation 4.19, as follows:

=

2

(4.19)
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Where ko is the relaxation constant [mg/cm2min], Co is the equilibrium penetrant
concentration, and L is the sample’s characteristic length (in the case of a thin film it
corresponds to the half-thickness of the sample, ½ l).
It should be noted that there are two more considerations associated with a case II
transport: (1) the concentration profile of the penetrant (buffer solution in the present
case) is step-type, and (2) both the dissolving front and the swollen-glassy interphase
(boundaries shown as XS and XG, respectively in Figure 4.31) move at a constant velocity
(Comyn 1985; Narasimhan and Peppas 1997).
The results in Table 4.13 show that the S30INM system has a lower k value than
the EPO30INM system in pH 1.2, these are 0.040 ± 0.004 min-1 and 0.06 ± 0.02 min-1,
respectively. Then it can be inferred that the ratio between relaxation constant and
equilibrium penetrant concentration (i.e. ko/Co) for the system EPO30INM in pH 1.2 is
slightly higher than in the system S30INM. This ratio represents the rate at which the
relaxation front moves toward the core of the sample (Enscore et al. 1977); thus, the
advance rate of the dissolving face and of the glassy-swollen interface is faster in the case
of EPO30INM in pH 1.2 than in the case of S30INM. As the name of this mechanism
indicates, the release rate is controlled by the relaxation rate of the solid solution
triggered by solvent absorption and subsequent swelling. Therefore, overall system
mobility and more specifically the mobility of the polymeric phase will greatly affect the
release rate, and hence polymer swelling can be can be seen as a viscous response of the
material (Comyn 1985). Since EPO has lower viscosity than PVCap-PVAc-PEG as well
as lower molecular weight (47 x 103 g/mol and 118 x 103 g/mol, respectively), then
relaxation and dissolution of EPO is easier compared to that of PVCap-PVAc-PEG.
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Thus, the relaxation front can move faster in the EPO30INM system than in the S30INM
system resulting in higher k value and faster release.
As expected the INM release from the EPO30INM systems in pH 7.4 is diffusion
controlled and the release exponent is 0.499 ± 0.008 (see Tables 4.12 and 4.13). Since
EPO is insoluble at pH 7.4 while INM is soluble, then it is logical that its release is
described by Fickian diffusion though the swollen polymer. As discussed above for the
limiting case for a thin film with n = 1, when n = 0.5 then the constant “k” in equation
4.18 also has physical meaning and is defined by equation 4.20.

=4

(4.20)

Where D is the diffusion coefficient [cm2/s], and L is the sample’s characteristic
length (i.e. half thickness of the sample, ½ l). In this case the Power law model becomes
the short time approximated solution for the diffusion equations through a thin film
(Crank 1975; Comyn 1985). Then the diffusion coefficient of INM through EPO in a
buffer solution with pH 7.4 is 6.6 x 10-12 cm2/s, which is in the same order of magnitude
compared to the values reported in the literature for other APIs and small molecules
diffusing through polymers (Enscore et al. 1977; Huang et al. 2006).
From a physical perspective, INM release in this case is driven by the solvent
concentration gradient across the sample (Peppas and Sahlin 1989; Amidon et al. 2000).
In addition, INM diffusion through the swollen layer with respect to the glassy region is
possible due to higher mobility and weaker API-polymer interactions. As mentioned in
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section 4.2.1, INM ionization is highly favored at pH 7.4 and thus its release under these
conditions is further favored.
Finally, CBZ’s release mechanism from the S15CBZ system is controlled by
anomalous transport. As can be seen in Table 4.13 the release exponent was determined
to be 0.71 ± 0.01. Anomalous transport results from the combined influence of both
diffusion and relaxation phenomena during drug release (Vrentas et al. 1975; Frisch
1980; Ritger and Peppas 1987a).

Specifically for the S15CBZ system coupling of

relaxation and diffusion may result from the two phases present in the system. It was
shown above that this system is an amorphous solid dispersion.

4.5.5 Effect of Cellular Structure on the API Release Rate
Figures 4.34 through 4.37 show comparisons between the API release profiles from
foamed and un-foamed disks of S30INM, S15CBZ and EPO30INM in pHs 1.2 and 7.4.
It is important to point out the in all cases the samples were placed in the USP apparatus
2 as disks without modifying the geometry of the samples. In other words, the cellular
structures were not disrupted or destroyed. Therefore, the changes in release/dissolution
profiles of the foamed samples with respect to their un-foamed counterpart can be
attributed solely to geometrical changes introduced by the cellular structure.
The results shown in Figures 4.34 through 4.37 indicate that API release was
accelerated upon foaming in all cases.

However, the degree in which the foamed

structure enhances API release rate differs among the systems been evaluated.
In the case of the S30INM system (see Figure 4.34) complete release is achieved
for both foamed and un-foamed samples. However, the time for completing release for
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the f-S30INM sample is 20 min, while the un-foamed sample required 35 min for
completing INM release; this represents a reduction in release time of 43 %.
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Figure 4.34 INM’s release profiles from the S30INM solid solutions: (×) un-foamed
disks (19∅ x 0.3 mm), and the corresponding () foamed disks in phosphate buffer
solution with pH 7.4. Inset plot shows a detail of the initial 5 min of the release profiles.
Dissolution profiles obtained using a USP apparatus 2. Tests were performed in
triplicate.
Since INM’s monograph states – for all its immediate release dosage forms – that
no less than 80 % of the drug must be released in 20 min then it is relevant to compare
the amount of INM released in 20 min and the time required to release 80 % of the API.
Within 20 min, 78 ± 3 % of INM is released from the un-foamed samples, but 99 ± 1 %
from the f-S30INM disks; this represents a 27 % increase in the amount of API been
released upon foaming. On the other hand, from the release profile it can be established
that 80 % of INM is released within 10 to 15 min from f-S30INM, but 20 to 25 min are
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required for the un-foamed samples. Therefore, by using cellular structures it is possible
to assure that the immediate release requirement is fulfilled.
The inset plot in Figure 4.34 shows a detail of the first 5 min of the release
profiles of the S30INM samples. In this detail of the release profiles a “burst” in release
can be seen for the f-S30INM sample; 13-fold more API is released from the foamed
sample compared to the un-foamed one. In 30 s the amount of INM released from
f-S30INM is 14 ± 2 % while only 1.1 ± 0.1 % from its un-foamed counterpart. This
behavior results from faster solvent absorption in the foamed samples compared to the
un-foamed ones due to higher surface area and shorter characteristic lengths along the
cell walls in the latter case. The characteristic length for the un-foamed disk is 150 μm
(half-thickness of the disk) while in the foamed samples it is 0.4 - 1.7 μm (i.e. the cell
wall thicknesses, reported in Table 4.11).
In the previous section it was shown that INM release from the S30INM system is
relaxation-controlled, in other words the swelling and dissolution kinetics of the solid
solution drive the release of the API.

Therefore, the change in sample geometry

introduced by the cellular structure affects the swelling kinetics of the solid solution not
only by changing the characteristic lengths but by introducing very complex velocity
profiles of the penetrant advancing front throughout the foamed structure. Since there is
a distribution of characteristic lengths there is also a distribution of swelling or
“relaxation” rates. This further contributes to accelerate the release rate in foamed
samples and it will be discussed in more detail in section 4.7.2.
The other system that has relaxation-controlled API release is EPO30INM in pH
1.2. The release profiles of INM from foamed and un-foamed samples from this system

125
are shown in Figure 4.35. As with S30INM, the most significant difference in release
rate due to the cellular structure is observed in the initial region of the release profile. In
30 s the amount of API released from the foamed samples is one-order of magnitude
higher compared to the amount released from the un-foamed samples; 10.8 ± 0.3 % from
f-EPO30INM and only 1.3 ± 0.3 % from the un-foamed disks. This results from faster
solvent absorption and faster swelling of the foamed samples sample due to an increase in
surface area and reduction in characteristic lengths from 150 μm to 0.5 - 10.6 μm (see
Table 4.11). However, after 2 min the profiles become parallel to each other.
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Figure 4.35 INM release profiles from the EPO30INM solid solutions: (×) un-foamed
disks (19∅ x 0.3 mm), and the corresponding () foamed disks in hydrochloric acid
buffer solution with pH 1.2. Dissolution profiles obtained using a USP apparatus 2.
Tests were performed in triplicate.
On the other hand, in both, foamed and un-foamed samples the apparent solubility
of INM in pH 1.2 is increased. A very high degree of oversaturation of INM in the
solution is evident in Figure 4.35; by UV analysis the concentration of drug was
determined to be as high as 28 mg/L while the solubility limit of INM in pH 1.2
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hydrochloric buffer solution is only 1 mg/L (Yazdanian et al. 2004). These results show
that a higher degree of oversaturation is obtained with the f-EPO30INM samples than
with the un-foamed ones. Due to this oversaturated state, INM tents to recrystallize and
precipitates, and as a result 100 % of release was not reached even if the solid solution
dissolved or disintegrated completely. Liu et al. (Liu et al. 2010) observed for this
system that the level of oversaturation as well as the duration of the oversaturated state
are related to the processing conditions used to produce the solid solution. Consequently,
it can be inferred that because the batch foaming process changes the thermal history of
the solid solution, then the increase in apparent solubility observed for the foamed
samples could result not only from the increase in release rate but also be due to the
conformation changes (i.e. changes in the spatial arrangement of the molecules)
introduced during the batch foaming process.
Figure 4.36 shows the release profiles of CBZ from foamed and un-foamed
amorphous solid dispersions. These results clearly show a significant enhancement on
the API release rate upon foaming. As an example in 60 min 90 ± 2 % of CBZ is
released from the f-S15CBZ disks while 49 ± 2 % from the un-foamed ones. In other
words, 83 % more CBZ is released from the foamed disks than from the un-foamed disks.
The monograph for CBZ establishes that in 60 min at least 75 % of the API should be
released, which is achieved after foaming the solid dispersion.
Also in Figure 4.36 it is evident that the final concentration of drug released, from
both foamed and un-foamed S15CBZ disks corresponds to 90 to 95 % of the nominal
drug loading. Since the in vitro dissolution tests is performed under sink conditions, and
no evidence of API precipitation is observed after completing the tests, then it can be
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assumed that a portion of the released CBZ is trapped within the PVCap-PVAc-PEG
micelles. As mentioned before, in section 4.2.1, the drug concentration been determined
through the UV analysis correspond to free drug.

When studying the dissolution

behavior of PVCap-PVAc-PEG, no UV signal of the polymer was observed when the
PVDF filters with pores size of 0.45μm were used, even though the polymer is a
chromophore. The dissolution profiles of pure PVCap-PVAc-PEG presented in section
4.6.2 were obtained through UV analysis without filtration. This observation suggests
that the PVCap-PVAc-PEG micelles cannot pass through the filter and therefore micellar
CBZ can not be detected.
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Figure 4.36 CBZ’s release profiles from the S15CBZ solid dispersion: (×) un-foamed
disks (19∅ x 0.3 mm), and the corresponding () foamed disks in deionized water. Inset
plot shows a detail of the initial 5min of the release profiles. Dissolution profiles
obtained using a USP apparatus 2. Tests were performed in triplicate.
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The inset in Figure 4.36 shows a detail of the first 5 min of the release profiles of
CBZ from the S15CBZ system. As observed for the complete release profiles, faster API
release is also observed from f-S15CBZ than from the un-foamed disk at the beginning of
the dissolution test. In 30 s, 5.5-fold more CBZ is released from the foamed sample than
from the un-foamed ones (6 ± 2 % and 1.1 ± 0.1 %, respectively). However, this
increment in the API release rate within 30 s is not as significant as it was observed for
S30INM and EPO30INM at pH1.2. These two systems have relaxation-controlled API
release, while the S15BZ system has anomalous controlled API release. Because the
swelling kinetics of the amorphous solid is not the limiting process for the release of CBZ
from the S15CBZ, then faster swelling contributes to enhanced release rate, but its
influence is less dominant than in the relaxation-controlled systems.
Finally, the effect of foaming on the release profile of INM from the solid
solution EPO30INM in pH 7.4 is shown in Figure 4.37. As in all other cases, faster API
release rate is achieved upon foaming. In 24 h the amount of INM released from the
f-EPO30INM samples is 36 % more than from the un-foamed samples (15 ± 1 % and
11 ± 1%, respectively).
It is surprising that the release rate was enhanced even though INM’s release in
controlled by Fickian diffusion through swollen EPO that does not dissolve under the test
conditions. Slower API rerelease upon foaming was expected for a system such as
EPO30INM in pH 7.4. Tortuosity generated by a honeycomb-like structure in a nondissolving cellular structure should extend the effective diffusional path of the API and
thus slow its release. However, as mentioned before some degree of open cells were
observed in the surface of the EPO30INM samples, therefore lessening the effect of
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tortuosity along the closed cells. In addition, as can be seen in Figure 4.38, dimensional
integrity of the foamed sample is disrupted during the in vitro dissolution test. In these
photographs it is evident that the porosity and number of open cells is increased
considerably after the 24 h dissolution test. This change in morphology also contributed
in the enhancement in release rate.
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Figure 4.37 INM’s release profiles from the EPO30INM solid solutions: () un-foamed
disks (19∅ x 0.3 mm), and the corresponding () foamed disks in phosphate buffer
solution with pH7.4. Dissolution profiles obtained using a USP apparatus 2. Tests were
performed in triplicate.
For this system the amount of solvent absorbed by the samples during the
dissolution test is determined by weight difference of the samples immediately after
extracting them from the dissolution apparatus and after drying under vacuum for 12 h.
The amount of solvent absorbed by the f-EPO30INM samples is 51 ± 4 wt % while 26 ±
4 wt% is absorbed by the un-foamed samples. This increase in the amount of absorbed
solvent upon foaming results from an increase in surface area and reduction in diffusional

130
length. Additionally, as the cellular structure collapses new available surfaces are created
further enhancing solvent absorption and API release. Furthermore, an increment in
absorbed water results in higher degree of swelling which then favors API diffusion by
providing increased mobility to the EPO chains, more available space for the diffusion of
the INM molecules and weaker INM-EPO interactions.

(a)

(b)

Figure 4.38 Photographs of foamed EPO30INM samples: (a) initial state of a foamed
sample, and (b) final state of a foamed sample after 24 h dissolution test in a phosphate
buffer solution with pH 7.4.
In summary, cellular structures allow to increase the release rate of an API
regardless of the mechanism controlling its release. However, in cases where the API
release is controlled by the swelling and dissolution kinetics of the amorphous solid
solution, foamed structures have a very strong impact in the very early stages of the
release of the API.
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4.5.5.1 Quantitative Comparison Between the Release Profiles from Foamed and
Un-Foamed Disks. In order to establish a quantitative comparison between two release
profiles, the USA Food and Drug Administration (FDA) in its Guidance for Industry
(FDA 1997) recommends the use of two mathematical indices, the difference factor (f1)
and similarity factor (f2). These indices were proposed by Moor and Flanner and are
defined according to the following expressions (FDA 1997; Shah et al. 1998):
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Where m is the number of time points, Rt percentage of API released from the
reference sample (in the present case the un-foamed sample) at time t and Tt is the
percentage of API released from the post change sample (in the present cases the foamed
sample) at time t.
The cumulative difference between two curves at each time point is given by f1.
In other words, f1 is a measure of the error between two curves and the closer its value is
to 0 the more alike the two release profiles are. Conversely, f2 is a measure of the
similarity between two curves. The value of f2 ranges between 0 and 100; a higher value
indicates that the two curves are more similar to each other. According to FDA’s
guidance, to consider two API release profiles to be similar f1 should be less than 15 and
f2 should be greater than 50. (FDA 1997; Shah et al. 1998)
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The difference and similarity factors are calculated for each un-foamed / foamed
pair using the software Wolfram Mathematica®. The results as well as the time ranges
used for the calculations are summarized in Table 4.14. The time ranges were selected
according to FDA’s guidance.

Table 4.14 Calculated Difference Factor (f1) and Similarity Factor (f2) for Foamed vs.
Un-foamed Release Profiles of S30INM, S15CBZ and EPO30INM
Time Range Used for the
System
f1
f2
Calculations [min]
S30INM

105.3

29.9

0.5-15

S15CBZ

139.3

25.3

0.5-75

EPO30INM_pH1.2

73.5

33.0

0.5-15

EPO30INM_pH7.4

109.4

66.0

15-1440

The results obtained for the EPO30INM in pH 7.4 are inconclusive. Using FDA
criteria the difference factor suggest that the profiles are different (f1 >> 15), but the
difference factor indicates that the profiles are similar (f2>50).
On the other hand, since f1 >> 15 and f2 < 50 for the following systems: S30INM,
S15CBZ and EPO30INM in pH 1.2, then it can be stated that the API release profile from
foamed samples is statistically different that the API release profile from the un-foamed
sample. Using these factors the impact foaming on API release can be ranked from
higher to lower impact as follows: S15CBZ > S30INM > EPO30INM in pH 1.2.
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4.6 Impact of Foaming on the Dissolution Profile of PVCap-PVAc-PEG

4.6.1 Morphology of Foamed PVCap-PVAc-PEG
Disks of 16∅ x 1 mm of PVCap-PVAc-PEG are foamed through the batch foaming
process described in Chapter 3 using ScCO2 as PBA at 90 °C and 10.34 MPa. During
bubble growth, free expansion of the sample takes place; the resulting foamed disks have
a closed cell structure as shown in Figure 4.39. The obtained cell size varied from 100 to
500 μm with cell wall thickness in the range 1-100 μm. The average density of the
foamed disks is 0.25 ± 0.05 g/cm3, approximately 4 times lower than the polymer’s
density 1.090 ± 0.005 g/cm3.
Figure 4.39 shows the SEM images of the cross-sectional surface of a foamed
disk. In the low magnification SEM in Figure 4.39 (a), is evident that the cells tend to be
much smaller toward the edges or skin of the sample than toward the center line of the
disk. This distribution in cell sizes results from a non-uniform CO2 concentration across
the sample at the moment of expansion. It is reasonable to state that it is higher toward
the surface compared to the central region of the samples. This results in a greater
amount of nucleation sites toward the surfaces than in the mid-section and therefore
formation of smaller cells toward the edges of the sample. The effect of exposure time of
the sample to the ScCO2 prior to foaming on cell morphology is discussed in more detail
in section 4.7.1.1.
The high magnification SEM image in Figure 4.39 (b) shows a similar rough
pattern as the one observed in the S30INM and S15CBZ samples. As mentioned before,
this surface pattern results from viscoelastic instabilities of the polymer undergoing
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biaxial deformation during cellular growth. Additionally, this pattern is expected to favor
the dissolution rate of the foamed samples.

(a)

(b)
Figure 4.39 SEM images of the cross-sectional area of a foamed PVCap-PVAc-PEG
disk: (a) 50X and (b) 500X
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4.6.2 Comparison Between Dissolution Profiles of Foamed and Un-Foamed
PVCap-PVAc-PEG
A comparison between the dissolution behavior of pure PVCap-PVAc-PEG in their unfoamed and foamed states is presented in Figure 4.40. The in vitro dissolution tests are
carried out in deionized water in a USP apparatus 2. The un-foamed and foamed disks of
approximately 240 mg are tested without breaking them or disturbing their morphology.
Complete dissolution was attained for both foamed and un-foamed samples.
However, Figure 4.40 clearly shows that the time required to complete dissolution is
significantly reduced upon foaming. The un-foamed disks require between 8.5 h and 9 h
to be completely dissolved, while foamed disks are completely dissolved within 5 h. This
represents a reduction in dissolution time of 70 to 80 % upon foaming.
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Figure 4.40 PVCap-PVAc PEG’s dissolution profiles: () un-foamed disks (16∅ x 1
mm), and the corresponding foamed disks () in deionized water. Dissolution profiles
obtained using a USP apparatus 2. Tests were performed in triplicate.
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Figure 4.41 Detail of the first 2 h of PVCap-PVAc PEG’s dissolution profiles: () unfoamed disks (16∅ x 1 mm), and the corresponding foamed disks ().in deionized water.
Dissolution profiles obtained using a USP apparatus 2. Tests were performed in
triplicate.
The dissolution profile of the un-foamed PVCap-PVAc-PEG clearly has an “S”
shape; Nogami et al. (Nogami et al. 1970) observed a similar shape for the dissolution
profile of PVP in 4:1 acetone:water solution. In Figure 4.41 it can be clearly seen that the
dissolution profile of the un-foamed samples has a very slow initial dissolution rate; the
amount of material been dissolved increases very slowly during the initial 60 min of the
in vitro dissolution test. During that time surface wetting, followed by water absorption
and polymer swelling take place. It is only after this swollen layer is formed and
established that true polymer dissolution can occur. Absorbed water plasticizes the
polymer providing enough molecular mobility for chain reptation to occur, which, as
depicted in Figure 4.42, is the molecular mechanism that controls disentanglement and
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mobility of the polymer chains as they go into solution (Narasimhan and Peppas 1997).
The time lag prior to true polymer dissolution is considered as the induction time for
dissolution (Narasimhan 2001; Miller-Chou and Koenig 2003).
(a)

(b)

(c)

Figure 4.42 Chain reptation and disentanglement process along the swollen layer: (a)
swollen and highly entangled system, (b) macromolecular disentanglement through chain
reptation, and (c) disentangled/dissolved chain (in bold). Source: (Narasimhan and
Peppas 1997).
By comparing the shape of the two curves in Figure 4.41 it is clear that, the
induction time for the un-foamed PVCap-PVAc-PEG disks is approximately 60 min, but
becomes extremely short for the foamed disks, less than 5 min. Therefore, it can be
concluded that wetting, water absorption and swelling rates are significantly enhanced
upon foaming.
Additionally, close comparison of the dissolution profiles suggests that the most
significant change in dissolution rates occurs during the initial stages of the test. For
example, in 15 min the amount of polymer dissolved from the foamed samples is 21-fold
higher than that dissolved from the un-foamed sample (13 ± 6 % of polymer dissolves
from the foamed sample, while only 0.6 ± 0.1 % dissolves from the un-foamed disk).
However, after the first 60 min the two curves seem to be parallel to each other (see
Figures 4.40 and 4.41), suggesting that once the foamed structure has formed the swollen
layer, dissolution proceeds as it would occur in an un-foamed sample.
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In addition to the difference in shape of the dissolution profiles, differences in the
swelling behavior were also observed. In the case of the un-foamed disk, first a swollen
layer is formed which progressively moves toward the interior core of the sample and at
the same time the size of the disks is reduced due to dissolution. In the case of the
foamed disks, the whole sample becomes very flexible (from being rigid and brittle) as
soon it is immersed in deionized water, an indication that the polymer is plasticized by
the absorbed water. Subsequently the cellular structure seems to collapse, and holes
throughout the samples can be seen as it dissolves. This collapse is similar to the one
shown for the EPO30INM system at pH 7.4 in Figure 4.38.
The enhancement in dissolution rate observed for PVCap-PVAc-PEG is a
consequence of faster solvent absorption, which is reflected as a large reduction in
induction time. Reduction in characteristic length for mass transfer and higher surface
area in the foamed disks promotes faster solvent absorption. In addition, the collapse of
the cellular structure as the polymer dissolves, further contributes to enhance its
dissolution rate.

4.7 Impact of Foam Morphology on the Release / Dissolution Behavior of the
S30INM Binary System
In section 4.6 it was shown that cellular structures can accelerate the API release rates
independently of their release mechanism. Then, in section 4.7 it was also shown that the
dissolution rate of pure PVCap-PVAc-PEG can be accelerated as well, through the
formation of closed cell foamed structures. The objective of this section is to gain
fundamental understanding of the influence of the cellular morphology of foamed
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samples on the API release rate and disintegration behavior of an amorphous solid
solution.

4.7.1 Characterization of the S30INM Foams Produced by Batch Foaming with
ScCO2
The batch foaming process using ScCO2 as PBA is used to produce foamed samples with
different cellular morphologies.

The detailed morphological characterization of the

cellular structures produced is presented next. Additionally, the impact of the foaming
process and the morphology of the foams produced on the state of INM are evaluated
immediately after foaming and after a 6-month physical stability test.
4.7.1.1 Morphology of the Cellular Structures of the Foamed S30INM Binary
System. Solid foams were produced through the batch foaming process described in
Chapter 3 employing ScCO2 as PBA. Disks of 16 ∅ x 1 mm were exposed to the PBA at
a 100°C (a temperature above the Tg of the S30INM system which is 62 ± 1°C as
reported in section 4.1) for 15, 30, and 60 min. The corresponding foamed samples are
referred to in the text as F15, F30 and F60, respectively.
The differences between un-foamed and foamed disks can be clearly seen
macroscopically in Figure 4.43 and in more detail in the SEM images of their crosssectional surfaces in Figure 4.44. The photographs of the samples (Figure 4.43) show
great levels of expansion of the disks as a result of the batch foaming process. This is a
consequence of the creation of closed-cells in the foamed samples. These can be clearly
seen in the SEM images of the cross-sectional areas of the samples in Figure 4.44, where
all foamed samples have honeycomb-like cross-sections. As expected, un-foamed disks
have a continuous non-porous cross-section, see Figures 4.44 (a) and (b).
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Figure 4.43 Photographs of (a) un-foamed disk and foamed disks: (b) F15, (c) F30, and
(d) F60.
The batch foaming process used in this study has four process variables which can
affect the foam characteristics and cellular morphology. These variables are: chamber
temperature, gas pressure, CO2 exposure time, and depressurization rate. A detailed
study of the effect of these process variables on the foam structure (i.e. cell sizes and
density) is out of the scope of the present discussion. However it can be found elsewhere
(Goel and Beckman 1994a; b; Arora et al. 1998; Sun et al. 2004), and in Appendix E
where photographs of foamed PVCap-PVAc-PEG samples produced at different
temperatures and pressures are shown.
The ScCO2 exposure time is varied between 15 and 60 min in order to produce
different foam morphologies and study their influence on API release. By varying ScCO2
exposure time the concentration of gas dissolved varies, affecting the cellular structure.
Furthermore under non-equilibrium conditions a gas concentration gradient across the
sample can be expected (Goel and Beckman 1994a; b). This is shown schematically in
Figure 4.45 and its consequences on the morphology of the foam morphology are
analyzed latter in this section. The different morphologies produced can be observed in
Figure 4.44, and a summary of their characteristics is presented in Table 4.15.
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Figure 4.44 SEM images of a cross-sectional surfaces of the S30INM samples (250X in
the left column and 5.00kX in the right). Un-foamed disk: (a) and (b), F15: (c) and (d),
F30: (e) and (f), and F60 (g) and (h).
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From the low magnification SEM images of the foamed samples [Figures 4.44
(c), (e), and (g)] it becomes evident that as the ScCO2 exposure time increases, the
cellular structure becomes more uniform with overall smaller cells. The values reported
in Table 4.15 show that the size of the largest cells is reduced from 600 to 200 μm by
increasing the gas exposure time. In addition, also in Table 4.15, it is evident that the
distribution of wall thickness becomes narrower with increasing ScCO2 exposure time.
The upper limit of the wall thickness is reduced significantly from 40.7 to 1.2 μm by
increasing the ScCO2 exposure time from 15 to 60 min.
Table 4.15 Summary of the Characteristics of the Foams Produced by the Batch
Foaming Process with ScCO2 at 10.34 MPa and 100 °C of S30INM Disks of 16∅ x 1
mm. Density of the Un-foamed Samples is Presented as Reference.
ScCO2 Exposure Sample’s Density Cell Size Range Wall Thickness
Sample
Time [min]
[g/cm3]
[μm]
[μm]
HME
(un-foamed)

0

1.01±0.05

-

-

F15

15

0.095±0.006

18-600

0.2-40.7

F30

30

0.036±0.002

18-400

0.2-9.7

F60

60

0.033±0.002

60-200

0.5-1.2

In addition to the cell sizes, close inspection of the cross sectional surfaces of the
foamed disks showed that the F15 and F30 samples have two cell size populations, see
Figures 4.44 (c) and (e), respectively.

Even though the difference in cell sizes is

significantly more pronounced for the F15 samples than for the F30 ones, in both cases a
skin / core-like morphology is obtained. Larger cells are obtained toward the core of the
disks and smaller ones formed toward and at the edges. On the other hand, foamed disks
produced by exposing the samples to ScCO2 for 60min (F60) have very uniform cell size
throughout the sample [Figure 4.44 (g)].
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The lack of uniformity observed in the F15 and F30 samples can be attributed to a
non-uniform CO2 concentration across the sample prior to foaming.

During the

pressurized step of the batch foaming process, the PBA diffuses and dissolves in the
sample. However, this is not an instantaneous process; sufficient time is needed to reach
equilibrium and uniform CO2 concentration throughout the disk (Goel and Beckman
1994a; Arora et al. 1998). In the cases of F15 and F30, the gas concentration at the
moment the pressure is release has not reached equilibrium resulting in a CO2
concentration gradient, being higher toward the edges (that is the “skin” region) than
toward the core of the sample, as it is schematically represented in Figure 4.45. Based on
the homogenous nucleation theory (Colton and Suh 1987; Kumar and Suh 1990; Goel
and Beckman 1994a), nucleation rates tend to be faster in high CO2 concentration regions
(i.e. disk’s “skin”). It is generally accepted that faster nucleation rates result in more
nuclei, leading to smaller cells toward the edges compared to the core.

Figure 4.45 Schematic representation of the CO2 concentration along the thickness of a
S30INM disk of 16∅ x 1 mm as a function of exposure time (15, 30, and 60 min) to
ScCO2; Ceq represent equilibrium CO2 concentration.
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On the other hand, as mentioned before, the low magnification SEM image of the
cross-sectional area of a F60 sample, Figure 4.44 (g), clearly shows that the cell size
distribution across the thickness of the disk is very uniform. These results suggest that
after 60 min of exposure to ScCO2, the gas concentration in the S30INM disk is uniform,
as shown schematically in Figure 4.45, and probably very close to the equilibrium gas
concentration. Therefore, it can be conclude that a uniform cell size distribution was
produced for the F60 samples due to uniform gas concentration.
The presence of the closed cells in the foamed samples resulted in a reduction in
density with respect to compression molded disks (i.e. un-foamed samples). From the
data presented in Table 4.15 it can be seen that all foamed samples have a significant
reduction in density with respect to the un-foamed HME sample (which is
1.01 ± 0.05 g/cm3). The F15 samples showed a ~10-fold reduction in density, while F30
and F60 have very similar densities, namely ~28 and ~30-fold density reduction with
respect to the un-foamed disks. These results indicate that the F30 and F60 samples have
similar porosities or void fractions, but, the cellular morphology or spatial arrangement of
the bubbles are different. This can be easily visualized through Figure 4.46. These
schemas represent an idealization of two foamed structures with same void fractions, and
therefore same densities, but with completely different cell sizes; one represents a foam
with large cells and the other a foam with small cells. Theoretically, the same free area,
and therefore the same density, can be obtained by replacing one big cell with several
small ones.
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Figure 4.46 Schematic representation of two closed-cell geometries with same free
space but with different configurations. These schematic representations are idealizations
of two foamed structures with same densities (i.e. same void fractions), but one has very
big cells and the other has small cells.
As observed for the F30 and F60 disks, where samples with similar densities have
different cell sizes is not uncommon and it has been reported in the literature by other
authors (Goel and Beckman 1994b; Arora et al. 1998).

As mentioned before, the

differences in cell sizes in these two samples results from differences in the amount of
gas dissolved in the sample at the moment of depressurization. The amount of dissolved
gas not only affects the nucleation rate and number of nuclei, but it also affects the
kinetics of bubble growth and therefore the final packing of the cells. The effect of gas
concentration in cellular growth is rather complex because many of the material
properties are affected by the amount of CO2 dissolved. Furthermore, the concentration
of dissolved CO2 is continuously changing during cellular growth, as dissolved gas
diffuses from bulk into the growing cells and is also lost along the sample outer surfaces
during expansion. From a general perspective, as the concentration of dissolved CO2
increases the system has lower viscosity and lower surface energy of the gas bubble /
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polymer interface. As a result the gas diffusion rate from the bulk into the bubbles is
increased. Additionally, the bi-axial stretching deformation of the material as the gas
bubbles grow is affected due to changes in the viscoelastic properties of the material
(Colton and Suh 1987; Goel and Beckman 1994a; b).
Finally, the high magnification SEM images of the cross-sectional areas of all the
foamed samples showed regular rough patterns similar to the ones observed for the
foamed samples f-S30INM and f-S15CBZ and PVCap-PVAc-PEG, which we discussed
earlier.
4.7.1.2 State of INM in the Foamed S30INM Samples.

Comprehensive

characterization of all samples is performed combining SEM, DSC, XRD and FT-IR.
Since each technique has a different level of detection sensitivity of crystalline content,
several characterization techniques were employed and combined in order to have a
higher level of confidence regarding the morphological state of INM in the different
samples.
It should be mentioned that the characterization of the samples is conducted
before and after the batch foaming process using ScCO2 as the PBA in order to establish
if this process induces morphological changes in the S30INM binary system after
compounding. Several factors may induce morphological changes in the API during
batch foaming operations with ScCO2. First, since amorphous states are metastable, by
increasing the system’s mobility through heating or in the presence of ScCO2, API
recrystallization may be induced. As mentioned above batch foaming of the S30INM
system is carried out above its Tg and the samples are subjected to this process
temperature for extended periods of time. Additionally, ScCO2 is known to act as
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plasticizer for many polymers, further contributing to increase macromolecular mobility
during batch foaming operations.

Another factor that may contribute to introduce

morphological changes to the S30INM system during batch foaming is the fact that
ScCO2 accelerates the crystallization of INM from its amorphous state, as was discussed
in detail in section 4.3.
Through SEM inspection of the samples, there is no evidence of crystalline
particles within the bulk of the samples, nor along the walls of the cells of foamed disks
(see Figure 4.44).

This can be seen as a strong indicator that INM exists in the

amorphous state in the un-foamed samples and it remains amorphous after the postprocessing batch foaming process. SEM analysis of fracture surfaces of melt mixed
samples has been used effectively by other authors to determine the presence of
crystalline API within the sample (Yang et al. 2010; Ha and Xanthos 2011).
A summary of the thermal properties of foamed and un-foamed samples is
presented in Table 4.16 and characteristic thermograms of the samples can be seen on
Figure 4.4. The results in Table 4.16 show that the Tg of un-foamed and foamed samples
are lower than that for the pure polymer (73 ± 2 °C), due to the plasticizing effect of
dissolved INM in PVCap-PVAc-PEG, but higher than that of amorphous INM
(46.33 ± 0.07 °C).
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Table 4.16 Summary of the Thermal Transitions Determined from DSC First Heating
(Unless Otherwise Specified) of Foamed and Un-foamed S30INM Samples. Properties
of PVCap-PVAc-PEG and INM are Shown as Reference (DSC Thermal Analyses Were
Performed in Triplicate)
Tm [°C]
Sample
Tg [°C]
PVCap-PVAc-PEG

73 ± 2

-

INM

46.33 ± 0.07*

161.0±0.3

Un-foamed disk

62 ± 1

-

F15

62 ± 3

-

F30

63 ± 1

-

F60

65 ± 1

-

* Value determined through DSC second heating

All the foamed and un-foamed samples showed a single glass transition
temperature and no endothermic peaks can be seen in the high temperature region on the
DSC thermograms of these samples (see Figure 4.4). These results suggest that in both
the un-foamed and foamed samples INM and the excipient exist as a single phase
amorphous system (i.e. an amorphous solid solution). As mentioned before, the unfoamed sample has a Tg 11 °C lower than that of the pure polymer, additionally, all
foamed samples show a similar shift in Tg with respect to PVCap-PVAc-PEG as the unfoamed sample. Although the F30 and F60 samples show slightly higher Tg values, the
small difference with respect to the un-foamed sample can be considered negligible and
within the experimental error (given by standard deviation). Also, it is important to keep
in mind that, although DSC is one of the most commonly used techniques to determine
residual crystallinity, it may not be capable of detecting small amounts of residual
crystallinity. Its minimum detection limit has been estimated to be ~2 wt% by Leuner
and Dressman (Leuner and Dressman 2000).
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Figure 4.47 Characteristic 1st heating thermograms (unless otherwise indicated) of: (a)
PVCap-PVAc-PEG, (b) F60, (c) F30, (d) F15, (e) un-foamed, (f) INM (2nd heating), and
(g) INM.
In agreement with SEM and DSC results, XRD patters show no evidence of the
presence of crystalline INM in both the un-foamed and foamed samples (see
Figure 4.48). Only pure INM (γ-INM) and the physical mixture show sharp peaks which
indicate the presence of a crystalline material. More specifically, diffraction patters of
these two samples show the characteristic γ-INM peaks, which are seen at 11.7°, 19.7°,
21.9° and 26.7° (2θ), as reported by Otsuka et al. (Otsuka et al. 2001). However, it
should be pointed out that in the physical mixture sample the intensity and definition of
these peak decreases compared to that of crystalline INM due to the presence of 70 wt%
of PVCap-PVAc-PEG, which is an amorphous material. On the other hand, PVCap-
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PVAc-PEG, and all the foamed and un-foamed S30INM samples only show the broad
diffraction pattern characteristic of amorphous materials.

PVCap-PVAc-PEG
F60

Intensity [a.u.]

F30

F15
21.8

19.7

26.7

11.7

un-foamed

Physical Mixture
19.7

21.9

26.7

11.7

γ−INM
5

10

15

20

25

30

2θ [degrees]
Figure 4.48 XRD patterns of crystalline INM, S30INM samples – physical mixture, unfoamed sample, and foamed samples (F15, F30, and F60) – and PVCap-PVAc-PEG.
Finally, FT-IR analysis of all the samples also shows strong evidence that INM
exists in the amorphous state in both the un-foamed and foamed samples (see
Figure 4.49). The characteristic peak for the stretching vibration of the C=O bond of
INM’s benzoyl group in un-foamed and all foamed samples appears at 1683 cm-1, which
corresponds to amorphous INM.
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Figure 4.49 Comparison of the FT-IR spectra of the un-foamed and foamed (F15, F30,
and F60) S30INM samples. Spectra of pure PVCap-PVAc-PEG and INM (in its γ-form
and amorphous state) are shown as reference.
In summary, the comprehensive characterization of the foamed and un-foamed
S30INM samples carried out in this work through SEM, DSC, XRD, and FT-IR, strongly
suggests that INM is in amorphous state and forming a single phase with PVCap-PVAcPEG. Furthermore, the system remains as an amorphous solid solution after the batch
foaming process with ScCO2.
4.7.1.3 Long Term Physical Stability of the Foamed S30INM samples. Amorphous
solid solutions as any other amorphous material are frozen in a high-energy metastable
state (Hancock and Zografi 1997; Zhang et al. 2004). This high energy state is one of the
reasons amorphous systems exhibit higher API dissolution / release rates and higher
apparent solubility compared to their crystalline counterparts, and these may potentially
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lead to increased bioavailability. However, the high energy state in which an amorphous
material is frozen renders it thermodynamically driven toward a lower energy and a more
stable state, by recrystallization of the API (Hancock and Zografi 1997). This transition
is particularly critical in amorphous drug delivery systems because a change in state in
the active ingredient during the shelf-life of dosage forms results in a change in its
performance, and specifically in its bioavailability.
In addition to the higher free energy state in amorphous solid solution another
factor that may contribute to a phase transition of the API is water absorption by the
excipients. The majority of the polymeric excipients used during HME process are either
highly hydrophilic or water soluble, and, thus, prone to absorbing water from the
environment. Absorbed water acts as a plasticizer for the system and, as a result, the Tg
of the amorphous system is decreased and its mobility increased. As an example, the Tg
of PVP has been reported to decrease by 10 °C when stored at 25 °C and 80 % RH
(Ahlneck and Zografi 1990). Thus, as a result of increased mobility the recrystallization
of the API may be facilitated. API recrystallization, under high humidity conditions, in
HME-prepared amorphous solid solutions has been reported in the literature for several
API / polymer excipient pairs (Prodduturi et al. 2004; Patterson et al. 2007).
In the case of the foamed dosage forms, another factor that may further affect the
shelf life of a drug product is the considerable increase in surface area of the samples
upon foaming, as is evident in the SEM images shown in Figure 4.44. Therefore, water
uptake and exposure to environmental conditions is enhanced and thus potentially
detrimental to the stability of the amorphous solid solution. Specifically for the S30INM
system, the rough patterns along the wall of the cells, observed in the high magnification
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SEMs in Figure 4.44, signify an increase the surface area beyond the already higher
surface area that results from the cellular structure.
The shelf-life or long term physical stability of the S30INM system is evaluated
by placing the foamed and un-foamed samples in open container for 6 months in an
environmental chamber at constant 75 % RH. The temperature in the chamber was
continuously monitored but not controlled, with the recorded temperatures showing
fluctuations between 15° and 32 °C with average temperature of 25 ± 3 °C in the 6-month
period.
The state of INM in all the foamed and un-foamed samples after been stored for
6-month at 25 ± 3 °C and 75 % RH is examined through FT-IR spectroscopy. Figure
4.50 shows the spectra of the foamed and un-foamed samples before and after the long
term stability test. These results clearly show no change in the state of INM in any of the
samples.

There are no detectible changes in the spectra, as it can be seen in

Figure 4.50 (a) in the range between 2000 and 500 cm-1. In more detail, in Figure 4.50
(b) is evident that the peak associated with stretching vibration of the C=O bond in the
benzoyl group in INM appears at 1683 cm-1, corresponding to amorphous INM. These
results clearly indicate that INM did not recrystallize in either foamed or un-foamed
samples after the 6-month stability test.
Another important factor associated with the shelf life stability of a dosage form
is its dimensional stability. Figure 4.51 shows a comparison of the physical dimensions
of the samples before [Figure 4.51 (i)] and after the stability test [Figure 4.51 (ii)]. These
photographs clearly show that while the un-foamed samples have very high dimensional
stability, the foamed ones tent to shrink during the 6-month stability test. During the
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batch foaming process, the solid solution is subjected to plastic deformation at a
temperature where the material is softened but not in molten state. Therefore, residual
stresses are introduced to the material as well as high levels of orientation are introduced
to the sample. Once humidity is absorbed by the foamed samples, water is dissolved in
the amorphous solid solution plasticizing it. Due to the increased mobility and reduction
in mechanical strength of the solid solution (caused by plasticization), oriented polymer
chains can relax and as a result the foamed samples shrink.
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Figure 4.50 Comparison of the FT-IR spectra of the S30INM un-foamed and foamed
(F15, F30, and F60) samples: (black spectra) before and (red spectra) after 6-month
storage in open containers at 25 ± 3 °C and 75 % RH.
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Figure 4.51 Photographs comparing the S30INM samples (a) un-foamed, (b) F15, (c)
F30, and (d) F60 disks: (i) before stability test, and (ii) after 6-month in the
environmental chamber at 25 ± 3 °C and 75 % RH.
4.7.2 Effect of the Cellular Morphology on INM’s Release Rate
The release profiles of INM from un-foamed and foamed S30INM disks are presented in
Figure 4.52. However, when analyzing these results, it is important to have the following
key information in mind regarding the samples used in this study. First, all samples were
analyzed without grinding or in any way breaking the cellular structure. In other words,
the samples were placed in the dissolution bath as the disks shown in Figure 4.43. Since
the weight of the samples was kept constant (~240 mg of total weight and hence ~72 mg
of INM), the differences observed in the release profiles can be solely attributed to the
morphological dissimilarities of the three cellular structures.

Second, it should be

mentioned that, although the dimensions of the samples are “not patient compliant”, they
were chosen in order to gain fundamental understanding of the influence of the
morphology of the cellular structure on the release rate and disintegration behavior of the
dosage forms.
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Figure 4.52 INM’s release profiles from the S30INM solid solutions: () un-foamed
disks (16∅ x 1 mm), and the corresponding foamed disks F15 (), F30 (), and F60 ()
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Figure 4.53 Detail of the initial 14 min of INM’s release profiles from the S30INM solid
solutions: () un-foamed disks (16∅ x 1 mm), and the corresponding foamed disks F15
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From the complete dissolution profiles presented in Figure 4.52, it is evident that
all samples reached 100 % of release, although at different rates. Experimentally, it was
found that the release rate of the samples decreases in the following order: F15 > F30 >
F60 > un-foamed disks. The time required to reach 100% release is 120 min (2 h) for the
un-foamed disks, while for the foamed disks F15, F30, and F60 the times required for
completing INM’s release are 30, 60 and 90 min, respectively. In other words, the time
to complete the release of INM from the foamed samples is 25 to 75% shorter than that of
the un-foamed disks.
In Figures 4.52 and 4.53, it is evident that the shape of the INM’s release profiles
is affected by the cellular morphology of the sample. The differences among the release
profiles reflect differences in the disintegration/dissolution behavior of the samples, as
will be discussed below in more detail.
In section 4.5 was shown that INM release from the S30INM amorphous solid
solution is relaxation controlled, in order words it is controlled by the swelling and
dissolution kinetics of the whole solid solution. Figure 4.54 schematically shows the
physical aspects of “one-dimensional” swelling and dissolution of in polymer based
systems. Initially, a sample of thickness 2L is in a glassy state (as in the case of the unfoamed disks evaluated in this study).
The first steps toward dissolution are wetting of the amorphous solid solution
surface and solvent absorption. As the solvent (or body fluid) penetrates into the sample,
it acts as a plasticizer locally lowering the glass transition temperature of the system and
greatly increasing molecular mobility. Once the concentration of the solvent in the
boundary layer reaches a critical value the local glass transition temperature reaches the
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temperature of the solvent and a swollen layer is formed (see Figure 4.54 (b)) (Peppas et
al. 1994; Narasimhan and Peppas 1997). Due to the higher polymer mobility along the
swollen layer, the material in this region is in a rubbery state while in the dry region it
remains in a glassy state. As mentioned before, the length of time required to form the
swollen layer is the induction time of the dissolution process. Since the mobilities of the
polymer and API through this swollen layer are very high, it is only after the induction
time that API diffusion and true polymer dissolution can begin, see Figure 4.54 (c)
(Peppas et al. 1994; Narasimhan and Peppas 1997; Narasimhan 2001).

Figure 4.54 Schematic representation of one-dimensional polymeric swelling and
dissolution processes. (a) initial glassy solid solution of thickness 2L, (b) initial swelling
step where two boundaries are seen: rubbery-solvent inter-phase and glassy-rubbery
inter-phase, (c) true dissolution process starts when both inter-phases move inward, and
(d) final dissolution step where the entire solid solution is in the rubbery state.

In relaxation controlled systems, reports in the literature indicate that, once the
swollen layer is formed, the rates of solvent absorption and polymer dissolution are
synchronized, i.e., become equal (Peppas et al. 1994; Narasimhan and Peppas 1997;
Miller-Chou and Koenig 2003). In other word, the thickness of the swollen layer remains
constant and the two boundaries (i.e. the swollen-solvent and the swollen-glassy interphases) move at the same rate. This is represented in the relaxation model by a constant
advance rate of the swelling front (i.e. ko/Co in equation 4.19 in section 4.5.4). Then, as
polymer and API molecules are released to the solution, both glassy-rubbery and
rubbery-solvent inter-phases continue to move toward the core of the sample until the
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glassy region is completely depleted, followed by complete dissolution (Peppas et al.
1994; Narasimhan and Peppas 1997; Colombo et al. 2000; Narasimhan 2001; Siepmann
and Peppas 2001).
In the case of un-foamed disks, the release/dissolution behavior is in agreement
with the API release mechanism described above. Un-foamed disks show an induction
time of about one minute; in Figure 4.53 this is seen as a smooth and slow increase in the
release rate during the initial stages of the dissolution test. Afterwards, disintegration of
the sample occurs from the outside toward the inside. In other words, the sample’s size is
reduced slowly and gradually.
In the case of INM’s release from foamed samples, although all the mass transfer
processes described above take place, there are some differences in the disintegration
behavior. These differences lead to faster release and are described below.
First, it is interesting to note that in Figure 4.53 the induction time for the unfoamed disk can be clearly identified, but this is not the case for the foamed disks. In
other words, the release profiles of the foamed samples do not show a gradual and slow
increase in the amount of INM been released during the initial stages of the dissolution
test. On the contrary, all foamed samples show an initial “burst” on API release. For
example in the first one minute, the amount of INM released from the F15 disks is ~12fold more than that from the un-foamed disks (10.7 ± 0.6 % and 0.9 ± 0.2 % from the F15
and un-foamed disks, respectively). This suggests that in the foamed structures the
induction time is reduced from ~1 min to less than 30 s – time at which the first sample is
draw from the dissolution apparatus.

Therefore, it can be concluded that solvent

absorption rate is significantly accelerated upon foaming.
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Figure 4.55 SEM images of edge section of the fracture surface of foamed S30INM
disks: (a) F15, (b) F30, and (c) F60.
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In systems where the API release is relaxation controlled, as is the case for the
S30INM system, the API release rate and solvent absorption rates are inversely
proportional to the sample’s characteristic length (Enscore et al. 1977). For example, the
induction time for the S30INM disks is reduced from ~ 1 min for a sample of 16∅ x 1
mm to ~30 s for a sample of 19∅ x 0.3 mm (see Figure 4.34). Therefore, the reduction in
induction time in the foamed samples with respect to the un-foamed disk results from
shorter characteristic length and higher surface area through the walls of the cells. The
characteristic length for un-foamed disk is 0.5 mm (half its thickness); while for foamed
samples characteristic lengths are between 40.7 and 0.2 μm (i.e. wall thickness reported
in Table 4.15).
Among the foamed samples there are also differences during the initial stages of
the dissolution profiles. Within 30 s the amount of INM released from the F60 samples is
4.8 ± 0.2 %, while from the F15 and F30 samples it is 7.6 ± 0.4 % and 9 ± 2 %,
respectively (see Figure 4.53). At the beginning of the test, the F15 and F30 samples
have even faster release rates than F60 because they have higher cell density and smaller
cells along the disk surface, see Figure 4.55. As dissolution starts, these smaller cells
open due to dissolution and as a result the surface area for F15 and F30 is higher
compared to F60, thus the release rate of INM is further enhanced for F15 and F30.
It should also be noted that during the first 5 min of the dissolution test, the
release profiles of INM from the F15 and F30 samples are almost identical, see Figure
4.53. This is most likely associated with the similarities observed through the SEM
images of the cross section of these foamed disks. In Figures 4.55 (a) and (b) is clear that
F15 and F30, respectively, have an outer layer of cells of approximately 18 μm.
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However, it seems that once the outer layers are depleted, the dissolution of these two
samples continues at different rates (see Figure 4.53).
Even though all foamed samples showed a reduction in induction time, two
distinct disintegration behaviors are observed. These are schematically presented in
Figures 4.56 (a) and (b) and compared to the dissolution mechanism of the un-foamed
disks, Figure 4.56 (c).

Figure 4.56 Schematic representation of the dissolution/disintegration mechanism
observed for different samples: (a) F60 foamed disks, (b) F15 and F30 foamed disks and
(c) un-foamed disks.
Similar to the un-foamed disks, during the dissolution test of the F60 disks, the
samples progressively becomes smaller as disintegration/dissolution takes place.
However, the size reduction results from breakage of small pieces of the outer layers of
the foamed structure as shown schematically in Figure 4.56 (a). These small pieces
dissolve completely afterwards in the aqueous solution. Given that the disintegration
process occurs from the outside toward the inside, the shape of the release profiles of the
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un-foamed samples and the F60 samples are parallel to each other, see Figure 4.52.
Therefore, the release rate enhancement observed for the F60 disks with respect to the
un-foamed disks is primarily due to reduction of the induction time (i.e. faster swelling).
On the other hand, during dissolution of the F15 and F30 samples, random and
extensive breakage of the foamed structure is observed, this is shown schematically in
Figure 4.56 (b). In more detail, after swelling, the cellular structure started to collapse by
forming holes throughout the disk followed by random breakage/cleavage of the disks
into smaller pieces. This random and extensive breakage of the cellular structure resulted
in a significant increase in INM’s release rate with respect to un-foamed disk.
Based on the different disintegration mechanisms observed, it can be concluded
that the random and extensive breakdown of the disks is favored primarily by a nonuniform wall thickness distribution.

Unlike F60, F15 and F30 have very broad

distribution of wall thicknesses (see Table 4.15). Sections of the foamed sample, with
thinner wall thickness, tend to swell faster than the ones with thicker walls, introducing
stresses that induce disintegration by random breakage/cleavage of the foamed sample.
As it can be seen in Table 4.15, the wall thicknesses observed in the F15 samples have a
2 order of magnitude span (0.2 - 40.7 μm); while the wall thicknesses of the F30 samples
are in the range 0.2 – 9.7 μm. Therefore, F15 disks have a more pronounced nonuniformity of the cellular structure than F30 and thus it shows faster release rate. The
F60 samples only have a very small difference between maximum and minimum wall
thicknesses (0.5 -1.2 μm) and thus these samples do not experience extensive breakage
during dissolution.
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Besides the differences in swelling rates through the foamed samples caused by
differences in wall thickness, also residual stresses and chain orientation introduced
during batch foaming process affect the swelling and dissolution kinetics of polymer
based systems. In terms of orientation, it has been reported that when the solvent
absorption front moves parallel to the preferential orientation of the polymer chains then
⁄

∝ ; in contrast when absorption is perpendicular to its preferential orientation

⁄

∝

⁄

(Frisch 1980). In the case of un-foamed disks, due to the nature of the

compression molding process, polymer chains are radially oriented, thus, mass transfer
during swelling and dissolution is dominantly parallel to the polymer chains’ preferential
orientation. On the other hand, in the foamed samples polymer chains are bi-axially
oriented along the walls of the cells. These may also contribute toward a distribution of
swelling and dissolution rates through the samples, because in some regions the
advancing swelling front may be moving at a constant rate while in other regions at a
variable rate. As a result, internal stresses are buildup throughout the foamed structure,
and, thus, fracture is promoted during dissolution.
In terms of residual stresses, which exist in the foamed samples and became
evident during the 6-month stability stat, these may also favor fracture of the foamed
samples during dissolution. Although these residual stresses tent to be relaxed as a result
of solvent absorption, they may also promote environmental stress cracking during
dissolution.
4.7.2.1 Quantitative Comparison Between the Release Profiles from Foamed and
Un-Foamed Disks. The difference and similarity factors (f1 and f2, respectively) are
calculated using equations 4.21 and 4.22 presented in section 4.5.5.1 and the software
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Wolfram Mathematica®. INM’s release profiles from each foamed sample are compared
to that of the un-foamed samples. In addition INM’s release profiles from foamed
samples are also compered. The results from these analyses are summarized in Table
4.14, together with the time ranges used for the calculations, and the sample’s release
profile is used as reference in the calculation.
Table 4.17 Calculated Difference Factor (f1) and Similarity Factor (f2) for Several Pairs
of INM’s Release Profiles from S30INM solid solutions (UF is used to indicate the Unfoamed sample)
Time Range Used for the
Sample pair
f1
Reference Sample
f2
Calculations [min]
UF-F15

229.5

25.3

0.5 - 20

UF

UF-F30

123.1

31.4

0.5 - 30

UF

UF-F60

24.1

55.5

0.5 - 60

UF

F15-F30

22.7

43.3

0.5 - 20

F15

F15-F60

50.7

30.1

0.5 - 20

F15

F30-F60

36.3

39.4

0.5 - 30

F30

The results obtained for the pair UF-F60 (un-foamed vs. F60) are inconclusive.
Using FDA criteria (FDA 1997) the difference factor suggest that the profiles are
different (f1 > 15), but the difference factor indicates that the profiles are similar (f2>50).
It is interesting to note, that this behavior was also observed when comparing INM’s
release profiles from f-EPO30INM with un-foamed EPO30INM in pH 7.4, where the
release profiles also appear to be parallel to each other.
On the other hand, since f1 >> 15 and f2 < 50 for the F15 and F30 samples, when
compared to the un-foamed sample, then it can be stated that INM’s release profile from
these two foamed samples is statistically different than that of the un-foamed samples.
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Using these factors, the impact of the foam morphology on INM release can be ranked
from higher to lower impact as follows: F15 > F30 >F60.
Using the same approach the release profiles among foamed samples are also
compared. From the results presented in Table 4.17 it can be concluded that the release
profiles of INM from all three foamed morphologies are statistically different.
Additionally, the biggest statistical difference is observed between the pair F15 - F60,
followed by F30 - F60, and, finally, the least different are the pair F15 - F30.
The results from the statistical analyses are in agreement with the observed
disintegration/dissolution behavior of the samples. In the case of F15 and F30, which
both showed extensive breakage of the sample during disintegration, are the ones that
showed the highest statistical difference with respect to the release profile of the unfoamed sample, but among the foamed samples the pair F15 - F30 showed to be must
similar. On the other hand, F60 which has similar disintegration behavior as the unfoamed samples is the most statistically similar to the un-foamed disks and statistically
different to the profiles from F15 and F30.
4.7.2.2 Summary. The initial stages of API release from a solid solution is a “surface”
phenomenon, in other words is controlled by the surface characteristics of the samples
and, in the case of foamed samples, by the outer layer of cells. Therefore independently
of the overall cellular morphology, by reducing the characteristic length along the
sample’s surface (and as a consequence increasing its surface area of the sample), the
API release rate can be increased. And this enhancement in API release rate results
solely from a reduction in induction time (i.e. wetting, solvent absorption and swelling
are accelerated).
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On the other hand, in order to significantly reduce the dissolution/release rate, it is
essential to promote extensive and random breakage of the sample. In other words,
promote fast disintegration of the dosage form.

The key feature of the cellular

morphology in achieving this is to produce a non-uniform cellular structure with very
broad distribution of wall thicknesses, which introduces internal stresses to the foamed
structure by differences in the swelling rates throughout the sample.
It should be noted that in the present case, the non-uniformities in the cellular
structure are achieved by a batch process under non-equilibrium conditions. Therefore it
may not be possible to directly apply these findings to a commercial manufacturing
setting.

However, the fundamental knowledge gained indicates that differences in

swelling rates introduce internal stresses that promote disintegration by extensive fracture
of the foamed dosage form. Thus, it may be possible to mimic this phenomenon by
incorporating additional excipients, such as super-disintegrants (examples of which
include croscarmellose sodium and crospovidone) into the formulation been extruded.
Such disintegrant particulates, whose action mechanism is rapid swelling, will introduce
strong localized internal stresses and promote fracture and disintegration of the cellular
structure accelerating API release.

Furthermore by doing so it may be possible to

manufacture fast dissolving dosages by continuous or semi-continuous processes such as
foam extrusion and foam injection molding.

CHAPTER 5
CONCLUDING REMARKS AND SUGGESTED FUTURE WORK

5.1 Summary
The batch HMM and continuous HME processes are used to produce several amorphous
API / Polymer systems. Foamed samples are produced by batch foaming using ScCO2 as
the PBA, and by foamed extrusion via CO2 continuous injection between two melt seals
in the extruder. Comprehensive characterization of the binary systems is carried out
combining DSC, FT-IR, XRD, and SEM analyses.

These analyses show that the

S30INM and EPO30INM systems produced are amorphous solid solutions, while the
S15CBZ system is an amorphous solid dispersion. Furthermore, while subjecting pure
amorphous INM to the batch foaming process caused it to accelerate its recrystallization,
neither INM nor CBZ experienced any morphology changes during batch foaming of
both the amorphous solid solutions and the amorphous solid dispersion.
The most important contributions of this dissertation can be grouped into three
areas: (a) an understanding of the mechanism by which foamed dosages can lead to faster
API release as well as the key morphological aspects of the cellular structure needed to
achieve this, (b) an understanding of the correlation between the mechanism controlling
the release of an API from an amorphous dosage and the enhancement in its release rate
upon foaming, and (c) an understanding of the impact of the morphology of the cellular
structure on the milling efficiency of HME products and the dissolution performance of
the particles produced.
Foamed S30INM samples with three different morphologies are produced via
batch foaming. The API release rate and disintegration/dissolution behavior for the
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foamed samples are compared to that of the un-foamed sample. The time to complete the
release of INM from the foamed S30INM solid solutions is 25 to 75 % shorter than that
of the un-foamed samples. Furthermore, a strong correlation between foam morphology
and release rate enhancement is observed.

On one hand, the induction time for

dissolution (i.e. the time necessary for surface wetting, solvent absorption and swelling)
is significantly shorter for the foamed sample, as a result of higher surface area and
shorter characteristic lengths for mass transfer along the walls of the cells. However, the
key aspect for significantly enhancing the API release rate is shown to be the extensive
and random breakage / cleavage of the foamed dosage forms, leading to their
disintegration. This is facilitated in foamed structures with very broad distribution of
wall thicknesses, which leads to internal stresses due to different local swelling rates in
the sample. In this sense, such foam morphologies act as disintegrant-less disintegrants,
speeding up API release.
The impact of foaming on the API release profile from binary systems with
different release mechanisms is also investigated. Fitting the in vitro dissolution data to
the Power law model allowed the identification of the mechanism controlling the release
of the API from several systems. In the cases of the EPO30INM in pH 1.2 as well as the
S30INM systems, the INM’s release is relaxation controlled. On the contrary, INM’s
release from the EPO30INM system in pH 7.4 is controlled by Fickian diffusion. And in
the case of CBZ from the S15CBZ amorphous solid dispersion anomalous transport
controls its release. In all four cases the release rate of the APIs is increased upon
foaming. However, in the systems where the API release is controlled by the swelling
and dissolution kinetics of the amorphous system, the foamed structure has a stronger
impact in the very early stages of API release. Conversely, in the late stages of the
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dissolution process the API release rate is mainly affected by the disintegration behavior
(or dimensional integrity) of the foamed sample, which creates fresh and large surface
areas for release/dissolution. In addition, statistical indices are used to quantify the
impact of foaming on the release profile for all the systems; these statistical analyses
show that the strongest impact is observed for S15CBZ, followed by S30INM and then
EPO30INM in pH 1.2.
The foam extrusion process is used to produce the cellular S30INM amorphous
solid solutions. By varying the foam extrusion conditions two distinct cellular structures
are produced: (1) a high density foam of 0.24  0.05 g/cm3, which showed a highly nonuniform morphology with loosely packed cells of 0.8- 2.2 mm, and (2) a low density
foam of 0.071  0.004 g/cm3, with small and closely packed cells of 27 - 320 m, these
results in a cellular structure with thinner walls. The milling efficiency of these two
foamed extrudates is compared to that of the un-foamed extrudates prepared by
conventional HME process.

It is shown that the milling efficiency of the HME

extrudates is increased because of the presence of cellular structures. Foamed extrudates
compared to un-foamed ones, milled under the same conditions resulted in smaller
particles with a narrower particle size distribution and lower bulk density. Nonetheless,
by simply introducing some degree of porosity in the extrudate (as in the case of the high
density foam) without actually producing a foamed structure with closely packed cells
and thin walls still results in a tighter particle size distribution compared to un-foamed
extrudates; however, the particles produced by milling the high density foams have
comparable morphology and average size as the ones produced by milling the un-foamed
extrudates. Furthermore, the similarities between the particles produced by milling the
high-density foam and un-foamed extrudates are also reflected in their dissolution
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performance, these two samples show to have almost identical API release profiles.
Conversely, milled low-density extrudates have considerably smaller particles with
higher surface area, and, thus, their dissolution rate is significantly enhanced with respect
to that of crystalline INM and the other two milled solid solutions.
The substantial improvement in milling efficiency achieved through the foamed
extrudates has a direct impact in the currently used commercial manufacture practices,
because it signifies that in one milling pass it is possible to produce particles with narrow
particle size distributions and the desired mean size for the production of the final dosage
forms. Therefore, manufacturing time and costs can be reduced.

5.2 Suggested Future Work

5.2.1 Fast Disintegration of Foamed Samples
As mentioned earlier, in order to achieve a significant enhancement in API release rate
through foamed structures, it is necessary to have non-uniform cellular structures. In this
study these non-uniformities are obtained by a batch process under non-equilibrium CO2
concentration conditions.

Therefore it may not be possible to directly apply these

findings in a commercial manufacturing setting. However, the fundamental knowledge
gained indicates that differences in swelling rates introduced internal stresses that
promote disintegration of the foamed dosage form. Thus, it may be possible to mimic
this phenomenon by incorporating additional excipients, such as super-disintegrants
(examples of which include croscarmellose sodium and crospovidone) into the
formulation been extruded. Such disintegrant particulates, whose action mechanism is
rapid swelling, will introduce strong localized internal stresses and promote fracture and
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extensive disintegration of the cellular structure accelerating API release. Furthermore
by doing so it may be possible to manufacture fast dissolving dosages by continuous or
semi-continuous processes such as foam extrusion and foam injection molding.

5.2.2 Dimensional Stability of Cellular Structures
Since the foamed samples produced by batch foaming with ScCO2 showed poor
dimensional stability in a high humidity environment, it would be of interest to evaluate
the use of enteric coatings to act as a barrier against humidity during the shelf life of the
product.

However, to achieve this a solvent-free coating method must also be

investigated.

5.2.3 Milling Efficiency of Foamed Structures
Since a strong and positive correlation between foam structure and milling efficiency is
observed, it will be technologically important to perform a more detailed study of the
broad area of foam morphology-mechanical properties-milling efficiency, involving
parametric studies with the extrusion and milling processes, and characterization of the
fracture and compaction properties of the foamed structures and milled particulates.
Finally, studying the tableting performance of the particles produced by milling of
foamed and un-foamed extrudates is of great importance. Compaction of the ground
foamed extrudates during the tableting operation is expected to be facilitated, when
compared to the compaction of particles produced by milling un-foamed extrudates. The
particles produced by milling the foamed extrudates retained some of their cellular
structure, a feature which should enable particle deformation during compression of
otherwise tough and brittle particles.
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5.2.4 Foam Extrusion of Pharmaceutical Systems
During the HME process of a miscible binary system comprised of an API and polymer
excipient, it is well known that the API gradually dissolves in the molten polymer.
However, during the foam extrusion process (or gas - assisted HME process) the system
being processed becomes a ternary one composed by an API, the blowing agent gas and
the polymer excipient.

Therefore, it is of great importance to understand how the

presence of the gas affects the dissolution of the API in the polymer melt from a
thermodynamic as well as a kinetic perspective. Comprehensive rheology studies of
binary and ternary blends with different compositions should be performed in order to
gain rigorous understanding of the behavior of such ternary systems.

APPENDIX A
SCREW NOMENCLATURE

Figures A.1 and A.2 schematically shown the nomenclature used for the screw elements
(a)

(b)

Figure A.1 Detailed description of the nomenclature used for: conveying screw elements
and (b) kneading blocks. Source: (Leistritz 2012)

Figure A.2 Schematic representation of a conveying screw element and a kneading
block. Source: (Leistritz 2012)
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APPENDIX B
THERMAL STABILITY THROUGH TGA

B.1 TGA Ramp Analyses
Figures B.1 through B.3 show the weight loss curves for PVCap-PVAC-PEG, INM and
CBZ obtained through TGA ramp analyses performed at heating rate of 10 C/min in dry
air atmosphere.
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Figure B.1 TGA weight loss for PVCap-PVAc-PEG in dried air at a heating rate of 10
C/min.
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Figure B.2 TGA weight loss for INM in dried air at a heating rate of 10 C/min.
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Figure B.3 TGA weight loss for CBZ in dried air at a heating rate of 10 C/min.
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B.2 TGA Isothermal Analyses
Figures B.4 through B.5 show the TGA results for isothermal analyses for PVCapPVAC-PEG, INM and CBZ in dry air atmosphere.
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Figure B.4 TGA results for PVCap-PVAc-PEG isothermal analyses in dry air at: (a) 110
C, (b) 120 C, (c) 130 C, (d) 140 C, and (e) 150 C. Samples were heated to the
prescribed temperature at 40 C and held isothermally for 60 min.
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Figure B.5 TGA results for PVCap-PVAc-PEG isothermal analyses in dry air at: (a) 130
C, (b) 140 C, (c) 150 C, (d) 155 C, and (e) 160 C. Samples were heated to the
prescribed temperature at 40 C and held isothermally for 60 min.

APPENDIX C
CALCULATION OF THE THEORETICAL DENSITY OF FOAMED
EXTRUDATES

C.1

Theoretical Density Calculations for the LD-fHME Samples (4 w/w% CO2)

Flow rate of solids (S30INM) base of feeding rate of 1.5kg/h and measured density of unfoamed extrudates:

(

)(

)

⁄

(C.1)

Flow rate of CO2 exiting the die, based on experimentally set feeding rate of 1
g/min and CO2 density at 0.101MPa (NIST 2011):

(

)(

)

⁄

(C.2)

Then the volume fraction occupied by the gas can be calculated as follows:

⁄

(C.3)

Theoretical foam density can be calculated used the expression for void fraction
as follows:

(C.4)
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Where v is the void fraction, f density of the foamed material and uf the density
of the un-foamed material (Kaewmesri et al. 2006).
⁄

⁄

C.2 Density Values of CO2 at the Foam Extrusion Processing Conditions
The density values of CO2 used for the volume calculations in Chapter 4, section 4.4.1
are summarized in Table C.1.
Table C.1 Density Values of CO2 at Various Pressures and Temperatures
Pressure [MPa]
Density [g/cm3]
Temperature [C]
102

3.7

0.057

102

1.8

0.026

102

0.101

0.001

97

3.4

0.053

97

1.7

0.025

97

0.101

0.001

Source: (NIST 2011)

APPENDIX D
RHEOLOGICAL PROPERTIES OF PVCAP-PVAC-PEG

Rheological properties of PVCap-PVAc-PEG were determined combining capillary
rheometry and Rheometrics Mechanical Spectrometer (RMS) at different temperatures.
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Figure D.1 Superposition of shear viscosity with shear rate at several temperatures
(150, 160 and 170C). RC refers to Capillary Rheometry and RMS to Rheometrics
Mechanical Spectrometer.
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APPENDIX E
BATCH FOAMING PROCESSING WINDOW

Figure E.1 shows the effect of the batch foaming temperature and pressure on the
morphology of the foamed PVCap-PVAc-PEG samples

(a)

(b)

(c)

(d)

(f)
(e)
Figure E.1 Photographs of PVCap-PVAc-PEG (a) Un-foamed sample, and foamed
samples with CO2 for 30 min at (b) 74 °C and 6.89 MPa, (c) 80 °C and 6.89 MPa, (d) 85
°C and 6.89 MPa, (e) 74 °C and 4.83 MPa, and (f) 90 °C and 4.83 MPa.
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